
<html lang="en"     class="pb-page"  data-request-id="1541a12b-0d25-40a9-8e06-f1b6fabbc960"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";issue:issue:10.1021/jmcmar.2014.57.issue-23;requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text;article:article:10.1021/jm5014659"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="A Chemical Tuned Strategy to Develop Novel Irreversible EGFR-TK Inhibitors with Improved Safety and Pharmacokinetic Profiles" /></meta><meta name="dc.Creator" content="Guangxin  Xia" /></meta><meta name="dc.Creator" content="Wenteng  Chen" /></meta><meta name="dc.Creator" content="Jing  Zhang" /></meta><meta name="dc.Creator" content="Jiaan  Shao" /></meta><meta name="dc.Creator" content="Yong  Zhang" /></meta><meta name="dc.Creator" content="Wei  Huang" /></meta><meta name="dc.Creator" content="Leduo  Zhang" /></meta><meta name="dc.Creator" content="Weixing  Qi" /></meta><meta name="dc.Creator" content="Xing  Sun" /></meta><meta name="dc.Creator" content="Bojun  Li" /></meta><meta name="dc.Creator" content="Zhixiong  Xiang" /></meta><meta name="dc.Creator" content="Chen  Ma" /></meta><meta name="dc.Creator" content="Jia  Xu" /></meta><meta name="dc.Creator" content="Hailin  Deng" /></meta><meta name="dc.Creator" content="Yufeng  Li" /></meta><meta name="dc.Creator" content="Ping  Li" /></meta><meta name="dc.Creator" content="Hong  Miao" /></meta><meta name="dc.Creator" content="Jiansheng  Han" /></meta><meta name="dc.Creator" content="Yanjun  Liu" /></meta><meta name="dc.Creator" content="Jingkang  Shen" /></meta><meta name="dc.Creator" content="Yongping  Yu" /></meta><meta name="dc.Description" content="Gatekeeper T790 M mutation in EGFR is the most prevalent factor underlying acquired resistance. Acrylamide-bearing quinazoline derivatives are powerful irreversible inhibitors for overcoming resist..." /></meta><meta name="Description" content="Gatekeeper T790 M mutation in EGFR is the most prevalent factor underlying acquired resistance. Acrylamide-bearing quinazoline derivatives are powerful irreversible inhibitors for overcoming resist..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="December 1, 2014" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/jm5014659" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Â© 2014 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Fjm5014659" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Fjm5014659" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Fjm5014659" /></link>
        
    
    

<title>A Chemical Tuned Strategy to Develop Novel Irreversible EGFR-TK Inhibitors with Improved Safety and Pharmacokinetic Profiles | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/jm5014659" /></meta><meta property="og:title" content="A Chemical Tuned Strategy to Develop Novel Irreversible EGFR-TK Inhibitors with Improved Safety and Pharmacokinetic Profiles" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm5014659/20141205/images/large/jm-2014-014659_0001.jpeg" /></meta><meta property="og:description" content="Gatekeeper T790 M mutation in EGFR is the most prevalent factor underlying acquired resistance. Acrylamide-bearing quinazoline derivatives are powerful irreversible inhibitors for overcoming resistance. Nevertheless, concerns about the risk of nonspecific covalent modification have motivated the development of novel cysteine-targeting inhibitors. In this paper, we demonstrate that fluoro-substituted olefins can be tuned to alter Michael addition reactivity. Incorporation of these olefins into the quinazoline templates produced potent EGFR inhibitors with improved safety and pharmacokinetic properties. A lead compound 5a was validated against EGFRWT, EGFRT790M as well as A431 and H1975 cancer cell lines. Additionally, compound 5a displayed a weaker inhibition against the EGFR-independent cancer cell line SW620 when compared with afatinib. Oral administration of 5a at a dose of 30 mg/kg induced tumor regression in a murine-EGFRL858R/T790M driven H1975 xenograft model. Also, 5a exhibited improved oral bioavailability and safety as well as favorable tissue distribution properties and enhanced brain uptake. These findings provide the basis of a promising strategy toward the treatment of NSCLC patients with drug resistance." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/jm5014659"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/jm5014659">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=âtrueâ></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=âtrueâ></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=âtrueâ></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=âtrueâ></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Fjm5014659&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Fjm5014659&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/jm5014659&amp;href=/doi/10.1021/jm5014659" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2014</span><span class="cit-fg-volume">, 57</span><span class="cit-fg-issue">, 23</span><span class="cit-fg-pageRange">, 9889-9900</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/57/23" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/jm500930h" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/jm501021n" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">A Chemical Tuned Strategy to Develop Novel Irreversible EGFR-TK Inhibitors with Improved Safety and Pharmacokinetic Profiles</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Guangxin++Xia">Guangxin Xia</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â¡</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Wenteng++Chen">Wenteng Chen</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jing++Zhang">Jing Zhang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â¡</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jiaan++Shao">Jiaan Shao</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Yong++Zhang">Yong Zhang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â¡</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Wei++Huang">Wei Huang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Leduo++Zhang">Leduo Zhang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â¡</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Weixing++Qi">Weixing Qi</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Xing++Sun">Xing Sun</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â¡</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Bojun++Li">Bojun Li</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â¡</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Zhixiong++Xiang">Zhixiong Xiang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â¡</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Chen++Ma">Chen Ma</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â¡</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jia++Xu">Jia Xu</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â¡</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Hailin++Deng">Hailin Deng</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â¡</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Yufeng++Li">Yufeng Li</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â¡</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ping++Li">Ping Li</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â¡</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Hong++Miao">Hong Miao</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â¡</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jiansheng++Han">Jiansheng Han</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â¡</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Yanjun++Liu">Yanjun Liu</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â¡</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jingkang++Shen">Jingkang Shen</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>â¡</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>Â§</sup></span></span></li><span class="comma-separator">,Â andÂ </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Yongping++Yu">Yongping Yu</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-symbol">â </span> <span class="aff-text">Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Science, Zhejiang University, 866 Yuhangtang Road Zijin Campus, Hangzhou 310058, China</span></div><div class="aff-info" id="aff2"><span class="aff-symbol">â¡</span> <span class="aff-text">Central Research Institute, Shanghai Pharmaceutical Holding Co., Ltd., Building 4, No. 898 Ha Lei Road, Zhangjiang Hi-Tech Park, Shanghai 201203, China</span></div><div class="aff-info" id="aff3"><span class="aff-symbol">Â§</span> <span class="aff-text">State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, No. 555 Zuchongzhi Road, Zhangjiang Hi-Tech Park, Shanghai 201203, China</span></div><div class="corresp-info"><strong>*</strong>For Y. Yu: phone, 86-571-8820 8452; fax, 86-571-8820 8452; E-mail, <a href="/cdn-cgi/l/email-protection#c5bcbcb085bfafb0eba0a1b0eba6ab"><span class="__cf_email__" data-cfemail="60191915201a0a154e0504154e030e">[emailÂ protected]</span></a></div><div class="corresp-info"><strong>*</strong>For J. Shen: E-mail, <a href="/cdn-cgi/l/email-protection#2b414058434e456b464a4247055843484548054a48054845"><span class="__cf_email__" data-cfemail="2c46475f4449426c414d4540025f444f424f024d4f024f42">[emailÂ protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Fjm5014659&amp;href=/doi/10.1021%2Fjm5014659" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2014</span></span><span class="cit-volume">, 57</span><span class="cit-issue">, 23</span><span class="cit-pageRange">, 9889â9900</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">November 19, 2014</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>1 July 2014</li><li><span class="item_label"><b>Published</b> online</span>1 December 2014</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 11 December 2014</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/jm5014659" title="DOI URL">https://doi.org/10.1021/jm5014659</a></div><div class="article_header-article-copyright"><strong>Copyright Â© 2014 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D9889%26pageCount%3D12%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DGuangxin%2BXia%252C%2BWenteng%2BChen%252C%2BJing%2BZhang%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D57%26issueNum%3D23%26contentID%3Djm5014659%26title%3DA%2BChemical%2BTuned%2BStrategy%2Bto%2BDevelop%2BNovel%2BIrreversible%2BEGFR-TK%2BInhibitors%2Bwith%2BImproved%2BSafety%2Band%2BPharmacokinetic%2BProfiles%26numPages%3D12%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D9900%26publicationDate%3DDecember%2B2014">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/jm5014659"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">3901</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">40</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/jm5014659" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;A Chemical Tuned Strategy to Develop Novel Irreversible EGFR-TK Inhibitors with Improved Safety and Pharmacokinetic Profiles&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Guangxin&quot;,&quot;last_name&quot;:&quot;Xia&quot;},{&quot;first_name&quot;:&quot;Wenteng&quot;,&quot;last_name&quot;:&quot;Chen&quot;},{&quot;first_name&quot;:&quot;Jing&quot;,&quot;last_name&quot;:&quot;Zhang&quot;},{&quot;first_name&quot;:&quot;Jiaan&quot;,&quot;last_name&quot;:&quot;Shao&quot;},{&quot;first_name&quot;:&quot;Yong&quot;,&quot;last_name&quot;:&quot;Zhang&quot;},{&quot;first_name&quot;:&quot;Wei&quot;,&quot;last_name&quot;:&quot;Huang&quot;},{&quot;first_name&quot;:&quot;Leduo&quot;,&quot;last_name&quot;:&quot;Zhang&quot;},{&quot;first_name&quot;:&quot;Weixing&quot;,&quot;last_name&quot;:&quot;Qi&quot;},{&quot;first_name&quot;:&quot;Xing&quot;,&quot;last_name&quot;:&quot;Sun&quot;},{&quot;first_name&quot;:&quot;Bojun&quot;,&quot;last_name&quot;:&quot;Li&quot;},{&quot;first_name&quot;:&quot;Zhixiong&quot;,&quot;last_name&quot;:&quot;Xiang&quot;},{&quot;first_name&quot;:&quot;Chen&quot;,&quot;last_name&quot;:&quot;Ma&quot;},{&quot;first_name&quot;:&quot;Jia&quot;,&quot;last_name&quot;:&quot;Xu&quot;},{&quot;first_name&quot;:&quot;Hailin&quot;,&quot;last_name&quot;:&quot;Deng&quot;},{&quot;first_name&quot;:&quot;Yufeng&quot;,&quot;last_name&quot;:&quot;Li&quot;},{&quot;first_name&quot;:&quot;Ping&quot;,&quot;last_name&quot;:&quot;Li&quot;},{&quot;first_name&quot;:&quot;Hong&quot;,&quot;last_name&quot;:&quot;Miao&quot;},{&quot;first_name&quot;:&quot;Jiansheng&quot;,&quot;last_name&quot;:&quot;Han&quot;},{&quot;first_name&quot;:&quot;Yanjun&quot;,&quot;last_name&quot;:&quot;Liu&quot;},{&quot;first_name&quot;:&quot;Jingkang&quot;,&quot;last_name&quot;:&quot;Shen&quot;},{&quot;first_name&quot;:&quot;Yongping&quot;,&quot;last_name&quot;:&quot;Yu&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2014&quot;,&quot;month&quot;:&quot;12&quot;,&quot;day&quot;:&quot;01&quot;,&quot;issue&quot;:&quot;23&quot;,&quot;volume&quot;:&quot;57&quot;,&quot;pages&quot;:&quot;9889-9900&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/jm5014659&quot;},&quot;abstract&quot;:&quot;Gatekeeper T790 M mutation in EGFR is the most prevalent factor underlying acquired resistance. Acrylamide-bearing quinazoline derivatives are powerful irreversible inhibitors for overcoming resistance. Nevertheless, concerns about the risk of nonspecific covalent modification have motivated the development of novel cysteine-targeting inhibitors. In this paper, we demonstrate that fluoro-substituted olefins can be tuned to alter Michael addition reactivity. Incorporation of these olefins into the quinazoline templates produced potent EGFR inhibitors with improved safety and pharmacokinetic properties. A lead compound 5a was validated against EGFRWT, EGFRT790M as well as A431 and H1975 cancer cell lines. Additionally, compound 5a displayed a weaker inhibition against the EGFR-independent cancer cell line SW620 when compared with afatinib. Oral administration of 5a at a dose of 30 mg/kg induced tumor regression in a murine-EGFRL858R/T790M driven H1975 xenograft model. Also, 5a exhibited improved oral bioavailab&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Fjm5014659&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm5014659" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm5014659&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=jm5014659" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm5014659&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=jm5014659" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Fjm5014659&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm5014659&amp;href=/doi/10.1021/jm5014659" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/jm5014659" /></input><a href="/doi/pdf/10.1021/jm5014659" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (2 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/jm5014659&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Fjm5014659%26sid%3Dliteratum%253Aachs%26pmid%3D25409491%26genre%3Darticle%26aulast%3DXia%26date%3D2014%26atitle%3DA%2BChemical%2BTuned%2BStrategy%2Bto%2BDevelop%2BNovel%2BIrreversible%2BEGFR-TK%2BInhibitors%2Bwith%2BImproved%2BSafety%2Band%2BPharmacokinetic%2BProfiles%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D57%26issue%3D23%26spage%3D9889%26epage%3D9900%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">Â»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=290896" title="Cells">Cells</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/57/23" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jmcmar.2014.57.issue-23/20141211/jmcmar.2014.57.issue-23.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm5014659/20141205/images/medium/jm-2014-014659_0001.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm5014659/20141205/images/large/jm-2014-014659_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5014659&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Gatekeeper T790 M mutation in EGFR is the most prevalent factor underlying acquired resistance. Acrylamide-bearing quinazoline derivatives are powerful irreversible inhibitors for overcoming resistance. Nevertheless, concerns about the risk of nonspecific covalent modification have motivated the development of novel cysteine-targeting inhibitors. In this paper, we demonstrate that fluoro-substituted olefins can be tuned to alter Michael addition reactivity. Incorporation of these olefins into the quinazoline templates produced potent EGFR inhibitors with improved safety and pharmacokinetic properties. A lead compound <b>5a</b> was validated against EGFR<sup>WT</sup>, EGFR<sup>T790M</sup> as well as A431 and H1975 cancer cell lines. Additionally, compound <b>5a</b> displayed a weaker inhibition against the EGFR-independent cancer cell line SW620 when compared with afatinib. Oral administration of <b>5a</b> at a dose of 30 mg/kg induced tumor regression in a murine-EGFR<sup>L858R/T790M</sup> driven H1975 xenograft model. Also, <b>5a</b> exhibited improved oral bioavailability and safety as well as favorable tissue distribution properties and enhanced brain uptake. These findings provide the basis of a promising strategy toward the treatment of NSCLC patients with drug resistance.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_35540" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_35540" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The ErbB family kinases play a crucial regulatory role associated with a variety of malignancies, making this protein family an attractive drug target.<a onclick="showRef(event, 'ref1 ref2 ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref1 ref2 ref3 ref4">(1-4)</a> Despite the demonstrated clinical efficacy of reversible EGFR-TKIs,<a onclick="showRef(event, 'ref5 ref6'); return false;" href="javascript:void(0);" class="ref ref5 ref6">(5, 6)</a> not all patients with cancer respond to such treatment. The short-lived clinical outcome is partly due to the acquired drug resistant mutations in EGFR, which affect roughly 50% of the treated population.<a onclick="showRef(event, 'ref7 ref8'); return false;" href="javascript:void(0);" class="ref ref7 ref8">(7, 8)</a> The elucidated resistance mechanisms may be circumvented by irreversible kinase inhibitors. These inhibitors all rely on an acrylamide electrophilic warhead that forms a covalent bond with a conserved cysteine residue in EGFR (Cys797). The results enable a greater occupancy of the ATP binding site than is found with the reversible inhibitors, thus providing the ability to prolong the time of exposure and circumvent drug resistance.<a onclick="showRef(event, 'ref9 ref10'); return false;" href="javascript:void(0);" class="ref ref9 ref10">(9, 10)</a>Afatinib, an irreversible EGFR-TKI, was approved by the FDA for the treatment of patients with metastatic NSCLC in 2013.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> However, these irreversible kinase inhibitors all contain with a reactive âwarheadâ which can irreversibly bind to proteins other than the target, creating a toxicity burden.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a></div><div class="NLM_p last">In this study, we sought to exploit novel irreversible EGFR inhibitors to overcome the problem of drug resistance and to reduce the risk of nonspecific covalent binding.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> To this end, we focused on replacement of the acrylamide function by alternative and less reactive electrophiles. A novel quinazoline analogue bearing fluoro-substituted olefins was designed and synthesized. Their EGFR kinase inhibitory activity, in vitro antiproliferative effects as well as preliminary pharmacokinetic studies and in vivo antitumor efficacy were evaluated. Consequently some compounds with greater potency and superior safety index were identified. A lead compound <b>5a</b> was found to effectively inhibit EGFR<sup>WT</sup>, EGFR<sup>T790M</sup> as well as A431 and H1975 cancer cell lines. Oral administration of <b>5a</b> led to tumor regression in a murine-EGFR<sup>L858R/T790M</sup> driven H1975 xenograft model. Also, <b>5a</b> exhibited improved oral bioavailability, as well as favorable tissue distribution properties, increased safety index, and enhanced brain uptake. These findings provide a promising strategy for the development of novel treatments for NSCLC patients with drug resistance.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_22780" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_22780" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i3" class="anchor-spacer"></div><h3 class="article-section__title" id="_i3"> Chemistry</h3><div class="NLM_p">Attenuated electrophiles have a reduced likelihood of reacting irreversibly with off-target proteins.<a onclick="showRef(event, 'cit14a cit14b'); return false;" href="javascript:void(0);" class="ref cit14a cit14b">(14a, 14b)</a> Because of the high electronegativity, small size, and special chemical reactivity with respect to hydrogen, we hypothesized the replacement of hydrogen at the Î±-position of acrylamide with fluorine would chemically tune the Michael-type conjugate addition. To test this hypothesis, two simple Michael acceptors, <i>N</i>-phenylacrylamide (<b>A</b>) and 2-fluoro-<i>N</i>-phenylacrylamide (<b>B</b>), were synthesized and evaluated the Michael addition reaction rate with reduced glutathione (GSH) (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>). Each compound was reacted separately with 10.0 equiv of GSH in PBS buffer at pH = 7.0, and the reactions were monitored by HPLC-HRMS. The results indicate that the conjugation reaction of <b>A</b> and GSH is significantly faster than that of <b>B</b>, with the production of the thioether adduct being 95.4% and 20.7%, respectively (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>). Increasing concentrations of GSH was found to cause a stepwise decrease in the prominent UVâvisible absorption band of <b>B</b> (Î» = 214 nm). Fitting the titration data provides an apparent <i>k</i><sub>d</sub> of 33.3 mM (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>-c). We anticipated that the slower model reaction between GSH and <b>B</b> would possibly result in less nonspecific covalent modification during binding to target proteins.<a onclick="showRef(event, 'cit14c'); return false;" href="javascript:void(0);" class="ref cit14c">(14c)</a> Also, incorporation of fluorine into small molecules has been previously employed to optimize drug-like properties, such as changes in cell uptake, tissue distribution, metabolic stability, and improved pharmacokinetic properties.<a onclick="showRef(event, 'ref15 ref16 ref17 ref18'); return false;" href="javascript:void(0);" class="ref ref15 ref16 ref17 ref18">(15-18)</a> Consequently, we focused our efforts on the development of the fluoro-substituted olefin as a novel cysteine capture group.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm5014659/20141205/images/medium/jm-2014-014659_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm5014659/20141205/images/large/jm-2014-014659_0003.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. GSH conjugate addition to fluoro-substituted olefins. (1-a) model reaction between <i>N</i>-phenylacrylamide (A) or 2-fluoro-<i>N</i>-phenylacrylamide (B) and reduced GSH in PBS buffer. (1-b) Conjugate addition reactions of GSH (10 mM) with <b>A</b> (1 mM) or <b>B</b> (1 mM) at various time points (0â1440 min) and monitored by HPLC-HRMS. (1-c) <b>B</b> (1 mM) was treated with increasing concentrations of GSH (10â200 mM) and monitored by HPLC-HRMS.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm5014659/20141205/images/large/jm-2014-014659_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5014659&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Using a structure-based approach, quinazoline analogues bearing different geometric Î±-fluoro acrylamides were designed and synthesized. Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a> depicts the synthetic route for compounds <b>1</b>â<b>12</b>. Compounds <b>IV</b> are synthesized by coupling their precursor amines (<b>III</b>) with the desired carboxylic acid (<b>II</b>). 6-Amino-4-anilinoquinazoline (<b>III</b>) is prepared in six steps from commercially available 2-amino-4-fluorobenzoic acid as previously reported.<a onclick="showRef(event, 'ref19 ref20'); return false;" href="javascript:void(0);" class="ref ref19 ref20">(19, 20)</a> The selective hydrolysis of phosphate (<b>I</b>) affords the corresponding 2-(diethoxyphosphoryl)-2-fluoroacetic acid (<b>II</b>) in excellent yield.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> A HornerâWadsworthâEmmons olefination of the quinozoline intermediates (<b>IV</b>) and the substituted aldehydes (<b>VIII</b>) provides a mixture of isomers (<b>1</b>â<b>12</b>) in good yield.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> The corresponding aldehydes are prepared in two steps from secondary amines (<b>V</b>) by substitution with 2-bromo-1,1-dimethoxyethane (<b>VI</b>) and deprotection of the acetal in conc HCl.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> The isomers (<b>1</b>â<b>12</b>) were separated by semiprep HPLC or Thar SFC Pre80 for biological testing.</div><figure id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm5014659/20141205/images/medium/jm-2014-014659_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm5014659/20141205/images/large/jm-2014-014659_0008.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Compounds <b>1</b>â<b>12</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm5014659/20141205/images/large/jm-2014-014659_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5014659&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Conditions and reagents: (a) NaOH, EtOH, 0â5 Â°C; (b) (COCl<sub>2</sub>), Et<sub>3</sub>N, DCM/DMF, 0 Â°Cârt; (c) K<sub>2</sub>CO<sub>3</sub>, DMF, 90 Â°C; (d) conc HCl, relux; (e) NaOH, EtOHâH<sub>2</sub>O, rt.</p></p></figure><div class="NLM_p">Compound <b>5a</b> was selected to react with GSH under physiological conditions for 120 min (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>). In comparison to afatinib, compound <b>5a</b> produced the conjugate adduct slowly, only 3% of thioether was detected (afatinib: 66.5%). This result revealed that compound <b>5a</b> reacted more slowly with the thiol of GSH, potentially minimizing its chemical reactivity toward nonspecific targets.</div><figure id="fig2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm5014659/20141205/images/medium/jm-2014-014659_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm5014659/20141205/images/large/jm-2014-014659_0004.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. GSH conjugate addition of afatinib or compound <b>5a</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm5014659/20141205/images/large/jm-2014-014659_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5014659&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5"> Biological Evaluation</h3><div class="NLM_p">To determine the in vitro potency, compounds <b>1</b>â<b>12</b> were screened against wild-type EGFR, T790 M mutant EGFR, and HER2. Significant potency differences were observed among the compounds <b>1</b>â<b>12</b>, with distinct patterns of inhibition noted for the two types of EGFR kinases (IC<sub>50</sub> values range from 0.18 to 59.8 nM) (Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>). The biological assay results show some differences in activity based on the geometric arrangement of the analogues. For instance, the IC<sub>50</sub> values for compounds <b>5a</b> and <b>5b</b> on EGFR<sup>T790M</sup> were 5.52 and 25.8 nM, respectively. The same trend was observed for <b>4a/4b</b> (<b>4a</b>, 21.3 nM; <b>4b</b>, 42.9 nM). The <i>trans</i>-isomers displayed more potent than the <i>cis</i>-isomers in the EGFR<sup>T790M</sup> kinase assay. On the other hand, the profile against HER2 shows that quinazoline analogues bearing Î±-fluoro acrylamide are 2.5â89-fold less potent than afatinib (IC<sub>50</sub> = 17.3 nM), with the exception of compound <b>3a</b> (IC<sub>50</sub> = 1.38 nM). Activities of compounds <b>1</b>â<b>12</b> against tumor cells expressing EGFR mutations are demonstrated in two cancer cell lines (Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>). Gefitinib-sensitive cell line A431 is an epidermoid cell that is driven by amplified wild-type EGFR. Gefitinib-resistant cell line NCI-H1975 harbors the EGFR<sup>L858R/T790M</sup> double mutation. The most enzymatically potent compounds, <b>1a</b>, <b>3a</b>, and <b>5a</b>, also exhibit potent growth inhibitory activities in the A431 cells with IC<sub>50</sub> values of 0.55, 0.34, and 0.13 Î¼M, respectively, and are more potent than gefitinib. More importantly, compounds <b>1a</b>, <b>3a</b>, and <b>5a</b> display high inhibitory activities against the growth of gefitinib-resistant H1975 cells, similar to the effects of afatinib. Together, six hit compounds were identified that retained similar in vitro potency to afatinib (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>).</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. In Vitro Antiproliferative Activities against Gefitinib-Sensitive and -Resistant Cell Lines and the EGFR-TK Inhibitory Activities of Compounds <b>1</b>â<b>12</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm5014659/20141205/images/medium/jm-2014-014659_0009.gif" alt="" id="fx1" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm5014659/20141205/images/medium/jm-2014-014659_0010.gif" alt="" id="fx2" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>Table a</sup><p class="last">The antiproliferative activities of the compounds were evaluated using the CellTiter-Glo (Promega) Kit assay. The data shown are the means from three independent experiments.</p></div><div class="footnote" id="t1fn2"><sup>Table b</sup><p class="last">The kinase inhibitory activities of the compounds were evaluated using the Homogeneous time-resolved fluorescence (HTRF) method (Cisbio) assay. The data shown are the means from three independent experiments.</p></div></div><div></div></div><figure id="fig3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm5014659/20141205/images/medium/jm-2014-014659_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm5014659/20141205/images/large/jm-2014-014659_0005.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Antiproliferative activities and the kinase inhibitory activities of selected compounds. IC<sub>50</sub> values for A431 (4-a), NSCLC H1975 cell (4-b), EGFR<sup>WT</sup> (4-c), EGFR<sup>T790M</sup> (4-d), and HER2 (4-e), treated with indicated drugs. Values were calculated from at least eight data points. In general three independent determinations were performed.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm5014659/20141205/images/large/jm-2014-014659_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5014659&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The specificity of one of the most potent compounds, <b>1a</b>, was profiled against a commercial panel of 16 kinases (Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>). These kinases contain a cysteine residue that is sufficiently sensitive for electrophilic modification by many drugs, such as Akt1 (Cy296/Cys310), PDGFRÎ± (Cys814), FGFR2 (Cys486), and Src (Cys345).<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> As shown in Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>, compound <b>1a</b> demonstrates a favorable selectivity profile. EGFR<sup>WT</sup> and EGFR<sup>T790M</sup> are the only two kinases that experience marked inhibition (IC<sub>50</sub> of 0.20 and 6.67 nM, respectively). These findings confirm that attenuated electrophiles conjugated to quinazolines would have a reduced likelihood of reacting with nonspecific proteins.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Selectivity Profiles for Compound <b>1a</b> versus a Panel of 16 Kinase Targets<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="left" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">kinase</th><th class="colsep0 rowsep0" align="center" char=".">IC<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" align="center">kinase</th><th class="colsep0 rowsep0" align="center" char=".">IC<sub>50</sub> (nM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">EGFR</td><td class="colsep0 rowsep0" align="char" char=".">0.20</td><td class="colsep0 rowsep0" align="left">AlK</td><td class="colsep0 rowsep0" align="char" char=".">>10000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">EGFR<sup>T790M</sup></td><td class="colsep0 rowsep0" align="char" char=".">6.67</td><td class="colsep0 rowsep0" align="left">AKT1</td><td class="colsep0 rowsep0" align="char" char=".">>10000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HER2</td><td class="colsep0 rowsep0" align="char" char=".">75.0</td><td class="colsep0 rowsep0" align="left">AKT2</td><td class="colsep0 rowsep0" align="char" char=".">>10000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HER4</td><td class="colsep0 rowsep0" align="char" char=".">23.0</td><td class="colsep0 rowsep0" align="left">c-Met</td><td class="colsep0 rowsep0" align="char" char=".">>10000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PDGFRÎ±</td><td class="colsep0 rowsep0" align="char" char=".">3596</td><td class="colsep0 rowsep0" align="left">FGFR2</td><td class="colsep0 rowsep0" align="char" char=".">>10000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PDGFRÎ²</td><td class="colsep0 rowsep0" align="char" char=".">2102</td><td class="colsep0 rowsep0" align="left">FLT3</td><td class="colsep0 rowsep0" align="char" char=".">6810</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">JAK2</td><td class="colsep0 rowsep0" align="char" char=".">>10000</td><td class="colsep0 rowsep0" align="left">ABL</td><td class="colsep0 rowsep0" align="char" char=".">2262</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">SYK</td><td class="colsep0 rowsep0" align="char" char=".">>10000</td><td class="colsep0 rowsep0" align="left">SRC</td><td class="colsep0 rowsep0" align="char" char=".">1731</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>a</sup><p class="last">The kinase inhibitory activities of the compounds were evaluated using the homogeneous time-resolved fluorescence (HTRF) method (Cisbio) assay. The data shown are the means from three independent experiments.</p></div></div></div><div class="NLM_p">These promising enzymatic and cellular potencies promoted us to further investigate the pharmacokinetic profiles. The influence of geometric isomerism on the compound clearance (Cl<sub>int</sub>) induced in various microsomes demonstrated remarkable differences between <i>cis</i>- and <i>trans</i>- isomer pairs (<a class="ref internalNav" href="#notes-1" aria-label="Supporting Information, Table S1">Supporting Information, Table S1</a> and Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>). The <i>cis</i>-isomer analogues suffer a 5â10-fold reduction in human, rat, and mouse liver microsomal stability when compared to the corresponding <i>trans</i>-isomers. For instance, the Cl<sub>int</sub> values for compounds <b>5a</b> and <b>5b</b> in human microsome were 2 Î¼L/min/mg protein and 60 Î¼L/min/mg protein, respectively. The same trend was observed for <b>2a/2b</b> (<b>2a</b>, 37 Î¼L/min/mg protein; <b>2b</b>, 151 Î¼L/min/mg protein), <b>4a</b>/<b>4b</b> (<b>4a</b>, 22 Î¼L/min/mg protein; <b>4b</b>, 124 Î¼L/min/mg protein) and <b>6a</b>/<b>6b</b> (<b>6a</b>, 18 Î¼L/min/mg protein; <b>6b</b>, 190 Î¼L/min/mg protein). Replacing the <i>N</i>,<i>N</i>-dimethyl group of compound <b>1a</b> with a polar piperidine obtained compound <b>2a</b> with an increasing dog LM stability (<b>1a</b>, 194 Î¼L/min/mg protein, vs <b>2a</b>, 34 Î¼L/min/mg protein). Modifying the 7-position of compound <b>1a</b> with (<i>S</i>)-tetrahydrofuran-3-ol led to compound <b>5a</b> with a remarkable increase in microsomal stability (HLM, RLM, mouse LM, dog LM, and monkey LM). These compounds were also evaluated for their ability to inhibit the major drug metabolizing enzymes. The inhibition of cytochrome P450 enzymes (CYPs) was evaluated by determining the activity of the compounds against CYPs 3A4, 2D6, 2C9, 1A2, and 2C19 in human liver microsomes. The results reveal essentially no inhibition, with IC<sub>50</sub> values >10 Î¼M (<a class="ref internalNav" href="#notes-1" aria-label="Supporting Information, Table S2">Supporting Information, Table S2</a> and Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>).</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Microsomal Stability and CYPs Inhibition Study of Selected Compounds</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">Â </th><th class="rowsep1 colsep0" colspan="5" align="center" char=".">Cl<sub>int</sub> (Î¼L/min/mgÂ protein)</th><th class="rowsep1 colsep0" align="center" char=".">IC<sub>50</sub> (Î¼M)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center" char=".">HLM</th><th class="colsep0 rowsep0" align="center" char=".">RLM</th><th class="colsep0 rowsep0" align="center" char=".">mouse LM</th><th class="colsep0 rowsep0" align="center" char=".">dog LM</th><th class="colsep0 rowsep0" align="center" char=".">monkey LM</th><th class="colsep0 rowsep0" align="center" char=".">CYPs inhibition (3A4, 2D6, 2C9, 1A2, andÂ 2C19)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1a</b></td><td class="colsep0 rowsep0" align="char" char=".">14</td><td class="colsep0 rowsep0" align="char" char=".">18</td><td class="colsep0 rowsep0" align="char" char=".">45</td><td class="colsep0 rowsep0" align="char" char=".">194</td><td class="colsep0 rowsep0" align="char" char=".">128</td><td class="colsep0 rowsep0" align="char" char=".">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2a</b></td><td class="colsep0 rowsep0" align="char" char=".">37</td><td class="colsep0 rowsep0" align="char" char=".">11</td><td class="colsep0 rowsep0" align="char" char=".">31</td><td class="colsep0 rowsep0" align="char" char=".">34</td><td class="colsep0 rowsep0" align="char" char=".">102</td><td class="colsep0 rowsep0" align="char" char=".">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>3a</b></td><td class="colsep0 rowsep0" align="char" char=".">27</td><td class="colsep0 rowsep0" align="char" char=".">33</td><td class="colsep0 rowsep0" align="char" char=".">47</td><td class="colsep0 rowsep0" align="char" char=".">95</td><td class="colsep0 rowsep0" align="char" char=".">97</td><td class="colsep0 rowsep0" align="char" char=".">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5a</b></td><td class="colsep0 rowsep0" align="char" char=".">2</td><td class="colsep0 rowsep0" align="char" char=".">14</td><td class="colsep0 rowsep0" align="char" char=".">12</td><td class="colsep0 rowsep0" align="char" char=".">39</td><td class="colsep0 rowsep0" align="char" char=".">31</td><td class="colsep0 rowsep0" align="char" char=".">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">canertinib</td><td class="colsep0 rowsep0" align="char" char=".">50</td><td class="colsep0 rowsep0" align="char" char=".">105</td><td class="colsep0 rowsep0" align="char" char=".">5</td><td class="colsep0 rowsep0" align="char" char=".">26</td><td class="colsep0 rowsep0" align="char" char=".">221</td><td class="colsep0 rowsep0" align="char" char=".">Â </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">afatinib</td><td class="colsep0 rowsep0" align="char" char=".">8</td><td class="colsep0 rowsep0" align="char" char=".">12</td><td class="colsep0 rowsep0" align="char" char=".">6</td><td class="colsep0 rowsep0" align="char" char=".">9</td><td class="colsep0 rowsep0" align="char" char=".">24</td><td class="colsep0 rowsep0" align="char" char=".">Â </td></tr></tbody></table></div></div><div class="NLM_p">Selected <i>trans</i>-isomers were further evaluated for their great potency. The pharmacokinetic profiles in BALB/c mice are summarized in <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information, Table S3">Supporting Information, Table S3</a>, and Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a>.</div><div class="NLM_p">Encouragingly, our studies demonstrated that the selected <i>trans</i>-isomers possessed greater oral bioavailability, higher maximal plasma concentration, and lower clearance rates than that of afatinib at an oral dose of 10 mg/kg. Also, the <i>cis</i>-isomer <b>2b</b> exhibited a reduced oral bioavailability (<i>F</i> = 16.5%) compared with its <i>trans</i>-isomer pair <b>2a</b>.</div><div class="NLM_p">The concentration of selected compounds in various tissues was detected at multiple time points over 6 h following a 30 mg/kg oral dose in BALB/c mice (Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a> and <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information, Table S4âS7">Supporting Information, Table S4âS7</a>). The mean drug concentration of all tested compounds in the lung is 10â25-fold higher than in plasma. Additionally, the concentration in the brain is higher than that of afatinib, especially with compounds <b>2a</b> and <b>5a</b>. This indicates that the quinazoline analogues bearing fluoro-substituted olefins experience enhanced brain uptake thereby rendering them viable for the treatment of NSCLC patients with brain metastasis. Also, the hERG potassium channel patch clamp assay<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> shows that the selected compounds have an IC<sub>50</sub> > 10 Î¼M. These results indicate that these analogues have minimal potential for cardiac toxicity (Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a>).</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Pharmacokinetic Properties of Selected Compounds in BALB/c Mice</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center" char=".">AUC(0ââ) (PO,Â Î¼MÂ·min)</th><th class="colsep0 rowsep0" align="center" char="."><i>C</i><sub>max</sub> (PO,Â Î¼M)</th><th class="colsep0 rowsep0" align="center" char=".">CL<sub>z</sub> (L/min/kg)</th><th class="colsep0 rowsep0" align="center" char="."><i>V</i><sub>z</sub> (L/kg)</th><th class="colsep0 rowsep0" align="center" char="."><i>F</i> (%)</th><th class="colsep0 rowsep0" align="center">lung/plasma/brain ratio<a class="ref internalNav" href="#t4fn3" aria-label="c">c</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1a</b><a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="char" char=".">460</td><td class="colsep0 rowsep0" align="char" char=".">0.79</td><td class="colsep0 rowsep0" align="char" char=".">0.05</td><td class="colsep0 rowsep0" align="char" char=".">14.0</td><td class="colsep0 rowsep0" align="char" char=".">98.5</td><td class="colsep0 rowsep0" align="center">nd<a class="ref internalNav" href="#t4fn4" aria-label="d">d</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2a</b><a class="ref internalNav" href="#t4fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="char" char=".">306</td><td class="colsep0 rowsep0" align="char" char=".">0.83</td><td class="colsep0 rowsep0" align="char" char=".">0.04</td><td class="colsep0 rowsep0" align="char" char=".">7.14</td><td class="colsep0 rowsep0" align="char" char=".">105</td><td class="colsep0 rowsep0" align="center">20/1.0/2.31</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2b</b><a class="ref internalNav" href="#t4fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="char" char=".">14.7</td><td class="colsep0 rowsep0" align="char" char=".">0.09</td><td class="colsep0 rowsep0" align="char" char=".">0.12</td><td class="colsep0 rowsep0" align="char" char=".">12.2</td><td class="colsep0 rowsep0" align="char" char=".">16.5</td><td class="colsep0 rowsep0" align="center">nd<a class="ref internalNav" href="#t4fn4" aria-label="d">d</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>3a</b><a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="char" char=".">994</td><td class="colsep0 rowsep0" align="char" char=".">2.66</td><td class="colsep0 rowsep0" align="char" char=".">0.02</td><td class="colsep0 rowsep0" align="char" char=".">3.94</td><td class="colsep0 rowsep0" align="char" char=".">89.4</td><td class="colsep0 rowsep0" align="center">11/1.0/0.29</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5a</b><a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="char" char=".">625</td><td class="colsep0 rowsep0" align="char" char=".">0.94</td><td class="colsep0 rowsep0" align="char" char=".">0.03</td><td class="colsep0 rowsep0" align="char" char=".">9.69</td><td class="colsep0 rowsep0" align="char" char=".">84.7</td><td class="colsep0 rowsep0" align="center">25/1.0/0.79</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">afatinib<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="char" char=".">29.4</td><td class="colsep0 rowsep0" align="char" char=".">0.13</td><td class="colsep0 rowsep0" align="char" char=".">0.27</td><td class="colsep0 rowsep0" align="char" char=".">36.2</td><td class="colsep0 rowsep0" align="char" char=".">37.4</td><td class="colsep0 rowsep0" align="center">18/1.0/0.14</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup>a</sup><p class="last">Compound <b>1a</b>, <b>3a</b>, <b>5a</b>, and afatinib were administered PO to fed male BALB/c mice at a dose of 10 mg/kg.</p></div><div class="footnote" id="t4fn2"><sup>b</sup><p class="last">Compound <b>2a</b> and <b>2b</b> were administered PO to fed male BALB/c mice at a dose of 5 mg/kg.</p></div><div class="footnote" id="t4fn3"><sup>c</sup><p class="last">Compounds <b>2a</b>, <b>3a</b>, <b>5a</b>, and afatinib were administered PO at a dose of 30 mg/kg.</p></div><div class="footnote" id="t4fn4"><sup>d</sup><p class="last">Not detected.</p></div></div></div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Inhibition of hERG Currents by Compounds <b>1a</b>, <b>2a</b>, <b>3a</b>, <b>4a</b>, <b>5a</b>, and <b>5b</b></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="center" /></col><col align="char" char="Â±" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center" char=".">no. of cells tested</th><th class="colsep0 rowsep0" align="center">% inhibition at 1Â Î¼M</th><th class="colsep0 rowsep0" align="center" char="Â±">% inhibition at 10Â Î¼M</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1a</b></td><td class="colsep0 rowsep0" align="char" char=".">4</td><td class="colsep0 rowsep0" align="center">2.55Â Â±Â 3.92</td><td class="colsep0 rowsep0" align="char" char="Â±">18.4Â Â±Â 3.71</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2a</b></td><td class="colsep0 rowsep0" align="char" char=".">4</td><td class="colsep0 rowsep0" align="center">0.71Â Â±Â 1.22</td><td class="colsep0 rowsep0" align="char" char="Â±">11.8Â Â±Â 5.98</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>3a</b></td><td class="colsep0 rowsep0" align="char" char=".">4</td><td class="colsep0 rowsep0" align="center">0Â Â±Â 0</td><td class="colsep0 rowsep0" align="char" char="Â±">3.06Â Â±Â 3.49</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4a</b></td><td class="colsep0 rowsep0" align="char" char=".">4</td><td class="colsep0 rowsep0" align="center">0.94Â Â±Â 1.64</td><td class="colsep0 rowsep0" align="char" char="Â±">11.1Â Â±Â 2.34</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5a</b></td><td class="colsep0 rowsep0" align="char" char=".">3</td><td class="colsep0 rowsep0" align="center">0Â Â±Â 0</td><td class="colsep0 rowsep0" align="char" char="Â±">14.8Â Â±Â 4.15</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5b</b></td><td class="colsep0 rowsep0" align="char" char=".">4</td><td class="colsep0 rowsep0" align="center">6.37Â Â±Â 7.28</td><td class="colsep0 rowsep0" align="char" char="Â±">39.5Â Â±Â 4.76</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">cisapride</td><td class="colsep0 rowsep0" align="char" char=".">2</td><td class="colsep0 rowsep0" align="center">92.4Â Â±Â 3.47 at 1 Î¼M (65.5Â Â±Â 0.1 at 0.1Â Î¼M)</td><td class="colsep0 rowsep0" align="char" char="Â±">Â </td></tr></tbody></table></div></div><div class="NLM_p">The cytotoxicity of compound <b>5a</b>, afatinib, and doxorubicin against the colon cancer cell line SW620 was also evaluated. The colon cancer cell line SW620 expresses neither EGFR nor HER-2 to a significant extent and therefore is a good counterscreen cell line for EGFR-targeting inhibitors. As shown in Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>, compound <b>5a</b> exhibited only an 11.5% growth inhibition of the cancer cell line SW620 at a concentration of 5 Î¼M. In contrast, at the concentration of 5 Î¼M, both afatinib and doxorubicin exhibited inhibition of 78.0% and 79.8%, respectively. These results indicate that compound <b>5a</b> possesses less cytotoxicity against the EGFR-independent cell line SW620 when compared to afatinib and doxorubicin.</div><figure id="fig4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm5014659/20141205/images/medium/jm-2014-014659_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm5014659/20141205/images/large/jm-2014-014659_0006.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Cytotoxicity comparison of compound <b>5a</b> and afatinib in EGFR-independent cancer cell line SW620.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm5014659/20141205/images/large/jm-2014-014659_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5014659&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Given the potent inhibition of EGFR<sup>T790M</sup> kinase and H1975 cell growth, together with the promising pharmacokinetic properties, the in vivo antitumor efficacy of compounds <b>2a</b>, <b>3a</b>, and <b>5a</b> were evaluated using an EGFR<sup>L858R/T790M</sup>-driven human H1975 xenograft mouse model. The tumor growth values (<i>T</i>/<i>C</i>%) of compounds <b>2a</b>, <b>3a</b>, <b>5a</b>, and afatinib were found to be 67.4%, 15.6%, 19.5%, and 30.3% at a dose of 30 mg/kg/day, respectively (Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a> and <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information, Figure S1">Supporting Information, Figure S1</a>). In addition, compound <b>5a</b> displays dose-dependent inhibition of tumor growth. The <i>T</i>/<i>C</i> values are 42.5%, 19.5%, and 9.4% at dosages of 15, 30, and 60 mg/kg/day, respectively (Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>). Importantly, the compound <b>5a</b> is well-tolerated, with no mortality or significant loss of body weight observed during treatment at a dose of 30 mg/kg.</div><figure id="fig5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm5014659/20141205/images/medium/jm-2014-014659_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm5014659/20141205/images/large/jm-2014-014659_0007.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Effect on tumor volume in xenograft model of H1975 of compounds <b>2a</b>, <b>3a</b>, <b>5a</b>, and afatinib. (<i>T</i>/<i>C</i> (%) = mean RTV of the treated group/mean RTV of the control group Ã 100%. The individual relative tumor volume (RTV) was calculated as follows: RTV = <i>V</i><sub>t</sub>/<i>V</i><sub>0</sub>, where <i>V</i><sub>t</sub> is the volume on each day of measurement, and <i>V</i><sub>0</sub> is the volume on the day of initial treatment.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm5014659/20141205/images/large/jm-2014-014659_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5014659&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i11">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_66852" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_66852" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">In this study, we report a new chemically tuned strategy to alter the overall biological profile of covalent EGFR inhibitors. The lead compound <b>5a</b> exhibited potent inhibition of EGFR mutation T790 M as well as gefitinib-resistant cell line H1975. Additionally, compound <b>5a</b> displayed weak inhibition against SW620, an EGFR-independent cell line. Further studies showed that compound <b>5a</b> possessed good pharmacokinetic profiles, favorable tissue distribution as well as an acceptable safety index. An in vivo antitumor efficacy study demonstrated that <b>5a</b> significantly inhibited tumor growth in an EGFR<sup>L858R/T790M</sup>-driven human NSCLC xenograft nude mouse model of H1975 at a dose of 30 mg/kg/day. The biological results demonstrate that compound <b>5a</b>, a quinazoline derivative bearing fluoro-substituted olefin tuned to alter Michael addition reactivity, is more potent and less toxic than afatinib. These findings provide the basis of a promising strategy toward the development of novel inhibitors with enhanced biological profiles.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i12">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_87181" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_87181" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> General Procedure</h3><div class="NLM_p">Unless otherwise noted, all solvents and chemicals were used as purchased without further purification. <sup>1</sup>H NMR spectra were recorded on a Bruker DRX-500 [Bruker Biospin, Germany], Bruker AVANCE III-400, and Varian Mercury-300. Chemical shifts are reported in ppm relative to the residual solvent peak (CDCl<sub>3</sub>, TMS: 0.00). Multiplicity was indicated as follows: s (singlet); d (doublet); t (triplet); q (quartet); m (multiplet); dd (doublet of doublet); dt (triplet of doublet); td (doublet of triplet); brs (broad singlet), etc. Intermediates were purified by column chromatography on silica gel (200â300 mesh), and the separation of the <i>Z</i>â<i>E</i> isomers were performed on GILSON 215 semiprep HPLC using PhenomenexGimini 10 Î¼m C18, 30 mm Ã 250 mm column at a flow rate of 30 mL/min or Thar SFC Pre80 (supercritical fluid chromatography, SFC) using an Agela AD-H 5 Î¼m, 20 mm Ã 250 mm column at a flow rate of 50 g/min using gradients MeOH (containing 0.1% DEA): CO<sub>2</sub> = 40:60. All reported yields are isolated yields after column chromatography. Purity of all biologically evaluated compounds was determined by HPLC analysis to be >95%. HPLC analysis was performed on Agilent 1200 using Agilent Eclipse XDB-C18 5 Î¼m 4.6 mm Ã 150 mm at a flow rate of 1 mL/min using the listed gradients: (mobile phase A, MeOH; mobile phase B, MeCN; mobile phase C, 0.01 mol/L KH<sub>2</sub>PO<sub>4</sub>, pH = 3.0) (Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a>).</div><div class="NLM_table-wrap" id="tbl6">Table 6<div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center" char=".">t/min</th><th class="colsep0 rowsep0" align="center" char=".">mobile phase AÂ (%)</th><th class="colsep0 rowsep0" align="center" char=".">mobile phase BÂ (%)</th><th class="colsep0 rowsep0" align="center" char=".">mobile phase CÂ (%)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char=".">0</td><td class="colsep0 rowsep0" align="char" char=".">5</td><td class="colsep0 rowsep0" align="char" char=".">0</td><td class="colsep0 rowsep0" align="char" char=".">95</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char=".">1.6</td><td class="colsep0 rowsep0" align="char" char=".">5</td><td class="colsep0 rowsep0" align="char" char=".">0</td><td class="colsep0 rowsep0" align="char" char=".">95</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char=".">8.5</td><td class="colsep0 rowsep0" align="char" char=".">10</td><td class="colsep0 rowsep0" align="char" char=".">20</td><td class="colsep0 rowsep0" align="char" char=".">70</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char=".">13</td><td class="colsep0 rowsep0" align="char" char=".">10</td><td class="colsep0 rowsep0" align="char" char=".">20</td><td class="colsep0 rowsep0" align="char" char=".">70</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char=".">18</td><td class="colsep0 rowsep0" align="char" char=".">15</td><td class="colsep0 rowsep0" align="char" char=".">35</td><td class="colsep0 rowsep0" align="char" char=".">50</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char=".">30</td><td class="colsep0 rowsep0" align="char" char=".">15</td><td class="colsep0 rowsep0" align="char" char=".">50</td><td class="colsep0 rowsep0" align="char" char=".">35</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char=".">35</td><td class="colsep0 rowsep0" align="char" char=".">15</td><td class="colsep0 rowsep0" align="char" char=".">50</td><td class="colsep0 rowsep0" align="char" char=".">35</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char=".">36.5</td><td class="colsep0 rowsep0" align="char" char=".">5</td><td class="colsep0 rowsep0" align="char" char=".">0</td><td class="colsep0 rowsep0" align="char" char=".">95</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char=".">40</td><td class="colsep0 rowsep0" align="char" char=".">5</td><td class="colsep0 rowsep0" align="char" char=".">0</td><td class="colsep0 rowsep0" align="char" char=".">95</td></tr></tbody></table></div></div><div class="NLM_p">The HPLC-HRMS of all compounds was confirmed on a Agilent 1290 HPLC-6224 time-of-flight mass spectrometer using PhenomenexLuna 5 Î¼ C18, 100 Ã, 150 mm Ã 4.60 mm 5 Î¼m column at a flow rate of 0.5 mL/min using liner gradients buffer B in A (B, CH<sub>3</sub>OH containing 0.1% formic acid; A, H<sub>2</sub>O containing 0.1% formic acid). Mobile phase B was increased linearly from 5% to 95% over 7 min and 95% over the next 2 min, after which the column was equilibrated to 5% for 1 min.</div><div id="sec4_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i14" class="anchor-spacer"></div><h4 class="article-section__title" id="_i14"> 2-(Diethoxyphosphoryl)-2-fluoroacetic Acid (<b>II</b>)</h4><div class="NLM_p last">To a solution of 2-(diethoxyphosphinyl)-2-fluoroacetic acid ethyl ester (4.5 g, 18.6 mmol) in 180 mL of ethanol was added a solution of sodium hydroxide (3.72 g, 93 mmol) in water (180 mL) The reaction mixture was stirred for 2 h at â5 Â°C and acidified to pH = 2â3 with 4 N HCl. The reaction mixture was evaporated under reduced pressure at room temperature to give the crude product, and the crude was dissolved in acetone to precipitate the salt, filtered, and the filtrate evaporated under reduced pressure to give the corresponding acid as white waxy solid; yield 95% (3.78 g). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) Î´ 5.27 (dd, <i>J</i> = 47.0, 13.0 Hz, 1H), 4.36â4.26 (m, 4H), 1.42â1.36 (m, 6H). HRMS (ESI): <i>m</i>/<i>z</i> calcd for (C<sub>6</sub>H<sub>12</sub>FO<sub>5</sub>P + H)<sup>+</sup>, 215.0484; found, 215.0494.</div></div><div id="sec4_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i15" class="anchor-spacer"></div><h4 class="article-section__title" id="_i15"> (<i>S</i>)-<i>N</i><sup>4â</sup>(3-Chloro-4-fluorophenyl)-7-((tetrahydrofuran-3-yl) oxy)quinazoline-4,6-diamine (<b>III</b>-<b>a</b>)</h4><div class="NLM_p last">To a solution of (<i>S</i>)-4-(3-chloro-4-fluorophenyl)-7-((tetrahydrofuran-3-yl) oxy)-6-nitro-quinazoline (2.02 g, 5.0 mmol) and NiCl<sub>2</sub>Â·6H<sub>2</sub>O (2.38 g, 10 mmol) in 40 mL of MeOH/DCM (V/V = 1:4) was added NaBH<sub>4</sub> (0.76 g, 20 mmol) at 0 Â°C. The mixture was stirred at 0 Â°C for 30 min then at room temperature for 30 min. The mixture was filtered, and the filtrate was evaporated to dryness under reduce pressure. The crude product was purified by flash column chromatography on silica gel eluting with CH<sub>2</sub>Cl<sub>2</sub>/MeOH = 10:1; yellow solid; yield 90% (1.68 g). <sup>1</sup>H NMR (500 MHz, DMSO) Î´ 10.26 (s, 1H), 8.56 (s, 1H), 8.11 (s, 1H), 7.76 (s, 1H), 7.57 (s, 1H), 7.46 (t, <i>J</i> = 9.0 Hz, 1H), 7.24 (s, 1H), 5.70 (s, 2H), 5.22 (s, 1H), 4.02â3.99 (m, 2H), 3.95â3.91 (m, 1H), 3.81â3.80 (m, 1H), 2.36â2.32 (m, 1H), 2.15â2.13 (m, 1H). HRMS (ESI): <i>m</i>/<i>z</i> calcd for (C<sub>18</sub>H<sub>16</sub>ClFN<sub>4</sub>O<sub>2</sub> + H)<sup>+</sup>, 375.1024; found, 375.1012.</div></div><div id="sec4_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i16" class="anchor-spacer"></div><h4 class="article-section__title" id="_i16"> Diethyl (2-((4-((3-Chloro-4-fluorophenyl)amino)-7-(((<i>S</i>)-tetrahydrofuran-3-yl)oxy)quinazolin-6-yl)amino)-1-fluoro-2-oxoethyl)phosphate (<b>IV</b>-<b>a</b>)</h4><div class="NLM_p last">To a solution of the above compound (<b>III</b>-<b>a</b>) (0.37 g, 1.0 mmol) and Et<sub>3</sub>N (0.15 g, 1.5 mmol) in DMF (10 mL) was added dropwise a solution of compound (<b>II</b>) (0.32 g, 1.5 mmol) in DMF (5 mL) at ice bath. The reaction mixture was stirred at ice bath for 30 min and then warmed to room temperature for overnight. The completion of the reaction was detected via LC-MS. After completion, the reaction was quenched with saturated aqueous NaHCO<sub>3</sub> and then extracted with EtOAc (30 mL Ã 3) three times. The organic layer was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and evaporated under reduced pressure. The crude product was purified by silica gel with DCM/MeOH = 40:1; yellow solid; yield 60% (0.34 g). <sup>1</sup>H NMR (500 MHz, DMSO) Î´ 9.94 (s, 1H), 9.64 (s, 1H), 8.89 (s, 1H), 8.55 (s, 1H), 8.09 (dd, <i>J</i> = 6.5, 2.5 Hz, 1H), 7.78â7.75 (m, 1H), 7.43 (t, <i>J</i> = 9.0 Hz, 1H), 7.34 (s, 1H), 6.02 (dd, <i>J</i> = 45.0, 11.0 Hz, 1H), 5.22 (s, 1H), 4.20 (dd, <i>J</i> = 15.0, 7.0 Hz, 4H), 4.02â3.99 (m, 2H), 3.95â3.91 (m, 1H), 3.81â3.80 (m, 1H), 2.36â2.32 (m, 1H), 2.15â2.13 (m, 1H), 1.29 (dt, <i>J</i> = 10.0, 7.0 Hz, 6H). HRMS (ESI): <i>m</i>/<i>z</i> calcd for (C<sub>24</sub>H<sub>26</sub>ClF<sub>2</sub>N<sub>4</sub>O<sub>6</sub>P + H)<sup>+</sup>, 571.1325; found, 571.1335.</div></div><div id="sec4_1_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i17" class="anchor-spacer"></div><h4 class="article-section__title" id="_i17"> Diethyl (2-((4-((3-Chloro-4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)amino)-1-fluoro-2-oxoethyl)phosphonate (<b>VI</b>-<b>b</b>)</h4><div class="NLM_p last">The preparation was according to the compound (<b>VI</b>-<b>a</b>). The crude product was purified by silica gel with DCM/MeOH = 40:1; yellow solid; yield 70% (0.36 g). <sup>1</sup>H NMR (500 MHz, DMSO) Î´ 9.94 (s, 1H), 9.64 (s, 1H), 8.89 (s, 1H), 8.55 (s, 1H), 8.09 (dd, <i>J</i> = 6.5, 2.5 Hz, 1H), 7.77 (ddd, <i>J</i> = 9.0, 4.0, 2.5 Hz, 1H), 7.43 (t, <i>J</i> = 9.0 Hz, 1H), 7.34 (s, 1H), 6.02 (dd, <i>J</i> = 45.0, 11.0 Hz, 1H), 4.20 (dd, <i>J</i> = 15.5, 8.0 Hz, 4H), 4.03 (s, 3H), 1.29 (dt, <i>J</i> = 10.0, 7.5 Hz, 6H).</div></div><div id="sec4_1_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i18" class="anchor-spacer"></div><h4 class="article-section__title" id="_i18"> Diethyl (2-((4-((3-Chloro-4-(pyridin-2-ylmethoxy)phenyl)amino)-7-ethoxyquinazolin-6-yl)amino)-1-fluoro-2-oxoethyl)phosphonate (<b>VI</b>-<b>c</b>)</h4><div class="NLM_p last">The preparation was according to the compound (<b>VI</b>-<b>a</b>). The crude product was purified by silica gel with DCM/MeOH = 40:1; yellow solid; yield 50% (0.31 g). <sup>1</sup>H NMR (500 MHz, DMSO) Î´ 9.81 (s, 1H), 9.49 (s, 1H), 8.87 (s, 1H), 8.60 (d, <i>J</i> = 4.0 Hz, 1H), 8.49 (s, 1H), 7.94 (d, <i>J</i> = 2.0 Hz, 1H), 7.89 (td, <i>J</i> = 8.0, 2.0 Hz, 1H), 7.65 (dd, <i>J</i> = 9.0, 2.5 Hz, 1H), 7.59 (d, <i>J</i> = 8.0 Hz, 1H), 7.40â7.35 (m, 1H), 7.29 (s, 1H), 7.25 (d, <i>J</i> = 9.0 Hz, 1H), 6.03 (dd, <i>J</i> = 45.0, 11.5 Hz, 1H), 5.29 (s, 2H), 4.30 (q, <i>J</i> = 7.0 Hz, 2H), 4.26â4.14 (m, 4H), 1.44 (t, <i>J</i> = 7.0 Hz, 3H), 1.29 (dt, <i>J</i> = 13.5, 7.0 Hz, 6H).</div></div><div id="sec4_1_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i19" class="anchor-spacer"></div><h4 class="article-section__title" id="_i19"> Diethyl (2-((4-((3-Chloro-4-((3-fluorobenzyl)oxy)phenyl)amino)-7-methoxyquinazolin-6-yl)amino)-1-fluoro-2-oxoethyl)phosphonate (<b>VI</b>-<b>d</b>)</h4><div class="NLM_p last">The preparation was according to the compound (<b>VI</b>-<b>a</b>). The crude product was purified by silica gel with DCM/MeOH = 40:1; yellow solid; yield 50% (0.31 g). <sup>1</sup>H NMR (500 MHz, DMSO) Î´ 9.84 (s, 1H), 9.66 (s, 1H), 8.86 (s, 1H), 8.50 (s, 1H), 7.94 (s, 1H), 7.67â7.65(m, 1H), 7.48â7.46 (m, 1H), 7.34â7.31 (m, 3H), 7.25 (d, <i>J</i> = 9.0 Hz, 2H), 7.21â7.18 (m, 1H), 6.03 (dd, <i>J</i> = 45.0, 11.0 Hz, 1H), 5.26 (s, 2H), 4.20 (dd, <i>J</i> = 14.0, 7.0 Hz, 4H), 4.02 (s, 3H), 1.29 (dd, <i>J</i> = 14.0, 7.0 Hz, 6H).</div></div><div id="sec4_1_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i20" class="anchor-spacer"></div><h4 class="article-section__title" id="_i20"> Diethyl (2-((4-((3-Bromophenyl)amino)-7-methoxyquinazolin-6-yl)amino)-1-fluoro-2-oxoethyl)phosphonate (<b>VI</b>-<b>e</b>)</h4><div class="NLM_p last">The preparation was according to the compound (<b>VI</b>-<b>a</b>). The crude product was purified by silica gel with DCM/MeOH = 40:1; yellow solid; yield 75% (0.41 g). <sup>1</sup>H NMR (500 MHz, DMSO) Î´ 9.94 (s, 1H), 9.67 (s, 1H), 8.90 (s, 1H), 8.57 (s, 1H), 8.13 (s, 1H), 7.83 (d, <i>J</i> = 8.5 Hz, 1H), 7.37â7.32 (m, 2H), 7.29 (d, <i>J</i> = 8.0 Hz, 1H), 6.03 (dd, <i>J</i> = 45.0, 11.0 Hz, 1H), 4.21 (dd, <i>J</i> = 15.0, 7.5 Hz, 4H), 4.03 (s, 3H), 1.29 (dt, <i>J</i> = 9.5, 7.0 Hz, 6H).</div></div><div id="sec4_1_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i21" class="anchor-spacer"></div><h4 class="article-section__title" id="_i21"> 1-(2,2-Dimethoxyethyl)piperidine (<b>VII</b>-<b>a</b>)</h4><div class="NLM_p last">A mixture of 2-bromoacetaldehyde diethyl acetal (4.18 g, 25 mmol), piperidine (2.13 g, 25 mmol), and K<sub>2</sub>CO<sub>3</sub> (6.9 g, 50 mmol) was stirred at 120 Â°C for 16 h. The reaction was cooled to room temperature, diluted with water (20 mL), and extracted with DCM (3 Ã 30 mL) three times. The combined organic layer was washed with saturated aqueous NaHCO<sub>3</sub> and brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to get colorless oil directly for further reaction. HRMS (ESI): <i>m</i>/<i>z</i> calcd for (C<sub>9</sub>H<sub>19</sub>NO<sub>2</sub> + H)<sup>+</sup>, 174.1494; found, 174.1498.</div></div><div id="sec4_1_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22"> 2-(Piperidin-1-yl)acetaldehyde Hydrochloride (<b>VIII</b>-<b>a</b>)</h4><div class="NLM_p last">A solution of intermediate (<b>VII</b>-<b>a</b>) (1.73 g, 10 mmol) dissolved in concentrated aqueous HCl (20 mL) was refluxed at 110 Â°C for 4.5 h. The reaction mixture was concentrated in reduced pressure to obtain dark oil, which was used without purification. HRMS (ESI): <i>m</i>/<i>z</i> calcd for (C<sub>7</sub>H<sub>13</sub>NO + H)<sup>+</sup>, 128.1920; found, 128.1930.</div></div><div id="sec4_1_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23"> <i>N</i>-(4-((3-Chloro-4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)-4-(dimethylamino)-2-fluorobut-2-enamide (<b>1a</b>+<b>1b</b>)</h4><div class="NLM_p last">NaOH (0.32 g, 8.0 mmol) was dissolved in EtOHâH<sub>2</sub>O (10 mL:1 mL). The phosphonate (0.24 g, 1.0 mmol) was added to the above solution. After the mixture became clear, the corresponding aldehyde (2.0 mmol) was added at 0â5 Â°C in an ice bath. The reaction mixture was warmed to room temperature and stirred at room temperature for the indicated time. The reaction mixture was adjusted to pH = 1â2 with 2 N HCl and washed with EtOAc (3 Ã 30 mL) three times. The aqueous layers were adjusted to pH = 10.0 with 4N NaOH and extracted with EtOAc (3 Ã 30 mL) three times. The combined organic layer was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated in reduced pressure to obtain the crude product. TLC <i>R</i><sub>f</sub> = 0.30 (EtOAc/MeOH = 5:1). The two isomers were not separated on the TLC plate. The separation of the <i>Z</i>â<i>E</i> isomers were performed on GILSON 215 semiprep HPLC using PhenomenexGimini 10 Î¼ C18, 30 mm Ã 250 mm column at a flow rate of 30 mL/min using liner gradients mobile phase B in A (B, CH<sub>3</sub>CN containing 0.05% ammonium hydroxide; A, H<sub>2</sub>O). Mobile phase B was increased linearly from 51% to 100% over 15.5 min and 100% over the next 2.5 min, after which the column was equilibrated to 51% for 2 min.</div></div><div id="sec4_1_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> (<i>Z</i>)-<i>N</i>-(4-((3-Chloro-4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)-4-(dimethylamino)-2-fluorobut-2-enamide (<b>1a</b>)</h4><div class="NLM_p last">The retention time of <i>Z</i>-isomer is 14.5 min; light-yellow solid; yield 15%. <sup>1</sup>H NMR (300 MHz, DMSO) Î´ 11.41(s, 1 H), 10.30 (s, 1 H), 8.99 (s, 1 H), 8.88 (s, 1 H), 8.04 (dd, <i>J</i> = 2.7 Hz, 1 H), 7.77â7.70 (m, 1 H), 7.58 (s, 1 H), 7.56 (dd, <i>J</i> = 2.7 Hz, 1 H), 6.47 (td, <i>J</i> = 33.6, 7.5 Hz, 1 H), 4.03 (s, 3 H), 3.99 (br, 2 H), 2.79 (s, 6 H).</div></div><div id="sec4_1_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> <i>N</i>-(4-((3-Chloro-4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)-2-fluoro-4-(piperidin-1-yl)but-2-enamide (<b>2a</b>+<b>2b</b>)</h4><div class="NLM_p last">The preparation was according to the compound (<b>1a</b>+<b>1b</b>). TLC <i>R</i><sub>f</sub> = 0.53, 0.56 (DCM/MeOH = 10:1, the two isomers can be separated). The separation of the <i>Z</i>â<i>E</i> isomers were performed on Thar SFC Pre80 (supercritical fluid chromatography, SFC) using Agela AD-H 5 Î¼, 20 mm Ã 250 mm column at a flow rate of 50 g/min using gradients MeOH (containing 0.1% DEA): CO<sub>2</sub> = 40:60.</div></div><div id="sec4_1_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> (<i>Z</i>)-<i>N</i>-(4-((3-Chloro-4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)-2-fluoro-4-(piperidin-1-yl)but-2-enamide (<b>2a</b>)</h4><div class="NLM_p last">The retention time of the <i>Z</i>-isomer is 6.85 min; light-yellow solid; yield 35.4%. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 9.01 (s, 1H), 8.88 (d, <i>J</i> = 4.4 Hz, 1H), 8.66 (s, 1H), 7.95 (dd, <i>J</i> = 6.8, 2.8 Hz, 1H), 7.81 (dd, <i>J</i> = 3.2, 0.5 Hz, 1H), 7.55 (ddd, <i>J</i> = 9.0, 4.0, 2.8 Hz, 1H), 7.27 (s, 1H), 7.14 (t, <i>J</i> = 8.8 Hz, 1H), 6.45 (dt, <i>J</i> = 36.0, 7.2 Hz, 1H), 4.07 (s, 3H), 3.34 (d, <i>J</i> = 7.2 Hz, 2H), 2.54â2.50 (m, 4H), 1.68â1.64 (m, 4H), 1.50â1.46 (m, 2H). HRMS (ESI): <i>m</i>/<i>z</i> calcd for (C<sub>24</sub>H<sub>24</sub>ClF<sub>2</sub>N<sub>5</sub>O<sub>2</sub> + H)<sup>+</sup>, 488.1665; found, 488.1656.</div></div><div id="sec4_1_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> (<i>E</i>)-<i>N</i>-(4-((3-Chloro-4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)-2-fluoro-4-(piperidin-1-yl)but-2-enamide (<b>2b</b>)</h4><div class="NLM_p last">The retention time of the <i>E</i>-isomer is 4.65 min; light-yellow solid; yield 28.2%. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 9.23 (s, 1H), 8.96 (s, 1H), 8.67 (s, 1H), 7.93 (dd, <i>J</i> = 6.8, 2.8 Hz, 1H), 7.73 (s, 1H), 7.57 (ddd, <i>J</i> = 9.0, 4.0, 2.8 Hz, 1H), 7.28 (s, 1H), 7.16 (t, <i>J</i> = 8.8 Hz, 1H), 6.20 (dt, <i>J</i> = 22.8, 5.6 Hz, 1H), 4.07 (s, 3H), 3.79â3.74 (m, 2H), 2.64â2.61 (m, 4H), 1.73â1.68 (m, 4H), 1.54â1.47 (m, 2H). HRMS (ESI): <i>m</i>/<i>z</i> calcd for (C<sub>24</sub>H<sub>24</sub>ClF<sub>2</sub>N<sub>5</sub>O<sub>2</sub> + H)<sup>+</sup>, 488.1665; found, 488.1656.</div></div><div id="sec4_1_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> <i>N</i>-(4-((3-Chloro-4-(pyridin-2-ylmethoxy)phenyl)amino)-7-ethoxyquinazolin-6-yl)-4-(dimethylamino)-2-fluorobut-2-enamide (<b>3a</b>+<b>3b</b>)</h4><div class="NLM_p last">The preparation was according to the compound (<b>1a</b>+<b>1b</b>). TLC <i>R</i><sub>f</sub> = 0.53, 0.56 (DCM/MeOH = 10:1, the two isomers could be separated). The separation of the <i>Z</i>â<i>E</i> isomers was performed according to compound (<b>2a</b>+<b>2b</b>).</div></div><div id="sec4_1_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> (<i>Z</i>)-<i>N</i>-(4-((3-Chloro-4-(pyridin-2-ylmethoxy)phenyl)amino)-7-ethoxyquinazolin-6-yl)-4-(dimethylamino)-2-fluorobut-2-enamide (<b>3a</b>)</h4><div class="NLM_p last">The retention time of <i>Z</i>-isomer is 5.12 min; light-yellow solid; yield 34.2%. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 9.00 (s, 1H), 8.98 (d, <i>J</i> = 5.6 Hz, 1H), 8.63 (s, 1H), 8.59 (d, <i>J</i> = 4.4 Hz, 1H), 7.88 (d, <i>J</i> = 2.8 Hz, 1H), 7.79â7.78 (m, 1H), 7.75 (d, <i>J</i> = 7.6, 1.6 Hz, 1H), 7.67 (d, <i>J</i> = 8.0 Hz, 1H), 7.52 (dd, <i>J</i> = 8.8, 2.8 Hz, 1H), 7.25 (s, 1H), 7.01 (d, <i>J</i> = 8.8 Hz, 1H), 6.39 (dt, <i>J</i> = 36.4, 7.2 Hz, 1H), 5.30 (s, 2H), 4.30 (q, <i>J</i> = 6.8 Hz, 2H), 3.26 (dd, <i>J</i> = 7.2, 2.4 Hz, 2H), 2.32 (s, 6H), 1.57 (t, <i>J</i> = 7.2 Hz, 4H). HRMS (ESI): <i>m</i>/<i>z</i> calcd for (C<sub>28</sub>H<sub>28</sub>ClFN<sub>6</sub>O<sub>3</sub> + H)<sup>+</sup>, 551.1973; found, 551.1967.</div></div><div id="sec4_1_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> (<i>E</i>)-<i>N</i>-(4-((3-Chloro-4-(pyridin-2-ylmethoxy)phenyl)amino)-7-ethoxyquinazolin-6-yl)-4-(dimethylamino)-2-fluorobut-2-enamide (<b>3b</b>)</h4><div class="NLM_p last">The retention time of the <i>E</i>-isomer is 6.06 min; light-yellow solid; yield 25.8%. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 9.19 (d, <i>J</i> = 4.8 Hz, 1H), 8.98 (s, 1H), 8.65 (s, 1H), 8.60 (dd, <i>J</i> = 5.6, 0.8 Hz, 1H), 7.86 (d, <i>J</i> = 2.8 Hz, 1H), 7.78â7.74 (m, 1H), 7.7â7.66 (m, 1H), 7.55â7.52 (m, 1H), 7.48â7.47 (m, 1H), 7.03 (d, <i>J</i> = 9.2 Hz, 1H), 6.25â6.19 (m, 1H), 5.35 (m, 1H), 5.30 (s, 2H), 4.31 (q, <i>J</i> = 7.2 Hz, 2H), 3.96â3.92 (m, 2H), 2.59â2.55 (s, 6H), 1.57 (t, <i>J</i> = 6.8 Hz, 3H). HRMS (ESI): <i>m</i>/<i>z</i> calcd for (C<sub>28</sub>H<sub>28</sub>ClFN<sub>6</sub>O<sub>3</sub> + H)<sup>+</sup>, 551.1973; found, 551.1969.</div></div><div id="sec4_1_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> (<i>S</i>)-<i>N</i>-(4-((3-Chloro-4-fluorophenyl)amino)-7-((tetrahydrofuran-3-yl)oxy)quinazolin-6-yl)-2-fluoro-4-morpholinobut-2-enamide (<b>4a</b>+<b>4b</b>)</h4><div class="NLM_p last">The preparation was according to the compound (<b>1a</b>+<b>1b</b>). TLC <i>R</i><sub>f</sub> = 0.52, 0.56 (DCM/MeOH = 10:1, the two isomers could be separated) The separation of the <i>Z</i>â<i>E</i> isomers was performed according to compound (<b>2a</b>+<b>2b</b>).</div></div><div id="sec4_1_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> (<i>Z</i>)-(<i>S</i>)-<i>N</i>-(4-((3-Chloro-4-fluorophenyl)amino)-7-((tetrahydrofuran-3-yl)oxy)quinazolin-6-yl)-2-fluoro-4-morpholinobut-2-enamide (<b>4a</b>)</h4><div class="NLM_p last">The retention time of the <i>Z</i>-isomer is 5.52 min; light-yellow solid; yield 24.0%. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 9.03 (s, 1H), 8.91 (d, <i>J</i> = 4.4 Hz, 1H), 8.67 (s, 1H), 7.97 (dd, <i>J</i> = 6.4, 2.4 Hz, 1H), 7.75 (s, 1H), 7.59â7.55 (m, 1H), 7.22 (s, 1H), 7.17 (t, <i>J</i> = 8.8 Hz, 1H), 6.40 (dt, <i>J</i> = 36.4, 6.4 Hz, 1H), 5.21 (s, 2H), 4.14â4.05 (m, 4H), 4.00â3.94 (m, 1H), 3.76â3.74 (m, 4H), 3.31 (dd, <i>J</i> = 7.2, 2.4 Hz, 2H), 2.55â2.53 (m, 4H). HRMS (ESI): <i>m</i>/<i>z</i> calcd for (C<sub>26</sub>H<sub>26</sub>ClF<sub>2</sub>N<sub>5</sub>O<sub>4</sub> + H)<sup>+</sup>, 546.1719; found, 546.1706.</div></div><div id="sec4_1_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> (<i>E</i>)-(<i>S</i>)-<i>N</i>-(4-((3-Chloro-4-fluorophenyl)amino)-7-((tetrahydrofuran-3-yl)oxy)quinazolin-6-yl)-2-fluoro-4-morpholinobut-2-enamide (<b>4b</b>)</h4><div class="NLM_p last">The retention time of the <i>E</i>-isomer is 3.11 min; light-yellow solid; yield 17.4%. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 9.02 (s, 1H), 8.98 (d, <i>J</i> = 6.0 Hz, 1H), 8.67 (s, 1H), 7.96 (dd, <i>J</i> = 6.4, 2.8 Hz, 1H), 7.59â7.55 (m, 2H), 7.22 (s, 1H), 7.19 (d, <i>J</i> = 8.8 Hz, 1H), 6.08 (dt, <i>J</i> = 23.6, 6.4 Hz, 1H), 5.20 (s, 2H), 4.10â4.04 (m, 4H), 4.00â3.96 (m, 1H), 3.76â3.74 (m, 4H), 3.71 (dd, <i>J</i> = 6.8, 2.4 Hz, 2H), 2.58â2.55 (m, 4H). HRMS (ESI): <i>m</i>/<i>z</i> calcd for (C<sub>26</sub>H<sub>26</sub>ClF<sub>2</sub>N<sub>5</sub>O<sub>4</sub> + H)<sup>+</sup>, 546.1719; found, 546.1706.</div></div><div id="sec4_1_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> (<i>S</i>)-<i>N</i>-(4-((3-Chloro-4-fluorophenyl)amino)-7-((tetrahydrofuran-3-yl)oxy)quinazolin-6-yl)-4-(dimethylamino)-2-fluorobut-2-enamide (<b>5a</b>+<b>5b</b>)</h4><div class="NLM_p last">The preparation was according to the compound (<b>1a</b>+<b>1b</b>). TLC <i>R</i><sub>f</sub> = 0.53, 0.58 (DCM/MeOH = 10:1, the two isomers could be separated). The separation of the <i>Z</i>â<i>E</i> isomers was performed according to compound (<b>2a</b>+<b>2b</b>).</div></div><div id="sec4_1_22" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> (<i>Z</i>)-(<i>S</i>)-<i>N</i>-(4-((3-Chloro-4-fluorophenyl)amino)-7-((tetrahydrofuran-3-yl)oxy)quinazolin-6-yl)-4-(dimethylamino)-2-fluorobut-2-enamide (<b>5a</b>)</h4><div class="NLM_p last">The retention time of the <i>Z</i>-isomer is 5.20 min; light-yellow solid; yield 45.5%. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 9.05 (s, 1H), 8.91 (d, <i>J</i> = 6.8 Hz, 1H), 8.67 (s, 1H), 7.98 (dd, <i>J</i> = 6.8, 2.8 Hz, 1H), 7.73 (s, 1H), 7.59â7.55 (m, 1H), 7.22 (s, 1H), 7.18 (t, <i>J</i> = 8.8 Hz, 1H), 6.40 (dt, <i>J</i> = 36.4, 7.2 Hz, 1H), 5.22â5.19 (m, 1H), 4.12â4.07 (m, 4H), 4.00â3.94 (m, 1H), 3.26 (dd, <i>J</i> = 7.6, 2.8 Hz, 2H), 2.33 (s, 6H). HRMS (ESI): <i>m</i>/<i>z</i> calcd for (C<sub>24</sub>H<sub>24</sub>ClF<sub>2</sub>N<sub>5</sub>O<sub>3</sub> + H)<sup>+</sup>, 504.1614; found, 504.1605.</div></div><div id="sec4_1_23" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> (<i>E</i>)-(<i>S</i>)-<i>N</i>-(4-((3-Chloro-4-fluorophenyl)amino)-7-((tetrahydrofuran-3-yl)oxy)quinazolin-6-yl)-4-(dimethylamino)-2-fluorobut-2-enamide (<b>5b</b>)</h4><div class="NLM_p last">The retention time of the <i>E</i>-isomer is 4.53 min; light-yellow solid; yield 24.5%. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 9.26 (brs, 1H), 9.00 (s, 1H), 8.67 (s, 1H), 7.95 (dd, <i>J</i> = 6.4, 2.8 Hz, 1H), 7.62 (s, 1H), 7.59â7.54 (m, 1H), 7.22 (s, 1H), 7.18 (t, <i>J</i> = 8.8 Hz, 1H), 6.09 (dt, <i>J</i> = 24.8, 6.8 Hz, 1H), 5.20â5.16 (m, 2H), 4.10â4.04 (m, 4H), 3.98â3.95 (m, 1H), 3.60 (dd, <i>J</i> = 7.2, 2.8 Hz, 2H), 2.34 (s, 6H). HRMS (ESI): <i>m</i>/<i>z</i> calcd for (C<sub>24</sub>H<sub>24</sub>ClF<sub>2</sub>N<sub>5</sub>O<sub>3</sub> + H)<sup>+</sup>, 504.1614; found, 504.1603.</div></div><div id="sec4_1_24" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> <i>N</i>-(4-((3-Chloro-4-fluorophenyl) amino)-7-methoxyquinazolin-6-yl)-2-fluoro-4-(piperidin-1-yl)but-2-enamide (<b>6a</b>+<b>6b</b>)</h4><div class="NLM_p last">The preparation was according to the compound (<b>1a</b>+<b>1b</b>). TLC <i>R</i><sub>f</sub> = 0.52, 0.60 (DCM/MeOH = 10:1, the two isomers could be separated). The separation of the <i>Z</i>â<i>E</i> isomers was performed according to compound (<b>2a</b>+<b>2b</b>).</div></div><div id="sec4_1_25" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> (<i>Z</i>)-<i>N</i>-(4-((3-Chloro-4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)-2-fluoro-4-(piperidin-1-yl)but-2-enamide (<b>6a</b>)</h4><div class="NLM_p last">The retention time of the <i>Z</i>-isomer is 3.82 min; light-yellow solid; yield 27.0%. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 9.01 (s, 1H), 8.91 (d, <i>J</i> = 4.8 Hz, 1H), 8.67 (s, 1H), 7.95 (dd, <i>J</i> = 6.4, 2.4 Hz, 1H), 7.75 (s, 1H), 7.57â7.54 (m, 1H), 7.29 (s, 1H), 7.15 (t, <i>J</i> = 8.8 Hz, 1H), 6.38 (dt, <i>J</i> = 36.0, 7.2 Hz, 1H), 4.08 (s, 3H), 3.75 (t, <i>J</i> = 4.4 Hz, 4H), 3.31 (dd, <i>J =</i> 7.2, 2.4 Hz, 2H), 2.54 (t, <i>J</i> = 4.4 Hz, 4H). HRMS (ESI): <i>m</i>/<i>z</i> calcd for (C<sub>23</sub>H<sub>22</sub>ClF<sub>2</sub>N<sub>5</sub>O<sub>3</sub> + H)<sup>+</sup>, 490.1457; found, 490.1447.</div></div><div id="sec4_1_26" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> (<i>E</i>)-<i>N</i>-(4-((3-Chloro-4-fluorophenyl) amino)-7-methoxyquinazolin-6-yl)-2-fluoro-4-(piperidin-1-yl)but-2-enamide (<b>6b</b>)</h4><div class="NLM_p last">The retention time of the <i>E</i>-isomer is 2.67 min; light-yellow solid; yield 18.6%. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 9.05 (d, <i>J</i> = 5.2 Hz, 1H), 9.00 (s, 1H), 8.68 (s, 1H), 7.95 (dd, <i>J</i> = 6.4, 2.8 Hz, 1H), 7.58â7.54 (m, 2H), 7.30 (s, 1H), 7.17 (t, <i>J</i> = 8.4 Hz, 1H), 6.07 (dt, <i>J =</i> 23.6, 6.8 Hz, 1H), 4.08 (s, 3H), 3.75 (t, <i>J</i> = 4.8 Hz, 4H), 3.70 (dd, <i>J</i> = 6.8, 2.4 Hz, 2H), 2.57 (t, <i>J</i> = 4.8 Hz, 4H). HRMS (ESI): <i>m</i>/<i>z</i> calcd for (C<sub>23</sub>H<sub>22</sub>ClF<sub>2</sub>N<sub>5</sub>O<sub>3</sub> + H)<sup>+</sup>, 490.1457; found, 490.1451.</div></div><div id="sec4_1_27" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> (<i>S</i>)-<i>N</i>-(4-((3-Chloro-4-fluorophenyl)amino)-7-((tetrahydrofuran-3-yl)oxy)quinazolin-6-yl)-2-fluoro-4-(piperidin-1-yl)but-2-enamide (<b>7a</b>+<b>7b</b>)</h4><div class="NLM_p last">The preparation was according to the compound (<b>1a</b>+<b>1b</b>). TLC <i>R</i><sub>f</sub> = 0.52, 0.53 (DCM/MeOH = 10:1, the two isomers could be separated). The separation of the <i>Z</i>â<i>E</i> isomers was performed according to compound (<b>2a</b>+<b>2b</b>).</div></div><div id="sec4_1_28" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> (<i>Z</i>)-(<i>S</i>)-<i>N</i>-(4-((3-Chloro-4-fluorophenyl)amino)-7-((tetrahydrofuran-3-yl)oxy)quinazolin-6-yl)-2-fluoro-4-(piperidin-1-yl)but-2-enamide (<b>7a</b>)</h4><div class="NLM_p last">The retention time of the <i>Z</i>-isomer is 13.05 min; light-yellow solid; yield 38.1%. <sup>1</sup>H NMR (400 MHz, DMSO) Î´ 9.84 (s, 1H), 9.64 (s, 1H), 8.75 (s, 1H), 8.57 (s, 1H), 8.15 (dd, <i>J</i> = 6.4, 2.0 Hz, 1H), 7.82â7.79 (m, 1H), 7.44 (t, <i>J</i> = 9.2 Hz, 1H), 7.31 (s, 1H), 6.20 (dt, <i>J</i> = 36.8, 6.8 Hz, 1H), 5.33 (t, <i>J</i> = 5.6 Hz, 1H), 3.99 (dd, <i>J</i> = 10.4, 4.4 Hz, 1H), 3.88 (d, <i>J</i> = 8.8 Hz, 2H), 3.82â3.77 (m, 1H), 3.19 (d, <i>J</i> = 6.0 Hz, 2H), 2.38â2.30 (m, 4H), 2.07â1.96 (m, 2H), 1.53â1.49 (m, 4H), 1.40â1.39 (m, 2H). HRMS (ESI): <i>m</i>/<i>z</i> calcd for (C<sub>27</sub>H<sub>28</sub>ClF<sub>2</sub>N<sub>5</sub>O<sub>3</sub> + H)<sup>+</sup>, 544.1927; found, 544.1914.</div></div><div id="sec4_1_29" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> (<i>E</i>)-(<i>S</i>)-<i>N</i>-(4-((3-Chloro-4-fluorophenyl)amino)-7-((tetrahydrofuran-3-yl)oxy)quinazolin-6-yl)-2-fluoro-4-(piperidin-1-yl)but-2-enamide (<b>7b</b>)</h4><div class="NLM_p last">The retention time of the <i>E</i>-isomer is 11.19 min; light-yellow solid; yield 17.5%. <sup>1</sup>H NMR (400 MHz, DMSO) Î´ 10.06 (s, 1H), 9.84 (s, 1H), 8.74 (s, 1H), 8.57 (s, 1H), 8.14 (dd, <i>J</i> = 6.8, 2.4 Hz, 1H), 7.82â7.79 (m, 1H), 7.44 (t, <i>J</i> = 9.2 Hz, 1H), 7.32 (s, 1H), 6.09 (dt, <i>J</i> = 23.6, 13.6 Hz, 1H), 5.34 (t, <i>J</i> = 5.6 Hz, 1H), 4.00â3.97 (m, 1H), 3.90â3.85 (m, 2H), 3.82â3.79 (m, 1H), 3.47 (m, 2H), 2.41â2.33 (m, 4H), 2.07â1.96 (m, 2H), 1.51â1.48 (m, 4H), 1.39â1.37 (m, 2H). HRMS (ESI): <i>m</i>/<i>z</i> calcd for (C<sub>27</sub>H<sub>28</sub>ClF<sub>2</sub>N<sub>5</sub>O<sub>3</sub> + H)<sup>+</sup>, 544.1927; found, 544.1914.</div></div><div id="sec4_1_30" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> <i>N</i>-(4-((3-Chloro-4-((6-methylpyridin-3-yl)oxy)phenyl)amino)-7-ethoxyquinazolin-6-yl)-2-fluoro-4-(piperidin-1-yl)but-2-enamide (<b>8a</b>+<b>8b</b>)</h4><div class="NLM_p last">The preparation was according to the compound (<b>1a</b>+<b>1b</b>). TLC <i>R</i><sub>f</sub> = 0.52, 0.54 (DCM/MeOH = 10:1, the two isomers could be separated). The separation of the <i>Z</i>â<i>E</i> isomers was performed according to compound (<b>2a</b>+<b>2b</b>).</div></div><div id="sec4_1_31" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> (<i>Z</i>)-<i>N</i>-(4-((3-Chloro-4-((6-methylpyridin-3-yl)oxy)phenyl)amino)-7-ethoxyquinazolin-6-yl)-2-fluoro-4-(piperidin-1-yl)but-2-enamide (<b>8a</b>)</h4><div class="NLM_p last">The retention time of <i>Z</i>-isomer is 15.85 min; light-yellow solid; yield 33.2%. <sup>1</sup>H NMR (400 MHz, DMSO) Î´ 9.84 (s, 1H), 9.64 (s, 1H), 8.77 (s, 1H), 8.58 (s, 1H), 8.22 (s, 2H), 7.84 (dd, <i>J</i> = 8.8, 2.4 Hz, 1H), 7.31 (s, 1H), 7.27 (m, 2H), 7.21 (d, <i>J</i> = 8.8 Hz, 1H), 6.21 (dt, <i>J</i> = 36.8, 7.2 Hz, 1H), 4.28 (q, <i>J</i> = 6.8 Hz, 2H), 3.20 (d, <i>J</i> = 7.2 Hz, 2H), 2.45 (s, 3H), 2.39 (m, 4H), 1.52â1.41 (m, 9H). HRMS (ESI): <i>m</i>/<i>z</i> calcd for (C<sub>31</sub>H<sub>32</sub>ClFN<sub>6</sub>O<sub>3</sub> + H)<sup>+</sup>, 591.2286; found, 591.2266.</div></div><div id="sec4_1_32" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> (<i>E</i>)-<i>N</i>-(4-((3-Chloro-4-((6-methylpyridin-3-yl)oxy)phenyl)amino)-7-ethoxyquinazolin-6-yl)-2-fluoro-4-(piperidin-1-yl)but-2-enamide (<b>8b</b>)</h4><div class="NLM_p last">The retention time of the <i>E</i>-isomer is 8.48 min; light-yellow solid; yield: 17.0%. <sup>1</sup>H NMR (400 MHz, DMSO) Î´ 9.84 (s, 1H), 8.77 (s, 1H), 8.58 (s, 1H), 8.21 (d, <i>J</i> = 2.8 Hz, 2H), 7.83 (d, <i>J</i> = 8.8 Hz, 1H), 7.31 (s, 1H), 7.27 (m, 2H), 7.20 (d, <i>J</i> = 8.4 Hz, 1H), 6.09 (dt, <i>J</i> = 23.6, 7.0 Hz, 1H), 4.32â4.26 (m, 2H), 3.45â3.44 (m, 2H), 2.45 (s, 3H), 2.40 (m, 4H), 1.49â1.41 (m, 9H). HRMS (ESI): <i>m</i>/<i>z</i> calcd for (C<sub>31</sub>H<sub>32</sub>ClFN<sub>6</sub>O<sub>3</sub> + H)<sup>+</sup>, 591.2286; found, 591.2280.</div></div><div id="sec4_1_33" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> <i>N</i>-(4-((3-Chloro-4-(pyridin-2-ylmethoxy)phenyl)amino)-7-ethoxyquinazolin-6-yl)-2-fluoro-4-(piperidin-1-yl)but-2-enamide (<b>9a</b>+<b>9b</b>)</h4><div class="NLM_p last">The preparation was according to the compound (<b>1a</b>+<b>1b</b>). TLC <i>R</i><sub>f</sub> = 0.52, 0.53 (DCM/MeOH = 10:1, the two isomers could be separated). The separation of the <i>Z</i>â<i>E</i> isomers was performed according to compound (<b>2a</b>+<b>2b</b>).</div></div><div id="sec4_1_34" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> <i>N</i>-(4-((3-Chloro-4-((3-fluorobenzyl)oxy)phenyl)amino)-7-methoxyquinazolin-6-yl)-4-(dimethylamino)-2-fluorobut-2-enamide (<b>9a</b>+<b>9b</b>)</h4><div class="NLM_p last">The preparation was according to the compound (<b>1a</b>+<b>1b</b>). TLC <i>R</i><sub>f</sub> = 0.53, 0.56 (DCM/MeOH = 10:1, the two isomers could be separated) The separation of the <i>Z</i>â<i>E</i> isomers was performed according to compound (<b>3a</b>+<b>3b</b>).</div></div><div id="sec4_1_35" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> (<i>Z</i>)-<i>N</i>-(4-((3-Chloro-4-((3-fluorobenzyl)oxy)phenyl)amino)-7-methoxyquinazolin-6-yl)-4-(dimethylamino)-2-fluorobut-2-enamide (<b>9a</b>)</h4><div class="NLM_p last">The retention time of the <i>Z</i>-isomer is 8.61 min; light-yellow solid; yield 40.3%. <sup>1</sup>H NMR (400 MHz, DMSO) Î´ 9.75 (s, 1H), 9.69 (s, 1H), 8.68 (s, 1H), 8.53 (s, 1H), 7.99 (d, <i>J</i> = 2.8 Hz, 1H), 7.71 (dd, <i>J</i> = 9.2, 2.8 Hz, 1H), 7.50â7.44 (m, 1H), 7.34â7.30 (m, 3H), 7.25 (d, <i>J</i> = 9.2 Hz, 1H), 7.20â7.16 (m, 1H), 6.19 (dt, <i>J</i> = 36.0, 7.2 Hz, 1H), 5.25 (s, 2H), 3.99 (s, 3H), 3.18â3.15 (m, 2H), 2.19 (s, 6H). HRMS (ESI): <i>m</i>/<i>z</i> calcd for (C<sub>26</sub>H<sub>26</sub>ClF<sub>2</sub>N<sub>5</sub>O<sub>3</sub> + H)<sup>+</sup>, 554.1770; found, 554.1780.</div></div><div id="sec4_1_36" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> (<i>E</i>)-<i>N</i>-(4-((3-Chloro-4-((3-fluorobenzyl)oxy)phenyl)amino)-7-methoxyquinazolin-6-yl)-4-(dimethylamino)-2-fluorobut-2-enamide (<b>9b</b>)</h4><div class="NLM_p last">The retention time of the <i>E</i>-isomer is 5.09 min; light-yellow solid; yield 21.7%. <sup>1</sup>H NMR (400 MHz, DMSO) Î´ 10.92 (s, 1H), 9.70 (s, 1H), 8.78 (s, 1H), 8.51 (s, 1H), 7.97 (d, <i>J</i> = 2.4 Hz, 1H), 7.69 (dd, <i>J</i> = 8.8, 2.8 Hz, 1H), 7.50â7.44 (m, 1H), 7.34â7.30 (m, 3H), 7.25 (d, <i>J</i> = 9.2 Hz, 1H), 7.21â7.16 (m, 1H), 6.11 (dt, <i>J</i> = 23.6, 6.8 Hz, 1H), 5.25 (s, 2H), 4.01 (s, 3H), 3.37 (s, 2H), 2.23 (s, 6H). HRMS (ESI): <i>m</i>/<i>z</i> calcd for (C<sub>26</sub>H<sub>26</sub>ClF<sub>2</sub>N<sub>5</sub>O<sub>3</sub> + H)<sup>+</sup>, 554.1770; found, 554.1784.</div></div><div id="sec4_1_37" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50"> <i>N</i>-(4-((3-Chloro-4-((6-methylpyridin-3-yl)oxy)phenyl)amino)-7-ethoxyquinazolin-6-yl)-4-(dimethylamino)-2-fluorobut-2-enamide (<b>10a</b>+<b>10b</b>)</h4><div class="NLM_p last">The preparation was according to the compound (<b>1a</b>+<b>1b</b>). TLC <i>R</i><sub>f</sub> = 0.52, 0.56 (DCM/MeOH = 10:1, the two isomers could be separated). The separation of the <i>Z</i>â<i>E</i> isomers was performed according to compound (<b>2a</b>+<b>2b</b>).</div></div><div id="sec4_1_38" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51"> (<i>Z</i>)-<i>N</i>-(4-((3-Chloro-4-((6-methylpyridin-3-yl)oxy)phenyl)amino)-7-ethoxyquinazolin-6-yl)-4-(dimethylamino)-2-fluorobut-2-enamide (<b>10a</b>)</h4><div class="NLM_p last">The retention time of the <i>Z</i>-isomer is 5.77 min; light-yellow solid; yield 45%. <sup>1</sup>H NMR (400 MHz, DMSO) Î´ 9.84 (s, 1H), 9.63 (s, 1H), 8.78 (s, 1H), 8.57 (s, 1H), 8.25â8.21 (s, 2H), 7.84 (dd, <i>J</i> = 9.2, 2.4 Hz, 1H), 7.30 (s, 1H), 7.27â7.26 (m, 2H), 7.20 (d, <i>J</i> = 8.8 Hz, 1H), 6.20 (dt, <i>J</i> = 36.4, 7.2 Hz, 1H), 4.27 (q, <i>J</i> = 6.8 Hz, 2H), 2.45 (s, 3H), 2.19 (s, 6H), 1.42 (t, <i>J</i> = 6.8 Hz, 3H). HRMS (ESI): <i>m</i>/<i>z</i> calcd for (C<sub>28</sub>H<sub>28</sub>ClFN<sub>5</sub>O<sub>3</sub> + H)<sup>+</sup>, 551.1973; found, 551.1983.</div></div><div id="sec4_1_39" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52"> (<i>E</i>)-<i>N</i>-(4-((3-Chloro-4-((6-methylpyridin-3-yl)oxy)phenyl)amino)-7-ethoxyquinazolin-6-yl)-4-(dimethylamino)-2-fluorobut-2-enamide (<b>10b</b>)</h4><div class="NLM_p last">The retention time of the <i>E</i>-isomer is 3.69 min; light-yellow solid; yield 24.3%. <sup>1</sup>H NMR (400 MHz, DMSO) Î´ 9.84 (s, 1H), 8.81 (s, 1H), 8.56 (s, 1H), 8.22â8.20 (m, 2H), 7.83 (dd, <i>J</i> = 8.8, 2.4 Hz, 1H), 7.30 (s, 1H), 7.27â7.26 (m, 2H), 7.20 (d, <i>J</i> = 8.8 Hz, 1H), 6.11 (dt, <i>J</i> = 23.2, 7.2 Hz, 1H), 4.29 (q, <i>J</i> = 6.8 Hz, 2H), 2.45 (s, 3H), 2.22 (s, 6H), 1.43 (t, <i>J</i> = 6.8 Hz, 3H). HRMS (ESI): <i>m</i>/<i>z</i> calcd for (C<sub>28</sub>H<sub>28</sub>ClFN<sub>5</sub>O<sub>3</sub> + H)<sup>+</sup>, 551.1973; found, 551.1988.</div></div><div id="sec4_1_40" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53"> <i>N</i>-(4-((3-Chloro-4-(cyclopropylmethoxy)phenyl)amino)-7-ethoxyquinazolin-6-yl)-4-(dimethylamino)-2-fluorobut-2-enamide (<b>11a</b>+<b>11b</b>)</h4><div class="NLM_p last">The preparation was according to the compound (<b>1a</b>+<b>1b</b>). TLC <i>R</i><sub>f</sub> = 0.52, 0.53 (DCM/MeOH = 10:1, the two isomers could be separated). The separation of the <i>Z</i>â<i>E</i> isomers were performed according to compound (<b>2a</b>+<b>2b</b>).</div></div><div id="sec4_1_41" class="NLM_sec NLM_sec_level_3"><div id="ac_i54" class="anchor-spacer"></div><h4 class="article-section__title" id="_i54"> (<i>Z</i>)-<i>N</i>-(4-((3-Chloro-4-(cyclopropylmethoxy)phenyl)amino)-7-ethoxyquinazolin-6-yl)-4-(dimethylamino)-2-fluorobut-2-enamide (<b>11a</b>)</h4><div class="NLM_p last">The retention time of the <i>Z</i>-isomer is 4.07 min; light-yellow solid; yield 43.4%. <sup>1</sup>H NMR (400 MHz, DMSO) Î´ 9.69 (s, 1H), 9.65 (s, 1H), 8.74 (s, 1H), 8.51 (s, 1H), 7.96 (d, <i>J</i> = 2.4 Hz, 1H), 7.69 (dd, <i>J</i> = 8.8, 2.4 Hz, 1H), 7.28 (s, 1H), 7.15 (d, <i>J</i> = 8.8 Hz, 1H), 6.20 (dt, <i>J</i> = 36.4, 7.2 Hz, 1H), 4.27 (q, <i>J</i> = 7.2 Hz, 2H), 3.92 (d, <i>J</i> = 6.8 Hz, 2H), 3.18 (dd, <i>J</i> = 7.2, 2.0 Hz, 2H), 2.20 (s, 6H), 1.42 (t, <i>J</i> = 7.2 Hz, 3H), 1.12 (t, <i>J</i> = 7.2 Hz, 1H), 0.63â0.56 (m, 2H), 0.39â0.33 (m, 2H). HRMS (ESI): <i>m</i>/<i>z</i> calcd for (C<sub>26</sub>H<sub>29</sub>ClFN<sub>5</sub>O<sub>3</sub> + H)<sup>+</sup>, 514.2021; found, 514.2017.</div></div><div id="sec4_1_42" class="NLM_sec NLM_sec_level_3"><div id="ac_i55" class="anchor-spacer"></div><h4 class="article-section__title" id="_i55"> (<i>E</i>)-<i>N</i>-(4-((3-Chloro-4-(cyclopropylmethoxy)phenyl)amino)-7-ethoxyquinazolin-6-yl)-4-(dimethylamino)-2-fluorobut-2-enamide (<b>11b</b>)</h4><div class="NLM_p last">The retention time of the <i>E</i>-isomer is 3.16 min; light-yellow solid; yield 26.6%. <sup>1</sup>H NMR (400 MHz, DMSO) Î´ 10.52 (s, 1H), 9.69 (s, 1H), 8.77 (s, 1H), 8.50 (s, 1H), 7.94 (d, <i>J</i> = 2.4 Hz, 1H), 7.68 (dd, <i>J</i> = 8.8, 2.4 Hz, 1H), 7.28 (s, 1H), 7.15 (d, <i>J</i> = 9.2 Hz, 1H), 6.12 (dt, <i>J</i> = 23.2, 6.8 Hz, 1H), 4.28 (q, <i>J</i> = 7.0 Hz, 2H), 3.92 (d, <i>J</i> = 6.8 Hz, 2H), 3.37â3.38 (m, 2H), 2.22 (s, 6H), 1.43 (t, <i>J</i> = 7.2 Hz, 3H), 1.27â1.24 (m, 1H), 0.66â0.56 (m, 2H), 0.37â0.36 (m, 2H). HRMS (ESI): <i>m</i>/<i>z</i> calcd for (C<sub>26</sub>H<sub>29</sub>ClFN<sub>5</sub>O<sub>3</sub> + H)<sup>+</sup>, 514.2021; found, 514.2017.</div></div><div id="sec4_1_43" class="NLM_sec NLM_sec_level_3"><div id="ac_i56" class="anchor-spacer"></div><h4 class="article-section__title" id="_i56"> <i>N</i>-(4-((3-Bromophenyl)amino)-7-methoxyquinazolin-6-yl)-4-(dimethylamino)-2-fluorobut-2-enamide (<b>12a</b>+<b>12b</b>)</h4><div class="NLM_p last">The preparation was according to the compound (<b>1a</b>+<b>1b</b>). TLC <i>R</i><sub>f</sub> = 0.52, 0.53 (DCM/MeOH = 10:1, the two isomers could be separated). The separation of the <i>Z</i>â<i>E</i> isomers were performed according to compound (<b>2a</b>+<b>2b</b>).</div></div><div id="sec4_1_44" class="NLM_sec NLM_sec_level_3"><div id="ac_i57" class="anchor-spacer"></div><h4 class="article-section__title" id="_i57"> (<i>Z</i>)-<i>N</i>-(4-((3-Bromophenyl)amino)-7-methoxyquinazolin-6-yl)-4-(dimethylamino)-2-fluorobut-2-enamide (<b>12a</b>)</h4><div class="NLM_p last">The retention time of the <i>Z</i>-isomer is 7.40 min; light-yellow solid; yield 38.5%. <sup>1</sup>H NMR (400 MHz, DMSO) Î´ 9.79 (s, 2H), 8.73 (s, 1H), 8.60 (s, 1H), 8.19 (t, <i>J</i> = 1.6 Hz, 1H), 7.88 (d, <i>J</i> = 8.8 Hz, 1H), 7.36â7.27 (m, 3H), 6.19 (dt, <i>J</i> = 36.4, 7.2 Hz, 1H), 4.00 (s, 2H), 3.17 (dd, <i>J</i> = 7.2, 2.0 Hz, 1H), 2.20 (s, 3H). HRMS (ESI): <i>m</i>/<i>z</i> calcd for (C<sub>21</sub>H<sub>21</sub>BrFN<sub>5</sub>O<sub>2</sub> + H)<sup>+</sup>, 474.0941; found, 476.0925.</div></div><div id="sec4_1_45" class="NLM_sec NLM_sec_level_3"><div id="ac_i58" class="anchor-spacer"></div><h4 class="article-section__title" id="_i58"> (<i>E</i>)-<i>N</i>-(4-((3-Bromophenyl)amino)-7-methoxyquinazolin-6-yl)-4-(dimethylamino)-2-fluorobut-2-enamide (<b>12b</b>)</h4><div class="NLM_p last">The retention time of the <i>E</i>-isomer is 5.19 min; light-yellow solid; yield 31.5%. <sup>1</sup>H NMR (400 MHz, DMSO) Î´ 10.99 (s, 1H), 9.81 (s, 2H), 8.83 (s, 1H), 8.60 (s, 1H), 8.16 (s, 1H), 7.87 (d, <i>J</i> = 8.0 Hz, 1H), 7.38â7.28 (m, 4H), 6.12(td, <i>J</i> = 23.2, 6.8 Hz, 1H), 4.02 (s, 3H), 3.27â3.25 (m, 2H), 2.22 (s, 6H). HRMS (ESI): <i>m</i>/<i>z</i> calcd for (C<sub>21</sub>H<sub>21</sub>BrFN<sub>5</sub>O<sub>2</sub> + H)<sup>+</sup>, 474.0941; found, 476.0925.</div></div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i59" class="anchor-spacer"></div><h3 class="article-section__title" id="_i59"> Biological Section</h3><div id="sec4_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i60" class="anchor-spacer"></div><h4 class="article-section__title" id="_i60"> Determination of the GSH Conjugates Addition to Substituted Olefins</h4><div id="sec4_2_1_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i61" class="anchor-spacer"></div><h5 class="article-section__title" id="_i61">1 Determination of GSH Conjugation with <i>N</i>-Phenylacrylamide (<b>A</b>) or 2-Fluoro-<i>N</i>-phenylacrylamide (<b>B</b>)</h5><div class="NLM_p last">Reactions of <i>N</i>-phenylacrylamide (<b>A</b>) or 2-fluoro-<i>N</i>-phenylacrylamide (<b>B</b>) with GSH were monitored with an Agilent 1290 HPLC-6224 time-of-flight mass spectrometer. Reactions were initiated by mixing various volumes of the Michael acceptor (100 mM in ACN) with the GSH (1.0 M GSH in PBS, pH = 7.4). Final solutions in 200 Î¼L of PBS (Costar flat-bottom clear 96-well plate, 300 Î¼L per well), containing 1 mM Michael acceptor and increasing concentrations of GSH (10â200 mM), were incubated for 1440 min at room temp prior to acquiring absorption spectra (214 nm). Formation of the thioether was quantified by area normalization method based on the peak area on HPLC spectrum. Data were fit using Excel to obtain equilibrium dissociation constants.</div></div><div id="sec4_2_1_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i62" class="anchor-spacer"></div><h5 class="article-section__title" id="_i62">2 Determination of GSH Conjugation with Compound <b>5a</b> or Afatinib</h5><div class="NLM_p last">Test reactions of compound <b>5a</b> or afatinib with GSH were also carried out. Reactions were initiated as described above by mixing equal volumes of compound <b>5a</b> or afatinib (100 mM in ACN) with solutions of GSH (1 M in PBS, pH = 7.4). After incubation, conjugate reaction was observed at various time points (0â120 min) by an Agilent 1290 HPLC-6224 time-of-flight mass spectrometer.</div></div></div><div id="sec4_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i63" class="anchor-spacer"></div><h4 class="article-section__title" id="_i63"> Cell Proliferation Assay</h4><div class="NLM_p last">The human epidermal carcinoma cell line A431 and human nonsmall cell lung cancer cell line NCI-H1975<sup>L858R/T790M</sup> were used to evaluate the potency of synthesized analogues in cell-based level. Both cell lines were purchased from American Type Culture Collection (ATCC). A431 was cultured with RPMI 1640 (GIBCO), and NCI-H1975<sup>L858R/T790M</sup> was cultured with Dulbeccoâs Modified Eagleâs Medium (GIBCO). Both mediums were supplemented with penicillin, streptomycin, and 10% fetal bovine serum. The assays were performed using the CellTiter-Glo (Promega) Kit. A431 and NCI-H1975<sup>L858R/T790M</sup> cells were seeded in density of 2000 cells/well and 1500 cells/well, respectively, in 384-well plates (Corning) for 24 h. Duplicate wells were treated with test or reference compounds for 48 h at various concentrations or DMSO (Sigma) as control. Plates were incubated at 37 Â°C in 5% CO<sub>2</sub> atmosphere. Cell proliferation was measured according to the manufacturerâs protocol. The IC<sub>50</sub> was calculated using GraphPad Prism 5.0.</div></div><div id="sec4_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i64" class="anchor-spacer"></div><h4 class="article-section__title" id="_i64"> Kinase Inhibition Assay</h4><div class="NLM_p last">The assays were performed in vitro using the homogeneous time-resolved fluorescence (HTRF) method (Cisbio). EGFR was purchased from Sigma. The kinases and substrates were incubated first with synthesized analogues for 5 min in enzymatic buffer (for EGFR). Then ATP (Sigma) was added into the reaction mixture to start the enzyme reaction. The ATP concentrations used in each enzyme reaction were 1.65 Î¼M for EGFR, equivalent to the <i>K</i><sub>m</sub> of ATP for the corresponding enzyme in this assay condition. The assays were conducted at room temperature for 30 min and stopped by detection reagents which contain EDTA. The detection step lasted for 1 h. The IC<sub>50</sub> was calculated using GraphPad Prism 5.0.</div></div><div id="sec4_2_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i65" class="anchor-spacer"></div><h4 class="article-section__title" id="_i65"> Microsomal Stability Assay</h4><div class="NLM_p last">All assays were conducted in single sample. The incubation mixtures were prepared in E-tube and were contained with 1 Î¼M test analogues, 0.5 mg/mL hepatic microsomes (from rat, mouse, dog, monkey, and human), and 1 mM NADPH in 100 mM potassium phosphate buffer solution (pH = 7.4). Reactions were initiated by the addition of NADPH and kept in a shaking water bath at 37 Â°C. After 0.5, 10, and 30 min incubations at 37 Â°C, the reactions were terminated by the addition of cold acetonitrile equivalent to the volume of the reaction mixture. The samples were vortexed for 10 min and then centrifuged at 10000 rpm for 10 min. The supernatant was subjected to LC/MS/MS (Waters UPLC/API4000 Q Trap). In the determination of the in vitro <i>t</i><sub>1/2</sub> (half-life, HL), the analyte peak areas were converted to percentage of drug remaining, using the <i>T</i> = 0 peak area values as 100%. The slope of the linear regression from log percentage remaining versus incubation time relationships (â<i>k</i>) was used in the conversion to the in vitro <i>t</i><sub>1/2</sub>, values by the in vitro <i>t</i><sub>1/2</sub>= â0.693/k. The percent remaining of test compound was calculated compared to the initial quantity at 0 time.</div></div><div id="sec4_2_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i66" class="anchor-spacer"></div><h4 class="article-section__title" id="_i66"> Measurement of CYP Inhibition Assay</h4><div class="NLM_p last">Inhibition activity of CYP was evaluated by incubating 100 Î¼M human hepatic microsomes in the presence of 10 Î¼M test compound. The incubation mixture was allowed to stand for 20 min at 37 Â°C. The incubation was terminated by the addition of acetonitrile equivalent to the volume of the incubation mixture. After the centrifugation, the supernatant was subjected to LC/MS/MS (Waters UPLC/API4000 Q Trap). The relative CYP activity was calculated via the percentage of metabolite product.</div></div><div id="sec4_2_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i67" class="anchor-spacer"></div><h4 class="article-section__title" id="_i67"> Pharmacokinetic Assay</h4><div class="NLM_p last">Male rats (SpragueâDawley rats, body-weight range of 180â220 g, iv, <i>n</i> = 2, po, <i>n</i> = 3) were administered analogue intravenously via the tail vein at 3 mg/kg, respectively, or orally at 10 mg/kg, respectively. At predetermined times 24 h or more after dosing, 0.4 mL blood was collected and the plasma was separated by centrifugation (8000 rpm, 5 min, Sigma 3K15). The concentrations of the compound were measured in the plasma using LC/MS/MS after protein precipitation with acetonitrile. The relevant estimated pharmacokinetic parameters for plasma were derived using DAS 2.0.</div></div><div id="sec4_2_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i68" class="anchor-spacer"></div><h4 class="article-section__title" id="_i68"> Mouse Tumor Xenograft Efficacy Study</h4><div class="NLM_p last">The efficacy study was conducted in strict accordance with protocols approved by the Institutional Animal Care and Use Committee of the Central Research Institute, Shanghai Pharmaceuticals Holding Co., Ltd. H1975 NSCLC xenografts were established by 3.0 Ã 10<sup>7</sup> cells subcutaneously inoculated in nude mice. Treatments were initiated when tumors reached a mean group size of 50â150 mm<sup>3</sup>. The mice were randomized to Control (10 mL/kg 0.5% CMC-Na + 0.4% Tween80, ig administration), afatinib (30 mg/kg, ig administration), <b>2a</b> (30 mg/kg, ig administration), <b>3a</b> (30 mg/kg, ig administration), <b>5a</b> (30 mg/kg, ig administration), <b>5a</b> (60 mg/kg, ig administration), and <b>5a</b> (15 mg/kg, ig administration) every 2 days for 9 days. The size of tumors were measured individually twice per week with microcalipers. Tumor volume (<i>V</i>) was calculated as <i>V</i> = (length Ã width)<sup>2</sup>/2. The individual relative tumor volume (RTV) was calculated as follows: RTV = <i>V</i><sub>t</sub>/<i>V</i><sub>0</sub>, where <i>V</i><sub>t</sub> is the volume on each day of measurement and <i>V</i><sub>0</sub> is the volume on the day of initial treatment. Therapeutic effect of compound was expressed in terms of <i>T</i>/<i>C</i>% and the calculation formula is <i>T</i>/<i>C</i> (%) = mean RTV of the treated group/mean RTV of the control group Ã 100%.</div></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i69"><a href="/doi/suppl/10.1021/jm5014659">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_37367" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_37367" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">Additional figures and tables illustrating inhibition data, purity data, and <sup>1</sup>H NMR spectra. This material is available free of charge via the Internet at <a href="http://pubs.acs.org" class="extLink">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm5014659/suppl_file/jm5014659_si_001.pdf">jm5014659_si_001.pdf (5.03 MB)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/jm5014659" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_05076" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_05076" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jingkang Shen</span> - <span class="hlFld-Affiliation affiliation">Central
Research Institute, Shanghai Pharmaceutical
Holding Co., Ltd., Building
4, No. 898 Ha Lei Road, Zhangjiang Hi-Tech Park, Shanghai 201203, China</span>;Â 
    <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, No. 555 Zuchongzhi Road, Zhangjiang Hi-Tech Park, Shanghai 201203, China</span>;Â 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#a7cdccd4cfc2c9e7cac6cecb89d4cfc4c9c489c6c489c4c9"><span class="__cf_email__" data-cfemail="c2a8a9b1aaa7ac82afa3abaeecb1aaa1aca1eca3a1eca1ac">[emailÂ protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yongping Yu</span> - <span class="hlFld-Affiliation affiliation">Zhejiang
Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical
Science, Zhejiang University, 866 Yuhangtang Road Zijin Campus, Hangzhou 310058, China</span>;Â 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#d4adada194aebea1fab1b0a1fab7ba"><span class="__cf_email__" data-cfemail="60191915201a0a154e0504154e030e">[emailÂ protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Guangxin Xia</span> - <span class="hlFld-Affiliation affiliation">Central
Research Institute, Shanghai Pharmaceutical
Holding Co., Ltd., Building
4, No. 898 Ha Lei Road, Zhangjiang Hi-Tech Park, Shanghai 201203, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Wenteng Chen</span> - <span class="hlFld-Affiliation affiliation">Zhejiang
Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical
Science, Zhejiang University, 866 Yuhangtang Road Zijin Campus, Hangzhou 310058, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jing Zhang</span> - <span class="hlFld-Affiliation affiliation">Central
Research Institute, Shanghai Pharmaceutical
Holding Co., Ltd., Building
4, No. 898 Ha Lei Road, Zhangjiang Hi-Tech Park, Shanghai 201203, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jiaan Shao</span> - <span class="hlFld-Affiliation affiliation">Zhejiang
Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical
Science, Zhejiang University, 866 Yuhangtang Road Zijin Campus, Hangzhou 310058, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yong Zhang</span> - <span class="hlFld-Affiliation affiliation">Central
Research Institute, Shanghai Pharmaceutical
Holding Co., Ltd., Building
4, No. 898 Ha Lei Road, Zhangjiang Hi-Tech Park, Shanghai 201203, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Wei Huang</span> - <span class="hlFld-Affiliation affiliation">Zhejiang
Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical
Science, Zhejiang University, 866 Yuhangtang Road Zijin Campus, Hangzhou 310058, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Leduo Zhang</span> - <span class="hlFld-Affiliation affiliation">Central
Research Institute, Shanghai Pharmaceutical
Holding Co., Ltd., Building
4, No. 898 Ha Lei Road, Zhangjiang Hi-Tech Park, Shanghai 201203, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Weixing Qi</span> - <span class="hlFld-Affiliation affiliation">Zhejiang
Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical
Science, Zhejiang University, 866 Yuhangtang Road Zijin Campus, Hangzhou 310058, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xing Sun</span> - <span class="hlFld-Affiliation affiliation">Central
Research Institute, Shanghai Pharmaceutical
Holding Co., Ltd., Building
4, No. 898 Ha Lei Road, Zhangjiang Hi-Tech Park, Shanghai 201203, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Bojun Li</span> - <span class="hlFld-Affiliation affiliation">Central
Research Institute, Shanghai Pharmaceutical
Holding Co., Ltd., Building
4, No. 898 Ha Lei Road, Zhangjiang Hi-Tech Park, Shanghai 201203, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Zhixiong Xiang</span> - <span class="hlFld-Affiliation affiliation">Central
Research Institute, Shanghai Pharmaceutical
Holding Co., Ltd., Building
4, No. 898 Ha Lei Road, Zhangjiang Hi-Tech Park, Shanghai 201203, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Chen Ma</span> - <span class="hlFld-Affiliation affiliation">Central
Research Institute, Shanghai Pharmaceutical
Holding Co., Ltd., Building
4, No. 898 Ha Lei Road, Zhangjiang Hi-Tech Park, Shanghai 201203, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jia Xu</span> - <span class="hlFld-Affiliation affiliation">Central
Research Institute, Shanghai Pharmaceutical
Holding Co., Ltd., Building
4, No. 898 Ha Lei Road, Zhangjiang Hi-Tech Park, Shanghai 201203, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hailin Deng</span> - <span class="hlFld-Affiliation affiliation">Central
Research Institute, Shanghai Pharmaceutical
Holding Co., Ltd., Building
4, No. 898 Ha Lei Road, Zhangjiang Hi-Tech Park, Shanghai 201203, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yufeng Li</span> - <span class="hlFld-Affiliation affiliation">Central
Research Institute, Shanghai Pharmaceutical
Holding Co., Ltd., Building
4, No. 898 Ha Lei Road, Zhangjiang Hi-Tech Park, Shanghai 201203, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ping Li</span> - <span class="hlFld-Affiliation affiliation">Central
Research Institute, Shanghai Pharmaceutical
Holding Co., Ltd., Building
4, No. 898 Ha Lei Road, Zhangjiang Hi-Tech Park, Shanghai 201203, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hong Miao</span> - <span class="hlFld-Affiliation affiliation">Central
Research Institute, Shanghai Pharmaceutical
Holding Co., Ltd., Building
4, No. 898 Ha Lei Road, Zhangjiang Hi-Tech Park, Shanghai 201203, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jiansheng Han</span> - <span class="hlFld-Affiliation affiliation">Central
Research Institute, Shanghai Pharmaceutical
Holding Co., Ltd., Building
4, No. 898 Ha Lei Road, Zhangjiang Hi-Tech Park, Shanghai 201203, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yanjun Liu</span> - <span class="hlFld-Affiliation affiliation">Central
Research Institute, Shanghai Pharmaceutical
Holding Co., Ltd., Building
4, No. 898 Ha Lei Road, Zhangjiang Hi-Tech Park, Shanghai 201203, China</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>Guangxin Xia and Wenteng Chen contributed equally to this work.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d3291e4634-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i71">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_35787" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_35787" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We thank Marc A. Giulianotti in Torrey Pines Institute for Molecular Studies, USA, for critical reading this manuscript and Xiaoming Xie in Shanghai Pharmaceutical Holding Co., Ltd., for performing NMR spectrometry for structure elucidation. This project was supported from the National Natural Science Foundation of China (no. 81273356), Program for Zhejiang Leading Team of S&T Innovation, and the Osteoporosis and Breast Cancer Research Center, USA, to Y. Yu, and the China Postdoctoral Science Foundation Funded Project (2014M550331) to W. Chen. We are also grateful for additional financial support from New Drug Creation Project of the National Science and Technology Major Foundation of China (no. 2010ZX09401-404) to Shanghai Pharmaceutical Holding Co., Ltd.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i72" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i72"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i73" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i73"> Abbreviations Used</h2><tr><td class="NLM_term">Alk</td><td class="NLM_def"><p class="first last">anaplasticlymphoma kinase</p></td></tr><tr><td class="NLM_term">EGFR</td><td class="NLM_def"><p class="first last">epidermal growth factor receptor</p></td></tr><tr><td class="NLM_term">EGFR-TK</td><td class="NLM_def"><p class="first last">epidermal growth factor receptor tyrosine kinase</p></td></tr><tr><td class="NLM_term">FLT</td><td class="NLM_def"><p class="first last">FMS like tyrosine kinase</p></td></tr><tr><td class="NLM_term">GSH</td><td class="NLM_def"><p class="first last">glutathione</p></td></tr><tr><td class="NLM_term">HER</td><td class="NLM_def"><p class="first last">human epidermal growth factor receptor</p></td></tr><tr><td class="NLM_term">hERG</td><td class="NLM_def"><p class="first last">human ether-a-go-go-related gene</p></td></tr><tr><td class="NLM_term">JAK2</td><td class="NLM_def"><p class="first last">Janus kinase 2</p></td></tr><tr><td class="NLM_term">NSCLC</td><td class="NLM_def"><p class="first last">nonsmall-cell lung cancer</p></td></tr><tr><td class="NLM_term">PDGFR</td><td class="NLM_def"><p class="first last">platelet-derived growth factor receptor</p></td></tr><tr><td class="NLM_term">SFC</td><td class="NLM_def"><p class="first last">supercritical fluid chromatography</p></td></tr><tr><td class="NLM_term">Src</td><td class="NLM_def"><p class="first last">Rous sarcoma oncogene cellular homologue</p></td></tr><tr><td class="NLM_term">SYK</td><td class="NLM_def"><p class="first last">spleen tyrosine kinase</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i74">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_28617" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_28617" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 25 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Yarden, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sliwknowski, M. X.</span><span> </span><span class="NLM_article-title">Untangling the ErbB signalling network</span> <span class="citation_source-journal">Nature Rev. Mol. Cell. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">127</span><span class="NLM_x">â</span> <span class="NLM_lpage">137</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Fjm5014659&amp;key=10.1038%2F35052073" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Fjm5014659&amp;key=11252954" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Fjm5014659&amp;key=1%3ACAS%3A528%3ADC%252BD3MXivVWnt7k%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2001&pages=127-137&author=Y.+Yardenauthor=M.+X.+Sliwknowski&title=Untangling+the+ErbB+signalling+network"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Untangling the ErbB signalling network</span></div><div class="casAuthors">Yarden, Yosef; Sliwkowski, Mark X.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">127-137</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review, with 112 refs.  When epidermal growth factor and its relatives bind the ErbB family of receptors, they trigger a rich network of signaling pathways, culminating in responses ranging from cell division to death, motility to adhesion.  The network is often dysregulated in cancer and lends credence to the mantra that mol. understanding yields clin. benefit: over 25,000 women with breast cancer have now been treated with Herceptin, a recombinant antibody designed to block the receptor ErbB2.  Likewise, small-mol. enzyme inhibitors and monoclonal antibodies to ErbB1 are in advanced phases of clin. testing.  What can this pathway teach us about translating basic science into clin. use.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovhWL1HObvNrVg90H21EOLACvtfcHk0ljJOrgTOVL3ow"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXivVWnt7k%253D&md5=1561a9666f77fce888be821399870cd6</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2F35052073&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F35052073%26sid%3Dliteratum%253Aachs%26aulast%3DYarden%26aufirst%3DY.%26aulast%3DSliwknowski%26aufirst%3DM.%2BX.%26atitle%3DUntangling%2520the%2520ErbB%2520signalling%2520network%26jtitle%3DNature%2520Rev.%2520Mol.%2520Cell.%2520Biol.%26date%3D2001%26volume%3D2%26spage%3D127%26epage%3D137" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Hynes, N. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lane, H. A.</span><span> </span><span class="NLM_article-title">ErbB receptors and cancer: the complexity of targeted inhibitors</span> <span class="citation_source-journal">Nature Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">341</span><span class="NLM_x">â</span> <span class="NLM_lpage">354</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Fjm5014659&amp;key=10.1038%2Fnrc1609" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Fjm5014659&amp;key=15864276" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Fjm5014659&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjslertb0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2005&pages=341-354&author=N.+E.+Hynesauthor=H.+A.+Lane&title=ErbB+receptors+and+cancer%3A+the+complexity+of+targeted+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">ERBB receptors and cancer: the complexity of targeted inhibitors</span></div><div class="casAuthors">Hynes, Nancy E.; Lane, Heidi A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">341-354</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  ERBB receptor tyrosine kinases have important roles in human cancer.  In particular, the expression or activation of epidermal growth factor receptor and ERBB2 are altered in many epithelial tumors, and clin. studies indicate that they have important roles in tumor etiol. and progression.  Accordingly, these receptors have been intensely studied to understand their importance in cancer biol. and as therapeutic targets, and many ERBB inhibitors are now used in the clinic.  We will discuss the significance of these receptors as clin. targets, in particular the mol. mechanisms underlying response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrimBiy4bn4LrVg90H21EOLACvtfcHk0ljJOrgTOVL3ow"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjslertb0%253D&md5=54a45e004711da7017ee0f016696a36e</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fnrc1609&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1609%26sid%3Dliteratum%253Aachs%26aulast%3DHynes%26aufirst%3DN.%2BE.%26aulast%3DLane%26aufirst%3DH.%2BA.%26atitle%3DErbB%2520receptors%2520and%2520cancer%253A%2520the%2520complexity%2520of%2520targeted%2520inhibitors%26jtitle%3DNature%2520Rev.%2520Cancer%26date%3D2005%26volume%3D5%26spage%3D341%26epage%3D354" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Ciardiello, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tortora, G.</span><span> </span><span class="NLM_article-title">EGFR antagonists in cancer treatment</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">358</span><span class="NLM_x">, </span> <span class="NLM_fpage">1160</span><span class="NLM_x">â</span> <span class="NLM_lpage">1174</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Fjm5014659&amp;key=10.1056%2FNEJMra0707704" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Fjm5014659&amp;key=18337605" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Fjm5014659&amp;key=1%3ACAS%3A528%3ADC%252BD1cXjt1ahsL4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=358&publication_year=2008&pages=1160-1174&author=F.+Ciardielloauthor=G.+Tortora&title=EGFR+antagonists+in+cancer+treatment"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">EGFR antagonists in cancer treatment</span></div><div class="casAuthors">Ciardiello, Fortunato; Tortora, Giampaolo</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">358</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1160-1174</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">A review on epidermal growth factor receptor (EGFR) in human carcinogenesis, development of EGFR antagonists for anticancer therapy, and clin. efficacy of EGFR antagonists in human cancers.  Predicting the response to anti-EGFR drugs and future directions are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGNHvRENSffLVg90H21EOLACvtfcHk0liGmFxs1S-4xQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXjt1ahsL4%253D&md5=2834999545fd643c6f727d80d357134d</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1056%2FNEJMra0707704&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMra0707704%26sid%3Dliteratum%253Aachs%26aulast%3DCiardiello%26aufirst%3DF.%26aulast%3DTortora%26aufirst%3DG.%26atitle%3DEGFR%2520antagonists%2520in%2520cancer%2520treatment%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2008%26volume%3D358%26spage%3D1160%26epage%3D1174" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Roskoski, R.,  Jr.</span><span> </span><span class="NLM_article-title">Anaplastic lymphoma kinase (ALK): structure, oncogenic activation, and pharmacological inhibition</span> <span class="citation_source-journal">Pharmacol. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x">, </span> <span class="NLM_fpage">68</span><span class="NLM_x">â</span> <span class="NLM_lpage">94</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Fjm5014659&amp;key=10.1016%2Fj.phrs.2012.11.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Fjm5014659&amp;key=23201355" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Fjm5014659&amp;key=1%3ACAS%3A528%3ADC%252BC3sXovVygtg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2013&pages=68-94&author=R.+Roskoski&title=Anaplastic+lymphoma+kinase+%28ALK%29%3A+structure%2C+oncogenic+activation%2C+and+pharmacological+inhibition"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Anaplastic lymphoma kinase (ALK): Structure, oncogenic activation, and pharmacological inhibition</span></div><div class="casAuthors">Roskoski, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">68-94</span>CODEN:
                <span class="NLM_cas:coden">PHMREP</span>;
        ISSN:<span class="NLM_cas:issn">1043-6618</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Anaplastic lymphoma kinase was first described in 1994 as the NPM-ALK fusion protein that is expressed in the majority of anaplastic large-cell lymphomas.  ALK is a receptor protein-tyrosine kinase that was more fully characterized in 1997.  Physiol. ALK participates in embryonic nervous system development, but its expression decreases after birth.  ALK is a member of the insulin receptor superfamily and is most closely related to leukocyte tyrosine kinase (Ltk), which is a receptor protein-tyrosine kinase.  Twenty different ALK-fusion proteins have been described that result from various chromosomal rearrangements, and they have been implicated in the pathogenesis of several diseases including anaplastic large-cell lymphoma, diffuse large B-cell lymphoma, and inflammatory myofibroblastic tumors.  The EML4-ALK fusion protein and four other ALK-fusion proteins play a fundamental role in the development in about 5% of non-small cell lung cancers.  The formation of dimers by the amino-terminal portion of the ALK fusion proteins results in the activation of the ALK protein kinase domain that plays a key role in the tumorigenic process.  Downstream signaling from ALK fusion proteins involves the Ras/Raf/MEK/ERK1/2 cell proliferation module and the JAK/STAT cell survival pathway.  Furthermore, nearly two dozen ALK activating mutations participate in the pathogenesis of childhood neuroblastomas along with ALK overexpression.  The occurrence of oncogenic ALK, particularly in non-small cell lung cancer, has generated considerable interest and effort in developing ALK inhibitors.  Currently, crizotinib has been approved by the US Food and Drug Administration for the treatment of ALK-pos. non-small cell lung cancer along with an approved fluorescence in situ hybridization kit used for the diagnosis of the disease.  The emergence of crizotinib drug resistance with a median occurrence at approx. 10 mo after the initiation of therapy has stimulated the development of second-generation drugs for the treatment of non-small cell lung cancer and other disorders.  About 28% of the cases of crizotinib resistance are related to nearly a dozen different mutations of ALK in the EML4-ALK fusion protein; the other cases of resistance are related to the upregulation of alternative signaling pathways or to undefined mechanisms.  It is remarkable that the EML4-ALK fusion protein was discovered in 2007 and crizotinib was approved for the treatment of ALK-pos. non-small cell lung cancer in 2011, which is a remarkably short timeframe in the overall scheme of drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpv-sp0x0gqkrVg90H21EOLACvtfcHk0liGmFxs1S-4xQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXovVygtg%253D%253D&md5=c48d1a4b88a68d395b7acdf403f1875d</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2Fj.phrs.2012.11.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.phrs.2012.11.007%26sid%3Dliteratum%253Aachs%26aulast%3DRoskoski%26aufirst%3DR.%26atitle%3DAnaplastic%2520lymphoma%2520kinase%2520%2528ALK%2529%253A%2520structure%252C%2520oncogenic%2520activation%252C%2520and%2520pharmacological%2520inhibition%26jtitle%3DPharmacol.%2520Res.%26date%3D2013%26volume%3D68%26spage%3D68%26epage%3D94" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Maemondo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inoue, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobayashi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oizumi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isobe, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saijo, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hagiwara, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gemma, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nukiwa, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kudoh, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanazawa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagao, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakai, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shibuya, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akie, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chonabayashi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hasegawa, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayashibara, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hino, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hino, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ikebuchi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishii, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaneko, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kimura, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koba, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kojima, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kosaihira, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koyama, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miki, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minegishi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morikawa, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moriyama, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murayama, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagashima, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niizuma, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nitanai, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogura, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okamoto, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Osaki, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakai, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sugita, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suzuki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanaka, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tokunaga, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsukamoto, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uematsu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Usui, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yasuda, K.</span><span> </span><span class="NLM_article-title">Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">362</span><span class="NLM_x">, </span> <span class="NLM_fpage">2380</span><span class="NLM_x">â</span> <span class="NLM_lpage">2388</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Fjm5014659&amp;key=10.1056%2FNEJMoa0909530" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Fjm5014659&amp;key=20573926" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Fjm5014659&amp;key=1%3ACAS%3A528%3ADC%252BC3cXot1Gjt7Y%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=362&publication_year=2010&pages=2380-2388&author=M.+Maemondoauthor=A.+Inoueauthor=K.+Kobayashiauthor=S.+Oizumiauthor=H.+Isobeauthor=Y.+Saijoauthor=K.+Hagiwaraauthor=A.+Gemmaauthor=T.+Nukiwaauthor=S.+Kudohauthor=M.+Kanazawaauthor=K.+Nagaoauthor=Y.+Nakaiauthor=M.+Shibuyaauthor=K.+Akieauthor=N.+Chonabayashiauthor=Y.+Hasegawaauthor=K.+Hayashibaraauthor=M.+Hinoauthor=T.+Hinoauthor=K.+Ikebuchiauthor=Y.+Ishiiauthor=N.+Kanekoauthor=Y.+Kimuraauthor=H.+Kobaauthor=T.+Kojimaauthor=S.+Kosaihiraauthor=N.+Koyamaauthor=H.+Mikiauthor=Y.+Minegishiauthor=N.+Morikawaauthor=G.+Moriyamaauthor=Y.+Murayamaauthor=M.+Nagashimaauthor=K.+Niizumaauthor=H.+Nitanaiauthor=S.+Oguraauthor=Y.+Okamotoauthor=Y.+Osakiauthor=H.+Sakaiauthor=H.+Sugitaauthor=T.+Suzukiauthor=J.+Tanakaauthor=H.+Tokunagaauthor=T.+Tsukamotoauthor=K.+Uematsuauthor=K.+Usuiauthor=K.+Yasuda&title=Gefitinib+or+chemotherapy+for+non-small-cell+lung+cancer+with+mutated+EGFR"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR</span></div><div class="casAuthors">Maemondo, Makoto; Inoue, Akira; Kobayashi, Kunihiko; Sugawara, Shunichi; Oizumi, Satoshi; Isobe, Hiroshi; Gemma, Akihiko; Harada, Masao; Yoshizawa, Hirohisa; Kinoshita, Ichiro; Fujita, Yuka; Okinaga, Shoji; Hirano, Haruto; Yoshimori, Kozo; Harada, Toshiyuki; Ogura, Takashi; Ando, Masahiro; Miyazawa, Hitoshi; Tanaka, Tomoaki; Saijo, Yasuo; Hagiwara, Koichi; Morita, Satoshi; Nukiwa, Toshihiro</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">362</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">2380-2388</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Non-small-cell lung cancer with sensitive mutations of the epidermal growth factor receptor (EGFR) is highly responsive to EGFR tyrosine kinase inhibitors such as gefitinib, but little is known about how its efficacy and safety profile compares with that of std. chemotherapy.  We randomly assigned 230 patients with metastatic, non-small-cell lung cancer and EGFR mutations who had not previously received chemotherapy to receive gefitinib or carboplatin-paclitaxel.  The primary end point was progression-free survival; secondary end points included overall survival, response rate, and toxic effects.  In the planned interim anal. of data for the first 200 patients, progression-free survival was significantly longer in the gefitinib group than in the std.-chemotherapy group (hazard ratio for death or disease progression with gefitinib, 0.36; P<0.001), resulting in early termination of the study.  The gefitinib group had a significantly longer median progression-free survival (10.8 mo, vs. 5.4 mo in the chemotherapy group; hazard ratio, 0.30; 95% confidence interval, 0.22 to 0.41; P<0.001), as well as a higher response rate (73.7% vs. 30.7%, P<0.001).  The median overall survival was 30.5 mo in the gefitinib group and 23.6 mo in the chemotherapy group (P = 0.31).  The most common adverse events in the gefitinib group were rash (71.1%) and elevated aminotransferase levels (55.3%), and in the chemotherapy group, neutropenia (77.0%), anemia (64.6%), appetite loss (56.6%), and sensory neuropathy (54.9%).  One patient receiving gefitinib died from interstitial lung disease.  First-line gefitinib for patients with advanced non-small-cell lung cancer who were selected on the basis of EGFR mutations improved progression-free survival, with acceptable toxicity, as compared with std. chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1G31xQ-ZFWLVg90H21EOLACvtfcHk0lg6FBQPs7rnKw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXot1Gjt7Y%253D&md5=603963e646bf20ecfd936fc98467f5fd</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa0909530&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa0909530%26sid%3Dliteratum%253Aachs%26aulast%3DMaemondo%26aufirst%3DM.%26aulast%3DInoue%26aufirst%3DA.%26aulast%3DKobayashi%26aufirst%3DK.%26aulast%3DOizumi%26aufirst%3DS.%26aulast%3DIsobe%26aufirst%3DH.%26aulast%3DSaijo%26aufirst%3DY.%26aulast%3DHagiwara%26aufirst%3DK.%26aulast%3DGemma%26aufirst%3DA.%26aulast%3DNukiwa%26aufirst%3DT.%26aulast%3DKudoh%26aufirst%3DS.%26aulast%3DKanazawa%26aufirst%3DM.%26aulast%3DNagao%26aufirst%3DK.%26aulast%3DNakai%26aufirst%3DY.%26aulast%3DShibuya%26aufirst%3DM.%26aulast%3DAkie%26aufirst%3DK.%26aulast%3DChonabayashi%26aufirst%3DN.%26aulast%3DHasegawa%26aufirst%3DY.%26aulast%3DHayashibara%26aufirst%3DK.%26aulast%3DHino%26aufirst%3DM.%26aulast%3DHino%26aufirst%3DT.%26aulast%3DIkebuchi%26aufirst%3DK.%26aulast%3DIshii%26aufirst%3DY.%26aulast%3DKaneko%26aufirst%3DN.%26aulast%3DKimura%26aufirst%3DY.%26aulast%3DKoba%26aufirst%3DH.%26aulast%3DKojima%26aufirst%3DT.%26aulast%3DKosaihira%26aufirst%3DS.%26aulast%3DKoyama%26aufirst%3DN.%26aulast%3DMiki%26aufirst%3DH.%26aulast%3DMinegishi%26aufirst%3DY.%26aulast%3DMorikawa%26aufirst%3DN.%26aulast%3DMoriyama%26aufirst%3DG.%26aulast%3DMurayama%26aufirst%3DY.%26aulast%3DNagashima%26aufirst%3DM.%26aulast%3DNiizuma%26aufirst%3DK.%26aulast%3DNitanai%26aufirst%3DH.%26aulast%3DOgura%26aufirst%3DS.%26aulast%3DOkamoto%26aufirst%3DY.%26aulast%3DOsaki%26aufirst%3DY.%26aulast%3DSakai%26aufirst%3DH.%26aulast%3DSugita%26aufirst%3DH.%26aulast%3DSuzuki%26aufirst%3DT.%26aulast%3DTanaka%26aufirst%3DJ.%26aulast%3DTokunaga%26aufirst%3DH.%26aulast%3DTsukamoto%26aufirst%3DT.%26aulast%3DUematsu%26aufirst%3DK.%26aulast%3DUsui%26aufirst%3DK.%26aulast%3DYasuda%26aufirst%3DK.%26atitle%3DGefitinib%2520or%2520chemotherapy%2520for%2520non-small-cell%2520lung%2520cancer%2520with%2520mutated%2520EGFR%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2010%26volume%3D362%26spage%3D2380%26epage%3D2388" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Rosell, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carcereny, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gervais, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vergnenegre, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Massuti, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Felip, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palmero, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia-Gomez, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pallares, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanchez, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Porta, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cobo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garrido, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Longo, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moran, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Insa, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Marinis, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corre, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bover, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Illiano, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dansin, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Castro, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milella, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reguart, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Altavilla, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jimenez, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Provencio, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moreno, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Terrasa, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MuÃ±oz-Langa, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valdivia, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isla, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Domine, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Molinier, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mazieres, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baize, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia-Campelo, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robinet, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodriguez-Abreu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lopez-Vivanco, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gebbia, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferrera-Delgado, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bombaron, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bernabe, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bearz, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Artal, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortesi, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rolfo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanchez-Ronco, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drozdowskyj, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Queralt, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Aguirre, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramirez, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanchez, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Molina, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taron, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paz-Ares, L.</span><span> </span><span class="NLM_article-title">Spanish Lung Cancer Group in collaboration with Groupe FranÃ§ais de Pneumo-CancÃ©rologie and Associazione Italiana Oncologia Toracica. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomized phase 3 trial</span> <span class="citation_source-journal">Lancet Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">239</span><span class="NLM_x">â</span> <span class="NLM_lpage">246</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Fjm5014659&amp;key=10.1016%2FS1470-2045%2811%2970393-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Fjm5014659&amp;key=22285168" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Fjm5014659&amp;key=1%3ACAS%3A528%3ADC%252BC38XjsVCgsbk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2012&pages=239-246&author=R.+Rosellauthor=E.+Carcerenyauthor=R.+Gervaisauthor=A.+Vergnenegreauthor=B.+Massutiauthor=E.+Felipauthor=R.+Palmeroauthor=R.+Garcia-Gomezauthor=C.+Pallaresauthor=J.+M.+Sanchezauthor=R.+Portaauthor=M.+Coboauthor=P.+Garridoauthor=F.+Longoauthor=T.+Moranauthor=A.+Insaauthor=F.+De+Marinisauthor=R.+Correauthor=I.+Boverauthor=A.+Illianoauthor=E.+Dansinauthor=J.+de+Castroauthor=M.+Milellaauthor=N.+Reguartauthor=G.+Altavillaauthor=U.+Jimenezauthor=M.+Provencioauthor=M.+A.+Morenoauthor=J.+Terrasaauthor=J.+Mu%C3%B1oz-Langaauthor=J.+Valdiviaauthor=D.+Islaauthor=M.+Domineauthor=O.+Molinierauthor=J.+Mazieresauthor=N.+Baizeauthor=R.+Garcia-Campeloauthor=G.+Robinetauthor=D.+Rodriguez-Abreuauthor=G.+Lopez-Vivancoauthor=V.+Gebbiaauthor=L.+Ferrera-Delgadoauthor=P.+Bombaronauthor=R.+Bernabeauthor=A.+Bearzauthor=A.+Artalauthor=E.+Cortesiauthor=C.+Rolfoauthor=M.+Sanchez-Roncoauthor=A.+Drozdowskyjauthor=C.+Queraltauthor=I.+de+Aguirreauthor=J.+L.+Ramirezauthor=J.+J.+Sanchezauthor=M.+A.+Molinaauthor=M.+Taronauthor=L.+Paz-Ares&title=Spanish+Lung+Cancer+Group+in+collaboration+with+Groupe+Fran%C3%A7ais+de+Pneumo-Canc%C3%A9rologie+and+Associazione+Italiana+Oncologia+Toracica.+Erlotinib+versus+standard+chemotherapy+as+first-line+treatment+for+European+patients+with+advanced+EGFR+mutation-positive+non-small-cell+lung+cancer+%28EURTAC%29%3A+a+multicentre%2C+open-label%2C+randomized+phase+3+trial"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial</span></div><div class="casAuthors">Rosell, Rafael; Carcereny, Enric; Gervais, Radj; Vergnenegre, Alain; Massuti, Bartomeu; Felip, Enriqueta; Palmero, Ramon; Garcia-Gomez, Ramon; Pallares, Cinta; Sanchez, Jose Miguel; Porta, Rut; Cobo, Manuel; Garrido, Pilar; Longo, Flavia; Moran, Teresa; Insa, Amelia; De Marinis, Filippo; Corre, Romain; Bover, Isabel; Illiano, Alfonso; Dansin, Eric; de Castro, Javier; Milella, Michele; Reguart, Noemi; Altavilla, Giuseppe; Jimenez, Ulpiano; Provencio, Mariano; Moreno, Miguel Angel; Terrasa, Josefa; Munoz-Langa, Jose; Valdivia, Javier; Isla, Dolores; Domine, Manuel; Molinier, Olivier; Mazieres, Julien; Baize, Nathalie; Garcia-Campelo, Rosario; Robinet, Gilles; Rodriguez-Abreu, Delvys; Lopez-Vivanco, Guillermo; Gebbia, Vittorio; Ferrera-Delgado, Lioba; Bombaron, Pierre; Bernabe, Reyes; Bearz, Alessandra; Artal, Angel; Cortesi, Enrico; Rolfo, Christian; Sanchez-Ronco, Maria; Drozdowskyj, Ana; Queralt, Cristina; de Aguirre, Itziar; Ramirez, Jose Luis; Sanchez, Jose Javier; Molina, Miguel Angel; Taron, Miquel; Paz-Ares, Luis</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">239-246</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Summary: Background: Erlotinib has been shown to improve progression-free survival compared with chemotherapy when given as first-line treatment for Asian patients with non-small-cell lung cancer (NSCLC) with activating EGFR mutations.  We aimed to assess the safety and efficacy of erlotinib compared with std. chemotherapy for first-line treatment of European patients with advanced EGFR-mutation pos. NSCLC.  Methods: We undertook the open-label, randomized phase 3 EURTAC trial at 42 hospitals in France, Italy, and Spain.  Eligible participants were adults (>18 years) with NSCLC and EGFR mutations (exon 19 deletion or L858R mutation in exon 21) with no history of chemotherapy for metastatic disease (neoadjuvant or adjuvant chemotherapy ending â¥6 mo before study entry was allowed).  We randomly allocated participants (1:1) according to a computer-generated allocation schedule to receive oral erlotinib 150 mg per day or 3 wk cycles of std. i.v. chemotherapy of cisplatin 75 mg/m2 on day 1 plus docetaxel (75 mg/m2 on day 1) or gemcitabine (1250 mg/m2 on days 1 and 8).  Carboplatin (AUC 6 with docetaxel 75 mg/m2 or AUC 5 with gemcitabine 1000 mg/m2) was allowed in patients unable to have cisplatin.  Patients were stratified by EGFR mutation type and Eastern Cooperative Oncol. Group performance status (0 vs 1 vs 2).  The primary endpoint was progression-free survival (PFS) in the intention-to-treat population.  We assessed safety in all patients who received study drug (â¥1 dose).  This study is registered with ClinicalTrials.gov, no. NCT00446225.  Findings: Between Feb 15, 2007, and Jan 4, 2011, 174 patients with EGFR mutations were enrolled.  One patient received treatment before randomization and was thus withdrawn from the study; of the remaining patients, 86 were randomly assigned to receive erlotinib and 87 to receive std. chemotherapy.  The preplanned interim anal. showed that the study met its primary endpoint; enrollment was halted, and full evaluation of the results was recommended.  At data cutoff (Jan 26, 2011), median PFS was 9Â·7 mo (95% CI 8Â·4-12Â·3) in the erlotinib group, compared with 5Â·2 mo (4Â·5-5Â·8) in the std. chemotherapy group (hazard ratio 0Â·37, 95% CI 0Â·25-0Â·54; p<0Â·0001).  Main grade 3 or 4 toxicities were rash (11 [13%] of 84 patients given erlotinib vs none of 82 patients in the chemotherapy group), neutropenia (none vs 18 [22%]), anemia (one [1%] vs three [4%]), and increased amino-transferase concns. (two [2%] vs 0).  Five (6%) patients on erlotinib had treatment-related severe adverse events compared with 16 patients (20%) on chemotherapy.  One patient in the erlotinib group and two in the std. chemotherapy group died from treatment-related causes.  Interpretation: Our findings strengthen the rationale for routine baseline tissue-based assessment of EGFR mutations in patients with NSCLC and for treatment of mutation-pos. patients with EGFR tyrosine-kinase inhibitors.  Funding: Spanish Lung Cancer Group, Roche Farma, Hoffmann-La Roche, and Red Tematica de Investigacion Cooperativa en Cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFHsqWOF3EU7Vg90H21EOLACvtfcHk0ljCGTUTL20nrA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjsVCgsbk%253D&md5=9b7c83e16707fba2bc2f4a878effbfb3</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2811%2970393-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252811%252970393-X%26sid%3Dliteratum%253Aachs%26aulast%3DRosell%26aufirst%3DR.%26aulast%3DCarcereny%26aufirst%3DE.%26aulast%3DGervais%26aufirst%3DR.%26aulast%3DVergnenegre%26aufirst%3DA.%26aulast%3DMassuti%26aufirst%3DB.%26aulast%3DFelip%26aufirst%3DE.%26aulast%3DPalmero%26aufirst%3DR.%26aulast%3DGarcia-Gomez%26aufirst%3DR.%26aulast%3DPallares%26aufirst%3DC.%26aulast%3DSanchez%26aufirst%3DJ.%2BM.%26aulast%3DPorta%26aufirst%3DR.%26aulast%3DCobo%26aufirst%3DM.%26aulast%3DGarrido%26aufirst%3DP.%26aulast%3DLongo%26aufirst%3DF.%26aulast%3DMoran%26aufirst%3DT.%26aulast%3DInsa%26aufirst%3DA.%26aulast%3DDe%2BMarinis%26aufirst%3DF.%26aulast%3DCorre%26aufirst%3DR.%26aulast%3DBover%26aufirst%3DI.%26aulast%3DIlliano%26aufirst%3DA.%26aulast%3DDansin%26aufirst%3DE.%26aulast%3Dde%2BCastro%26aufirst%3DJ.%26aulast%3DMilella%26aufirst%3DM.%26aulast%3DReguart%26aufirst%3DN.%26aulast%3DAltavilla%26aufirst%3DG.%26aulast%3DJimenez%26aufirst%3DU.%26aulast%3DProvencio%26aufirst%3DM.%26aulast%3DMoreno%26aufirst%3DM.%2BA.%26aulast%3DTerrasa%26aufirst%3DJ.%26aulast%3DMu%25C3%25B1oz-Langa%26aufirst%3DJ.%26aulast%3DValdivia%26aufirst%3DJ.%26aulast%3DIsla%26aufirst%3DD.%26aulast%3DDomine%26aufirst%3DM.%26aulast%3DMolinier%26aufirst%3DO.%26aulast%3DMazieres%26aufirst%3DJ.%26aulast%3DBaize%26aufirst%3DN.%26aulast%3DGarcia-Campelo%26aufirst%3DR.%26aulast%3DRobinet%26aufirst%3DG.%26aulast%3DRodriguez-Abreu%26aufirst%3DD.%26aulast%3DLopez-Vivanco%26aufirst%3DG.%26aulast%3DGebbia%26aufirst%3DV.%26aulast%3DFerrera-Delgado%26aufirst%3DL.%26aulast%3DBombaron%26aufirst%3DP.%26aulast%3DBernabe%26aufirst%3DR.%26aulast%3DBearz%26aufirst%3DA.%26aulast%3DArtal%26aufirst%3DA.%26aulast%3DCortesi%26aufirst%3DE.%26aulast%3DRolfo%26aufirst%3DC.%26aulast%3DSanchez-Ronco%26aufirst%3DM.%26aulast%3DDrozdowskyj%26aufirst%3DA.%26aulast%3DQueralt%26aufirst%3DC.%26aulast%3Dde%2BAguirre%26aufirst%3DI.%26aulast%3DRamirez%26aufirst%3DJ.%2BL.%26aulast%3DSanchez%26aufirst%3DJ.%2BJ.%26aulast%3DMolina%26aufirst%3DM.%2BA.%26aulast%3DTaron%26aufirst%3DM.%26aulast%3DPaz-Ares%26aufirst%3DL.%26atitle%3DSpanish%2520Lung%2520Cancer%2520Group%2520in%2520collaboration%2520with%2520Groupe%2520Fran%25C3%25A7ais%2520de%2520Pneumo-Canc%25C3%25A9rologie%2520and%2520Associazione%2520Italiana%2520Oncologia%2520Toracica.%2520Erlotinib%2520versus%2520standard%2520chemotherapy%2520as%2520first-line%2520treatment%2520for%2520European%2520patients%2520with%2520advanced%2520EGFR%2520mutation-positive%2520non-small-cell%2520lung%2520cancer%2520%2528EURTAC%2529%253A%2520a%2520multicentre%252C%2520open-label%252C%2520randomized%2520phase%25203%2520trial%26jtitle%3DLancet%2520Oncol.%26date%3D2012%26volume%3D13%26spage%3D239%26epage%3D246" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Kobayashi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boggon, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dayaram, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">JÃ¤nne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kocher, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tenen, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halmos, B.</span><span> </span><span class="NLM_article-title">EGFR mutation and resistance of non-small-cell lung cancer to gefitinib</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">352</span><span class="NLM_x">, </span> <span class="NLM_fpage">786</span><span class="NLM_x">â</span> <span class="NLM_lpage">792</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Fjm5014659&amp;key=10.1056%2FNEJMoa044238" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Fjm5014659&amp;key=15728811" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Fjm5014659&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhsFCiurk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=352&publication_year=2005&pages=786-792&author=S.+Kobayashiauthor=T.+J.+Boggonauthor=T.+Dayaramauthor=P.+A.+J%C3%A4nneauthor=O.+Kocherauthor=M.+Meyersonauthor=B.+E.+Johnsonauthor=M.+J.+Eckauthor=D.+G.+Tenenauthor=B.+Halmos&title=EGFR+mutation+and+resistance+of+non-small-cell+lung+cancer+to+gefitinib"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">EGFR mutation and resistance of non-small-cell lung cancer to gefitinib</span></div><div class="casAuthors">Kobayashi, Susumu; Boggon, Titus J.; Dayaram, Tajhal; Jaenne, Pasi A.; Kocher, Olivier; Meyerson, Matthew; Johnson, Bruce E.; Eck, Michael J.; Tenen, Daniel G.; Halmos, Balizs</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">352</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">786-792</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Mutations of the epidermal growth factor receptor (EGFR) gene were identified in specimens from patients with non-small-cell lung cancer who have a response to anilinoquinazoline EGFR inhibitors.  Despite the dramatic responses to such inhibitors, most patients ultimately have a relapse.  The mechanism of the drug resistance is unknown.  Here the authors report the case of a patient with EGFR-mutant, gefitinib-responsive, advanced non-small-cell lung cancer who had a relapse after 2 years of complete remission during treatment with gefitinib.  The DNA sequence of the EGFR gene in his tumor biopsy specimen at relapse revealed the presence of a second point mutation, resulting in threonine-to-methionine amino acid change at position 790 of EGFR.  Structural modeling and biochem. studies showed that this second mutation led to gefitinib resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8XXhT1hrbe7Vg90H21EOLACvtfcHk0ljCGTUTL20nrA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhsFCiurk%253D&md5=808223ad566e2a3748977727cc5a9846</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa044238&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa044238%26sid%3Dliteratum%253Aachs%26aulast%3DKobayashi%26aufirst%3DS.%26aulast%3DBoggon%26aufirst%3DT.%2BJ.%26aulast%3DDayaram%26aufirst%3DT.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26aulast%3DKocher%26aufirst%3DO.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DJohnson%26aufirst%3DB.%2BE.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DTenen%26aufirst%3DD.%2BG.%26aulast%3DHalmos%26aufirst%3DB.%26atitle%3DEGFR%2520mutation%2520and%2520resistance%2520of%2520non-small-cell%2520lung%2520cancer%2520to%2520gefitinib%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2005%26volume%3D352%26spage%3D786%26epage%3D792" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Lee, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shin, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koh, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keam, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Min, H. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeon, Y. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chung, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heo, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, J. I.</span><span> </span><span class="NLM_article-title">Primary resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with non-small-cell lung cancer harboring TKI-sensitive EGFR mutations: an exploratory study</span> <span class="citation_source-journal">Ann. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">2080</span><span class="NLM_x">â</span> <span class="NLM_lpage">2087</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Fjm5014659&amp;key=10.1093%2Fannonc%2Fmdt127" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Fjm5014659&amp;key=23559152" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Fjm5014659&amp;key=1%3ACAS%3A280%3ADC%252BC3srisVOmsg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2013&pages=2080-2087&author=J.+K.+Leeauthor=J.+Y.+Shinauthor=S.+Kimauthor=S.+Leeauthor=C.+Parkauthor=J.+Y.+Kimauthor=Y.+Kohauthor=B.+Keamauthor=H.+S.+Minauthor=T.+M.+Kimauthor=Y.+K.+Jeonauthor=D.+W.+Kimauthor=D.+H.+Chungauthor=D.+S.+Heoauthor=S.+H.+Leeauthor=J.+I.+Kim&title=Primary+resistance+to+epidermal+growth+factor+receptor+%28EGFR%29+tyrosine+kinase+inhibitors+%28TKIs%29+in+patients+with+non-small-cell+lung+cancer+harboring+TKI-sensitive+EGFR+mutations%3A+an+exploratory+study"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Primary resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with non-small-cell lung cancer harboring TKI-sensitive EGFR mutations: an exploratory study</span></div><div class="casAuthors">Lee J K; Shin J-Y; Kim S; Lee S; Park C; Kim J-Y; Koh Y; Keam B; Min H S; Kim T M; Jeon Y-K; Kim D-W; Chung D H; Heo D S; Lee S-H; Kim J-I</div><div class="citationInfo"><span class="NLM_cas:title">Annals of oncology : official journal of the European Society for Medical Oncology / ESMO</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2080-7</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  The mechanism of primary resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in EGFR-mutant non-small-cell lung cancer (NSCLC) has not been clearly understood.  PATIENTS AND METHODS:  Eleven patients exhibiting primary resistance (disease progression <3 months) were identified among 197 consecutive NSCLC patients with TKI-sensitive EGFR mutations who received EGFR TKIs at Seoul National University Hospital.  Treatment-naive tumors were examined for concurrent genetic alterations using fluorescence in situ hybridization and targeted deep sequencing of cancer-related genes.  Deletion polymorphism of Bcl-2-interacting mediator of cell death (BIM) gene was examined to validate its predictive role for TKI outcome.  RESULTS:  The median progression-free survival (PFS) for patients receiving EGFR TKIs was 11.9 months, and the response rate 78.8%.  Among the 11 patients exhibiting primary resistance, a de novo T790M mutation was identified in one patient, and two exhibited mesenchymal-epithelial transition amplification and anaplastic lymphoma kinase fusion.  Targeted deep sequencing identified no recurrent, coexistent drivers of NSCLC.  Survival analysis revealed that patients with recurrent disease after surgery had a longer PFS than those with initial stage IV disease.  However, BIM deletion polymorphism, line of treatment, EGFR genotype, and smoking were not predictive of PFS for EGFR TKIs.  CONCLUSIONS:  We identified coexistent genetic alterations of cancer-related genes that could explain primary resistance in a small proportion of patients.  Our result suggests that the mechanism of primary resistance might be heterogeneous.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTHIZXFf_U3krjnyZkbE8yXfW6udTcc2ebyqU8I31dNNbntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3srisVOmsg%253D%253D&md5=ecaa76fdc8df60e276aa3792fa3b6338</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdt127&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdt127%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DJ.%2BK.%26aulast%3DShin%26aufirst%3DJ.%2BY.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DS.%26aulast%3DPark%26aufirst%3DC.%26aulast%3DKim%26aufirst%3DJ.%2BY.%26aulast%3DKoh%26aufirst%3DY.%26aulast%3DKeam%26aufirst%3DB.%26aulast%3DMin%26aufirst%3DH.%2BS.%26aulast%3DKim%26aufirst%3DT.%2BM.%26aulast%3DJeon%26aufirst%3DY.%2BK.%26aulast%3DKim%26aufirst%3DD.%2BW.%26aulast%3DChung%26aufirst%3DD.%2BH.%26aulast%3DHeo%26aufirst%3DD.%2BS.%26aulast%3DLee%26aufirst%3DS.%2BH.%26aulast%3DKim%26aufirst%3DJ.%2BI.%26atitle%3DPrimary%2520resistance%2520to%2520epidermal%2520growth%2520factor%2520receptor%2520%2528EGFR%2529%2520tyrosine%2520kinase%2520inhibitors%2520%2528TKIs%2529%2520in%2520patients%2520with%2520non-small-cell%2520lung%2520cancer%2520harboring%2520TKI-sensitive%2520EGFR%2520mutations%253A%2520an%2520exploratory%2520study%26jtitle%3DAnn.%2520Oncol.%26date%3D2013%26volume%3D24%26spage%3D2080%26epage%3D2087" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Yun, C.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mengwasser, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toms, A. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woo, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greulich, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span> </span><span class="NLM_article-title">The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">105</span><span class="NLM_x">, </span> <span class="NLM_fpage">2070</span><span class="NLM_x">â</span> <span class="NLM_lpage">2075</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Fjm5014659&amp;key=10.1073%2Fpnas.0709662105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Fjm5014659&amp;key=18227510" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Fjm5014659&amp;key=1%3ACAS%3A528%3ADC%252BD1cXitl2mu7k%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2008&pages=2070-2075&author=C.-H.+Yunauthor=K.+E.+Mengwasserauthor=A.+V.+Tomsauthor=M.+S.+Wooauthor=H.+Greulichauthor=K.+K.+Wongauthor=M.+Meyersonauthor=M.+J.+Eck&title=The+T790M+mutation+in+EGFR+kinase+causes+drug+resistance+by+increasing+the+affinity+for+ATP"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP</span></div><div class="casAuthors">Yun, Cai-Hong; Mengwasser, Kristen E.; Toms, Angela V.; Woo, Michele S.; Greulich, Heidi; Wong, Kwok-Kin; Meyerson, Matthew; Eck, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2070-2075</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Lung cancers caused by activating mutations in the epidermal growth factor receptor (EGFR) are initially responsive to small mol. tyrosine kinase inhibitors (TKIs), but the efficacy of these agents is often limited because of the emergence of drug resistance conferred by a second mutation, T790M.  Threonine 790 is the "gatekeeper" residue, an important determinant of inhibitor specificity in the ATP binding pocket.  The T790M mutation has been thought to cause resistance by sterically blocking binding of TKIs such as gefitinib and erlotinib, but this explanation is difficult to reconcile with the fact that it remains sensitive to structurally similar irreversible inhibitors.  Here, we show by using a direct binding assay that T790M mutants retain low-nanomolar affinity for gefitinib.  Furthermore, we show that the T790M mutation activates WT EGFR and that introduction of the T790M mutation increases the ATP affinity of the oncogenic L858R mutant by more than an order of magnitude.  The increased ATP affinity is the primary mechanism by which the T790M mutation confers drug resistance.  Crystallog. anal. of the T790M mutant shows how it can adapt to accommodate tight binding of diverse inhibitors, including the irreversible inhibitor HKI-272, and also suggests a structural mechanism for catalytic activation.  We conclude that the T790M mutation is a "generic" resistance mutation that will reduce the potency of any ATP-competitive kinase inhibitor and that irreversible inhibitors overcome this resistance simply through covalent binding, not as a result of an alternative binding mode.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXXP7TBlyrdrVg90H21EOLACvtfcHk0lj6lhO8GM91yg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXitl2mu7k%253D&md5=f5f5d791a65f73ca628d95e9922b8ea8</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0709662105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0709662105%26sid%3Dliteratum%253Aachs%26aulast%3DYun%26aufirst%3DC.-H.%26aulast%3DMengwasser%26aufirst%3DK.%2BE.%26aulast%3DToms%26aufirst%3DA.%2BV.%26aulast%3DWoo%26aufirst%3DM.%2BS.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DWong%26aufirst%3DK.%2BK.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26atitle%3DThe%2520T790M%2520mutation%2520in%2520EGFR%2520kinase%2520causes%2520drug%2520resistance%2520by%2520increasing%2520the%2520affinity%2520for%2520ATP%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2008%26volume%3D105%26spage%3D2070%26epage%3D2075" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Kwak, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sordella, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bell, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Godin-Heymann, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okimoto, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brannigan, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Driscoll, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fidias, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rabindran, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGinnis, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wissner, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharma, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isselbacher, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settleman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haber, D. A.</span><span> </span><span class="NLM_article-title">Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">102</span><span class="NLM_x">, </span> <span class="NLM_fpage">7665</span><span class="NLM_x">â</span> <span class="NLM_lpage">7670</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2005&pages=7665-7670&author=E.+L.+Kwakauthor=R.+Sordellaauthor=D.+W.+Bellauthor=N.+Godin-Heymannauthor=R.+A.+Okimotoauthor=B.+W.+Branniganauthor=P.+L.+Harrisauthor=D.+R.+Driscollauthor=P.+Fidiasauthor=T.+J.+Lynchauthor=S.+K.+Rabindranauthor=J.+P.+McGinnisauthor=A.+Wissnerauthor=S.+V.+Sharmaauthor=K.+J.+Isselbacherauthor=J.+Settlemanauthor=D.+A.+Haber&title=Irreversible+inhibitors+of+the+EGF+receptor+may+circumvent+acquired+resistance+to+gefitinib"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKwak%26aufirst%3DE.%2BL.%26aulast%3DSordella%26aufirst%3DR.%26aulast%3DBell%26aufirst%3DD.%2BW.%26aulast%3DGodin-Heymann%26aufirst%3DN.%26aulast%3DOkimoto%26aufirst%3DR.%2BA.%26aulast%3DBrannigan%26aufirst%3DB.%2BW.%26aulast%3DHarris%26aufirst%3DP.%2BL.%26aulast%3DDriscoll%26aufirst%3DD.%2BR.%26aulast%3DFidias%26aufirst%3DP.%26aulast%3DLynch%26aufirst%3DT.%2BJ.%26aulast%3DRabindran%26aufirst%3DS.%2BK.%26aulast%3DMcGinnis%26aufirst%3DJ.%2BP.%26aulast%3DWissner%26aufirst%3DA.%26aulast%3DSharma%26aufirst%3DS.%2BV.%26aulast%3DIsselbacher%26aufirst%3DK.%2BJ.%26aulast%3DSettleman%26aufirst%3DJ.%26aulast%3DHaber%26aufirst%3DD.%2BA.%26atitle%3DIrreversible%2520inhibitors%2520of%2520the%2520EGF%2520receptor%2520may%2520circumvent%2520acquired%2520resistance%2520to%2520gefitinib%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2005%26volume%3D102%26spage%3D7665%26epage%3D7670" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Bowles, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weickhardt, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jimeno, A.</span><span> </span><span class="NLM_article-title">Afatinib for the treatment of patients with EGFR-positive non-small cell lung cancer</span> <span class="citation_source-journal">Drugs Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">523</span><span class="NLM_x">â</span> <span class="NLM_lpage">535</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Fjm5014659&amp;key=10.1358%2Fdot.2013.49.09.2016610" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Fjm5014659&amp;key=1%3ACAS%3A280%3ADC%252BC2c%252FlslyltQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2013&pages=523-535&author=D.+W.+Bowlesauthor=A.+Weickhardtauthor=A.+Jimeno&title=Afatinib+for+the+treatment+of+patients+with+EGFR-positive+non-small+cell+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Afatinib for the treatment of patients with EGFR-positive non-small cell lung cancer</span></div><div class="casAuthors">Bowles D W; Weickhardt A; Jimeno A</div><div class="citationInfo"><span class="NLM_cas:title">Drugs of today (Barcelona, Spain : 1998)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">523-35</span>
        ISSN:<span class="NLM_cas:issn">1699-3993</span>.
    </div><div class="casAbstract">Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are valuable treatments for EGFR-mutated non-small cell lung cancer (NSCLC).  Anti-EGFR antibodies are widely used in the treatment of head and neck squamous cell carcinomas (HNSCC) and in KRAS wild-type colorectal cancer.  The first-generation, reversible EGFR inhibitors erlotinib and gefitinib in the first-line setting provide superior progression-free survival and quality of life compared to conventional chemotherapy in NSCLC harboring activating EGFR mutations.  However, these therapies eventually fail and new options are needed.  Afatinib is a novel irreversible inhibitor of the ErbB family members EGFR, tyrosine kinase-type cell surface receptors HER2 and HER4.  It shows preclinical efficacy in NSCLC with common EGFR-activating mutations and the T790M mutation typically associated with EGFR TKI resistance.  Preclinical activity is seen in other tumor types as well, including HNSCC.  Clinically, afatinib has been evaluated in the broad-reaching LUX Lung trial program, with significant activity seen in the first and later-line settings.  It is also under investigation in multiple other tumor types.  This review will stress on afatinib's preclinical pharmacology, pharmacokinetics and clinical activity with a focus on NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSlb14qikVjeLt7lRqEFUJVfW6udTcc2ebz951f0Z1S6Lntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2c%252FlslyltQ%253D%253D&md5=d509f8e61df416962613be4a29dd6b47</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1358%2Fdot.2013.49.09.2016610&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1358%252Fdot.2013.49.09.2016610%26sid%3Dliteratum%253Aachs%26aulast%3DBowles%26aufirst%3DD.%2BW.%26aulast%3DWeickhardt%26aufirst%3DA.%26aulast%3DJimeno%26aufirst%3DA.%26atitle%3DAfatinib%2520for%2520the%2520treatment%2520of%2520patients%2520with%2520EGFR-positive%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DDrugs%2520Today%26date%3D2013%26volume%3D49%26spage%3D523%26epage%3D535" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Wissner, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Overbeek, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reich, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brawner Floyd, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mamuya, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosfjord, E. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Discafani, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rabindran, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gruber, B. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hallett, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nilakantan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.-F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greenberger, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsou, H.-R.</span><span> </span><span class="NLM_article-title">Synthesis and structureâactivity relationships of 6, 7-disubstituted 4-anilinoquinoline-3-carbonitriles. The design of an orally active, irreversible inhibitor of the tyrosine kinase activity of the epidermal growth factor receptor (EGFR) and the human epidermal growth factor receptor-2 (HER-2)</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">49</span><span class="NLM_x">â</span> <span class="NLM_lpage">63</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm020241c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=49-63&author=A.+Wissnerauthor=E.+Overbeekauthor=M.+F.+Reichauthor=M.+Brawner+Floydauthor=B.+D.+Johnsonauthor=N.+Mamuyaauthor=E.+C.+Rosfjordauthor=C.+Discafaniauthor=R.+Davisauthor=X.+Shiauthor=S.+K.+Rabindranauthor=B.+C.+Gruberauthor=F.+Yeauthor=W.+A.+Hallettauthor=R.+Nilakantanauthor=R.+Shenauthor=Y.-F.+Wangauthor=L.+M.+Greenbergerauthor=H.-R.+Tsou&title=Synthesis+and+structure%E2%80%93activity+relationships+of+6%2C+7-disubstituted+4-anilinoquinoline-3-carbonitriles.+The+design+of+an+orally+active%2C+irreversible+inhibitor+of+the+tyrosine+kinase+activity+of+the+epidermal+growth+factor+receptor+%28EGFR%29+and+the+human+epidermal+growth+factor+receptor-2+%28HER-2%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1021%2Fjm020241c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm020241c%26sid%3Dliteratum%253Aachs%26aulast%3DWissner%26aufirst%3DA.%26aulast%3DOverbeek%26aufirst%3DE.%26aulast%3DReich%26aufirst%3DM.%2BF.%26aulast%3DBrawner%2BFloyd%26aufirst%3DM.%26aulast%3DJohnson%26aufirst%3DB.%2BD.%26aulast%3DMamuya%26aufirst%3DN.%26aulast%3DRosfjord%26aufirst%3DE.%2BC.%26aulast%3DDiscafani%26aufirst%3DC.%26aulast%3DDavis%26aufirst%3DR.%26aulast%3DShi%26aufirst%3DX.%26aulast%3DRabindran%26aufirst%3DS.%2BK.%26aulast%3DGruber%26aufirst%3DB.%2BC.%26aulast%3DYe%26aufirst%3DF.%26aulast%3DHallett%26aufirst%3DW.%2BA.%26aulast%3DNilakantan%26aufirst%3DR.%26aulast%3DShen%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DY.-F.%26aulast%3DGreenberger%26aufirst%3DL.%2BM.%26aulast%3DTsou%26aufirst%3DH.-R.%26atitle%3DSynthesis%2520and%2520structure%25E2%2580%2593activity%2520relationships%2520of%25206%252C%25207-disubstituted%25204-anilinoquinoline-3-carbonitriles.%2520The%2520design%2520of%2520an%2520orally%2520active%252C%2520irreversible%2520inhibitor%2520of%2520the%2520tyrosine%2520kinase%2520activity%2520of%2520the%2520epidermal%2520growth%2520factor%2520receptor%2520%2528EGFR%2529%2520and%2520the%2520human%2520epidermal%2520growth%2520factor%2520receptor-2%2520%2528HER-2%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D46%26spage%3D49%26epage%3D63" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Schwartz, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuzmic, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solowiej, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergqvist, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bolanos, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Almaden, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagata, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryan, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalvie, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kath, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wani, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, B. M.</span><span> </span><span class="NLM_article-title">Covalent EGFR inhibitor analysis reveals importance of reversible interactions to potency and mechanisms of drug resistance</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">111</span><span class="NLM_x">, </span> <span class="NLM_fpage">173</span><span class="NLM_x">â</span> <span class="NLM_lpage">178</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Fjm5014659&amp;key=10.1073%2Fpnas.1313733111" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Fjm5014659&amp;key=24347635" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Fjm5014659&amp;key=1%3ACAS%3A528%3ADC%252BC2cXps1eluw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2014&pages=173-178&author=P.+A.+Schwartzauthor=P.+Kuzmicauthor=J.+Solowiejauthor=S.+Bergqvistauthor=B.+Bolanosauthor=C.+Almadenauthor=A.+Nagataauthor=K.+Ryanauthor=J.+Fengauthor=D.+Dalvieauthor=J.+C.+Kathauthor=M.+Xuauthor=R.+Waniauthor=B.+M.+Murray&title=Covalent+EGFR+inhibitor+analysis+reveals+importance+of+reversible+interactions+to+potency+and+mechanisms+of+drug+resistance"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Covalent EGFR inhibitor analysis reveals importance of reversible interactions to potency and mechanisms of drug resistance</span></div><div class="casAuthors">Schwartz, Phillip A.; Kuzmic, Petr; Solowiej, James; Bergqvist, Simon; Bolanos, Ben; Almaden, Chau; Nagata, Asako; Ryan, Kevin; Feng, Junli; Dalvie, Deepak; Kath, John C.; Xu, Meirong; Wani, Revati; Murray, Brion William</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">173-178</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Covalent inhibition is a reemerging paradigm in kinase drug design, but the roles of inhibitor binding affinity and chem. reactivity in overall potency are not well-understood.  To characterize the underlying mol. processes at a microscopic level and det. the appropriate kinetic consts., specialized exptl. design and advanced numerical integration of differential equations are developed.  Previously uncharacterized investigational covalent drugs reported here are shown to be extremely effective epidermal growth factor receptor (EGFR) inhibitors (kinact/Ki in the range 105-107 M-1s-1), despite their low specific reactivity (kinact â¤ 2.1 Ã 10-3 s-1), which is compensated for by high binding affinities (Ki < 1 nM).  For inhibitors relying on reactivity to achieve potency, noncovalent enzyme-inhibitor complex partitioning between inhibitor dissocn. and bond formation is central.  Interestingly, reversible binding affinity of EGFR covalent inhibitors is highly correlated with antitumor cell potency.  Furthermore, cellular potency for a subset of covalent inhibitors can be accounted for solely through reversible interactions.  One reversible interaction is between EGFR-Cys797 nucleophile and the inhibitor's reactive group, which may also contribute to drug resistance.  Because covalent inhibitors target a cysteine residue, the effects of its oxidn. on enzyme catalysis and inhibitor pharmacol. are characterized.  Oxidn. of the EGFR cysteine nucleophile does not alter catalysis but has widely varied effects on inhibitor potency depending on the EGFR context (e.g., oncogenic mutations), type of oxidn. (sulfinylation or glutathiolation), and inhibitor architecture.  These methods, parameters, and insights provide a rational framework for assessing and designing effective covalent inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTpPuRq8MwCLVg90H21EOLACvtfcHk0lhAiIQzlwJjTA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXps1eluw%253D%253D&md5=47197c5e7876a238eefb2e8e7de305ea</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1313733111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1313733111%26sid%3Dliteratum%253Aachs%26aulast%3DSchwartz%26aufirst%3DP.%2BA.%26aulast%3DKuzmic%26aufirst%3DP.%26aulast%3DSolowiej%26aufirst%3DJ.%26aulast%3DBergqvist%26aufirst%3DS.%26aulast%3DBolanos%26aufirst%3DB.%26aulast%3DAlmaden%26aufirst%3DC.%26aulast%3DNagata%26aufirst%3DA.%26aulast%3DRyan%26aufirst%3DK.%26aulast%3DFeng%26aufirst%3DJ.%26aulast%3DDalvie%26aufirst%3DD.%26aulast%3DKath%26aufirst%3DJ.%2BC.%26aulast%3DXu%26aufirst%3DM.%26aulast%3DWani%26aufirst%3DR.%26aulast%3DMurray%26aufirst%3DB.%2BM.%26atitle%3DCovalent%2520EGFR%2520inhibitor%2520analysis%2520reveals%2520importance%2520of%2520reversible%2520interactions%2520to%2520potency%2520and%2520mechanisms%2520of%2520drug%2520resistance%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2014%26volume%3D111%26spage%3D173%26epage%3D178" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Serafimova, I. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pufall, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krishnan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duda, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maglathlin, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McFarland, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">FrÃ¶din, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taunton, J.</span><span> </span><span class="NLM_article-title">Reversible targeting of noncatalytic cysteines with chemically tuned electrophiles</span> <span class="citation_source-journal">Nature Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">471</span><span class="NLM_x">â</span> <span class="NLM_lpage">476</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14a&amp;dbid=16&amp;doi=10.1021%2Fjm5014659&amp;key=10.1038%2Fnchembio.925" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14a&amp;dbid=8&amp;doi=10.1021%2Fjm5014659&amp;key=22466421" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14a&amp;dbid=32&amp;doi=10.1021%2Fjm5014659&amp;key=1%3ACAS%3A528%3ADC%252BC38XkvVKitrw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2012&pages=471-476&author=I.+M.+Serafimovaauthor=M.+A.+Pufallauthor=S.+Krishnanauthor=K.+Dudaauthor=M.+S.+Cohenauthor=R.+L.+Maglathlinauthor=J.+M.+McFarlandauthor=R.+M.+Millerauthor=M.+Fr%C3%B6dinauthor=J.+Taunton&title=Reversible+targeting+of+noncatalytic+cysteines+with+chemically+tuned+electrophiles"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14aR"><div class="casContent"><span class="casTitleNuber">14a</span><div class="casTitle"><span class="NLM_cas:atitle">Reversible targeting of noncatalytic cysteines with chemically tuned electrophiles</span></div><div class="casAuthors">Serafimova, Iana M.; Pufall, Miles A.; Krishnan, Shyam; Duda, Katarzyna; Cohen, Michael S.; Maglathlin, Rebecca L.; McFarland, Jesse M.; Miller, Rand M.; Froedin, Morten; Taunton, Jack</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">471-476</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Targeting noncatalytic cysteine residues with irreversible acrylamide-based inhibitors is a powerful approach for enhancing pharmacol. potency and selectivity.  Nevertheless, concerns about off-target modification motivate the development of reversible cysteine-targeting strategies.  Here we show that electron-deficient olefins, including acrylamides, can be tuned to react with cysteine thiols in a rapidly reversible manner.  Installation of a nitrile group increased the olefins' intrinsic reactivity, but, paradoxically, eliminated the formation of irreversible adducts.  Incorporation of these electrophiles into a noncovalent kinase-recognition scaffold produced slowly dissocg., covalent inhibitors of the p90 ribosomal protein S6 kinase RSK2.  A cocrystal structure revealed specific noncovalent interactions that stabilize the complex by positioning the electrophilic carbon near the targeted cysteine.  Disruption of these interactions by protein unfolding or proteolysis promoted instantaneous cleavage of the covalent bond.  Our results establish a chem.-based framework for engineering sustained covalent inhibition without accumulating permanently modified proteins and peptides.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlcv3GjPOB6rVg90H21EOLACvtfcHk0lhAiIQzlwJjTA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XkvVKitrw%253D&md5=6455a9a029714beb317286f71ac1326b</span></div><a href="/servlet/linkout?suffix=cit14a&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.925&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.925%26sid%3Dliteratum%253Aachs%26aulast%3DSerafimova%26aufirst%3DI.%2BM.%26aulast%3DPufall%26aufirst%3DM.%2BA.%26aulast%3DKrishnan%26aufirst%3DS.%26aulast%3DDuda%26aufirst%3DK.%26aulast%3DCohen%26aufirst%3DM.%2BS.%26aulast%3DMaglathlin%26aufirst%3DR.%2BL.%26aulast%3DMcFarland%26aufirst%3DJ.%2BM.%26aulast%3DMiller%26aufirst%3DR.%2BM.%26aulast%3DFr%25C3%25B6din%26aufirst%3DM.%26aulast%3DTaunton%26aufirst%3DJ.%26atitle%3DReversible%2520targeting%2520of%2520noncatalytic%2520cysteines%2520with%2520chemically%2520tuned%2520electrophiles%26jtitle%3DNature%2520Chem.%2520Biol.%26date%3D2012%26volume%3D8%26spage%3D471%26epage%3D476" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit14b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Miller, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paavilainen, V. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krishnan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serafimova, I. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taunton, J.</span><span> </span><span class="NLM_article-title">Electrophilic fragment-based design of reversible covalent kinase inhibitors</span> <span class="citation_source-journal">J. Am. Soc. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">135</span><span class="NLM_x">, </span> <span class="NLM_fpage">5298</span><span class="NLM_x">â</span> <span class="NLM_lpage">5301</span></span><div class="citationLinks">[<a href="/doi/10.1021/ja401221b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref14/cit14b&amp;dbid=32&amp;doi=10.1021%2Fjm5014659&amp;key=1%3ACAS%3A528%3ADC%252BC3sXltVClu7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=135&publication_year=2013&pages=5298-5301&author=R.+M.+Millerauthor=V.+O.+Paavilainenauthor=S.+Krishnanauthor=I.+M.+Serafimovaauthor=J.+Taunton&title=Electrophilic+fragment-based+design+of+reversible+covalent+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14bR"><div class="casContent"><span class="casTitleNuber">14b</span><div class="casTitle"><span class="NLM_cas:atitle">Electrophilic Fragment-Based Design of Reversible Covalent Kinase Inhibitors</span></div><div class="casAuthors">Miller, Rand M.; Paavilainen, Ville O.; Krishnan, Shyam; Serafimova, Iana M.; Taunton, Jack</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">135</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">5298-5301</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Fragment-based ligand design and covalent targeting of noncatalytic cysteines have been employed to develop potent and selective kinase inhibitors.  Here, we combine these approaches, starting with a panel of low-mol.-wt., heteroaryl-substituted cyanoacrylamides, which we have previously shown to form reversible covalent bonds with cysteine thiols.  Using this strategy, we identify electrophilic fragments with sufficient ligand efficiency and selectivity to serve as starting points for the first reported inhibitors of the MSK1 C-terminal kinase domain.  Guided by X-ray co-crystal structures, indazole fragment 1 was elaborated to afford 12 (RMM-46), a reversible covalent inhibitor that exhibits high ligand efficiency and selectivity for MSK/RSK-family kinases.  At nanomolar concns., 12 blocked activation of cellular MSK and RSK, as well as downstream phosphorylation of the crit. transcription factor, CREB.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrax7wBNWOT8rVg90H21EOLACvtfcHk0lh1qPucv58-Bg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXltVClu7g%253D&md5=c6100b56ce6f587f6afb834aeafec351</span></div><a href="/servlet/linkout?suffix=cit14b&amp;dbid=16384&amp;doi=10.1021%2Fja401221b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja401221b%26sid%3Dliteratum%253Aachs%26aulast%3DMiller%26aufirst%3DR.%2BM.%26aulast%3DPaavilainen%26aufirst%3DV.%2BO.%26aulast%3DKrishnan%26aufirst%3DS.%26aulast%3DSerafimova%26aufirst%3DI.%2BM.%26aulast%3DTaunton%26aufirst%3DJ.%26atitle%3DElectrophilic%2520fragment-based%2520design%2520of%2520reversible%2520covalent%2520kinase%2520inhibitors%26jtitle%3DJ.%2520Am.%2520Soc.%2520Chem.%26date%3D2013%26volume%3D135%26spage%3D5298%26epage%3D5301" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit14c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Nonoo, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Armstrong, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mann, D. J.</span><span> </span><span class="NLM_article-title">Kinetic template-guided tethering of fragments</span> <span class="citation_source-journal">ChemMedChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">2082</span><span class="NLM_x">â</span> <span class="NLM_lpage">2086</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&pages=2082-2086&author=R.+H.+Nonooauthor=A.+Armstrongauthor=D.+J.+Mann&title=Kinetic+template-guided+tethering+of+fragments"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNonoo%26aufirst%3DR.%2BH.%26aulast%3DArmstrong%26aufirst%3DA.%26aulast%3DMann%26aufirst%3DD.%2BJ.%26atitle%3DKinetic%2520template-guided%2520tethering%2520of%2520fragments%26jtitle%3DChemMedChem%26date%3D2012%26volume%3D7%26spage%3D2082%26epage%3D2086" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Bohm, H.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banner, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bendels, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kansy, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuhn, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MÃ¼ller, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Obst-Sander, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stahl, M.</span><span> </span><span class="NLM_article-title">Fluorine in medicinal chemistry</span> <span class="citation_source-journal">ChemBiolChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">637</span><span class="NLM_x">â</span> <span class="NLM_lpage">643</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Fjm5014659&amp;key=10.1002%2Fcbic.200301023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Fjm5014659&amp;key=15122635" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Fjm5014659&amp;key=1%3ACAS%3A280%3ADC%252BD2c3it1egug%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2004&pages=637-643&author=H.-J.+Bohmauthor=D.+Bannerauthor=S.+Bendelsauthor=M.+Kansyauthor=B.+Kuhnauthor=K.+M%C3%BCllerauthor=U.+Obst-Sanderauthor=M.+Stahl&title=Fluorine+in+medicinal+chemistry"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Fluorine in medicinal chemistry</span></div><div class="casAuthors">Bohm Hans-Joachim; Banner David; Bendels Stefanie; Kansy Manfred; Kuhn Bernd; Muller Klaus; Obst-Sander Ulrike; Stahl Martin</div><div class="citationInfo"><span class="NLM_cas:title">Chembiochem : a European journal of chemical biology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">637-43</span>
        ISSN:<span class="NLM_cas:issn">1439-4227</span>.
    </div><div class="casAbstract">Fluorinated compounds are synthesized in pharmaceutical research on a routine basis and many marketed compounds contain fluorine.  The present review summarizes some of the most frequently employed strategies for using fluorine substituents in medicinal chemistry.  Quite often, fluorine is introduced to improve the metabolic stability by blocking metabolically labile sites.  However, fluorine can also be used to modulate the physicochemical properties, such as lipophilicity or basicity.  It may exert a substantial effect on the conformation of a molecule.  Increasingly, fluorine is used to enhance the binding affinity to the target protein.  Recent 3D-structure determinations of protein complexes with bound fluorinated ligands have led to an improved understanding of the nonbonding protein-ligand interactions that involve fluorine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ4zDG_wo1YGtts4TFFB11gfW6udTcc2eY_LaFLGYnTmLntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2c3it1egug%253D%253D&md5=fa5ca2cfc278b83c80d5c96b18dfe312</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1002%2Fcbic.200301023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcbic.200301023%26sid%3Dliteratum%253Aachs%26aulast%3DBohm%26aufirst%3DH.-J.%26aulast%3DBanner%26aufirst%3DD.%26aulast%3DBendels%26aufirst%3DS.%26aulast%3DKansy%26aufirst%3DM.%26aulast%3DKuhn%26aufirst%3DB.%26aulast%3DM%25C3%25BCller%26aufirst%3DK.%26aulast%3DObst-Sander%26aufirst%3DU.%26aulast%3DStahl%26aufirst%3DM.%26atitle%3DFluorine%2520in%2520medicinal%2520chemistry%26jtitle%3DChemBiolChem%26date%3D2004%26volume%3D5%26spage%3D637%26epage%3D643" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Kirk, K. L.</span><span> </span><span class="NLM_article-title">Fluorine in medicinal chemistry: recent therapeutic applications of fluorinated small molecules</span> <span class="citation_source-journal">J. Fluorine Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">127</span><span class="NLM_x">, </span> <span class="NLM_fpage">1013</span><span class="NLM_x">â</span> <span class="NLM_lpage">1029</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Fjm5014659&amp;key=10.1016%2Fj.jfluchem.2006.06.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Fjm5014659&amp;key=1%3ACAS%3A528%3ADC%252BD28XnvVSrtb8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=2006&pages=1013-1029&author=K.+L.+Kirk&title=Fluorine+in+medicinal+chemistry%3A+recent+therapeutic+applications+of+fluorinated+small+molecules"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Fluorine in medicinal chemistry: Recent therapeutic applications of fluorinated small molecules</span></div><div class="casAuthors">Kirk, Kenneth L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Fluorine Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">127</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1013-1029</span>CODEN:
                <span class="NLM_cas:coden">JFLCAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-1139</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Advances in the development of newly developed fluorinated drugs, approved or in clin. trials, as organized by biol. targets/disease states, are reviewed.  In a few cases, compds. in early stages of development will be discussed, particularly where new promising targets are involved.  Important topics such as anticancer and antiviral drugs were covered in the two previous reviews in this series.  Included herein will be fluorinated drugs for treatment of diseases of the central nervous system, various cardiovascular diseases and obesity, antibacterial agents, and antifungal therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrd1vhHrZgNN7Vg90H21EOLACvtfcHk0lgXPkKf6S3pHA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XnvVSrtb8%253D&md5=890de242b8c5804fec1a9a7d35471ac1</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2Fj.jfluchem.2006.06.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jfluchem.2006.06.007%26sid%3Dliteratum%253Aachs%26aulast%3DKirk%26aufirst%3DK.%2BL.%26atitle%3DFluorine%2520in%2520medicinal%2520chemistry%253A%2520recent%2520therapeutic%2520applications%2520of%2520fluorinated%2520small%2520molecules%26jtitle%3DJ.%2520Fluorine%2520Chem.%26date%3D2006%26volume%3D127%26spage%3D1013%26epage%3D1029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Hagmann, W. K.</span><span> </span><span class="NLM_article-title">The many roles for fluorine in medicinal chemistry</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">4359</span><span class="NLM_x">â</span> <span class="NLM_lpage">4369</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm800219f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Fjm5014659&amp;key=1%3ACAS%3A528%3ADC%252BD1cXns1WjtLo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=4359-4369&author=W.+K.+Hagmann&title=The+many+roles+for+fluorine+in+medicinal+chemistry"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">The Many Roles for Fluorine in Medicinal Chemistry</span></div><div class="casAuthors">Hagmann, William K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4359-4369</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkZV7sio8RhbVg90H21EOLACvtfcHk0lgXPkKf6S3pHA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXns1WjtLo%253D&md5=821f8076bb0f632f687b1c90b05dd382</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Fjm800219f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800219f%26sid%3Dliteratum%253Aachs%26aulast%3DHagmann%26aufirst%3DW.%2BK.%26atitle%3DThe%2520many%2520roles%2520for%2520fluorine%2520in%2520medicinal%2520chemistry%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D4359%26epage%3D4369" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Ilardi, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vitaku, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Njardarson, J. T.</span><span> </span><span class="NLM_article-title">Data-mining for sulfur and fluorine: an evaluation of pharmaceuticals to reveal opportunities for drug design and discovery</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">2832</span><span class="NLM_x">â</span> <span class="NLM_lpage">2842</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm401375q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Fjm5014659&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsFyksb%252FE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=2832-2842&author=E.+A.+Ilardiauthor=E.+Vitakuauthor=J.+T.+Njardarson&title=Data-mining+for+sulfur+and+fluorine%3A+an+evaluation+of+pharmaceuticals+to+reveal+opportunities+for+drug+design+and+discovery"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Data-Mining for Sulfur and Fluorine: An Evaluation of Pharmaceuticals To Reveal Opportunities for Drug Design and Discovery</span></div><div class="casAuthors">Ilardi, Elizabeth A.; Vitaku, Edon; Njardarson, Jon T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2832-2842</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Among carbon, hydrogen, oxygen, and nitrogen, sulfur and fluorine are both leading constituents of the pharmaceuticals that comprise our medicinal history.  In efforts to stimulate the minds of both the general public and expert scientist, statistics were collected from the trends assocd. with therapeutics spanning 12 disease categories (a total of 1969 drugs) from our new graphical montage compilation: disease focused pharmaceuticals posters.  Each poster is a vibrant display of a collection of pharmaceuticals (including structural image, Food and Drug Administration (FDA) approval date, international nonproprietary name (INN), initial market name, and a color-coded subclass of function) organized chronol. and classified according to an assocn. with a particular clin. indication.  Specifically, the evolution and structural diversity of sulfur and the popular integration of fluorine into drugs introduced over the past 50 years are evaluated.  The presented qual. conclusions in this article aim to promote innovative insights into drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvH3H0yeaywrVg90H21EOLACvtfcHk0lgXPkKf6S3pHA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsFyksb%252FE&md5=b684f76341311979d0100ed68cffe714</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1021%2Fjm401375q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401375q%26sid%3Dliteratum%253Aachs%26aulast%3DIlardi%26aufirst%3DE.%2BA.%26aulast%3DVitaku%26aufirst%3DE.%26aulast%3DNjardarson%26aufirst%3DJ.%2BT.%26atitle%3DData-mining%2520for%2520sulfur%2520and%2520fluorine%253A%2520an%2520evaluation%2520of%2520pharmaceuticals%2520to%2520reveal%2520opportunities%2520for%2520drug%2520design%2520and%2520discovery%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D2832%26epage%3D2842" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Rewcastle, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palmer, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bridges, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Showalter, H. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McMichael, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kraker, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fry, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Denny, W. A.</span><span> </span><span class="NLM_article-title">Tyrosine kinase inhibitors. 9. Synthesis and evaluation of fused tricyclic quinazoline analogues as ATP site inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">918</span><span class="NLM_x">â</span> <span class="NLM_lpage">928</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm950692f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=1996&pages=918-928&author=G.+W.+Rewcastleauthor=B.+D.+Palmerauthor=A.+J.+Bridgesauthor=H.+D.+Showalterauthor=L.+Sunauthor=J.+Nelsonauthor=A.+McMichaelauthor=A.+J.+Krakerauthor=D.+W.+Fryauthor=W.+A.+Denny&title=Tyrosine+kinase+inhibitors.+9.+Synthesis+and+evaluation+of+fused+tricyclic+quinazoline+analogues+as+ATP+site+inhibitors+of+the+tyrosine+kinase+activity+of+the+epidermal+growth+factor+receptor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Fjm950692f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm950692f%26sid%3Dliteratum%253Aachs%26aulast%3DRewcastle%26aufirst%3DG.%2BW.%26aulast%3DPalmer%26aufirst%3DB.%2BD.%26aulast%3DBridges%26aufirst%3DA.%2BJ.%26aulast%3DShowalter%26aufirst%3DH.%2BD.%26aulast%3DSun%26aufirst%3DL.%26aulast%3DNelson%26aufirst%3DJ.%26aulast%3DMcMichael%26aufirst%3DA.%26aulast%3DKraker%26aufirst%3DA.%2BJ.%26aulast%3DFry%26aufirst%3DD.%2BW.%26aulast%3DDenny%26aufirst%3DW.%2BA.%26atitle%3DTyrosine%2520kinase%2520inhibitors.%25209.%2520Synthesis%2520and%2520evaluation%2520of%2520fused%2520tricyclic%2520quinazoline%2520analogues%2520as%2520ATP%2520site%2520inhibitors%2520of%2520the%2520tyrosine%2520kinase%2520activity%2520of%2520the%2520epidermal%2520growth%2520factor%2520receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1996%26volume%3D39%26spage%3D918%26epage%3D928" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Wu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xia, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shao, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weng, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deng, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, Y.</span><span> </span><span class="NLM_article-title">Design, synthesis, and biological evaluation of novel conformationally constrained inhibitors targeting EGFR</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">974</span><span class="NLM_x">â</span> <span class="NLM_lpage">978</span></span><div class="citationLinks">[<a href="/doi/10.1021/ml4002437" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=974-978&author=J.+Wuauthor=W.+Chenauthor=G.+Xiaauthor=J.+Zhangauthor=J.+Shaoauthor=B.+Tanauthor=C.+Zhangauthor=W.+Yuauthor=Q.+Wengauthor=H.+Liuauthor=M.+Huauthor=H.+Dengauthor=Y.+Haoauthor=J.+Shenauthor=Y.+Yu&title=Design%2C+synthesis%2C+and+biological+evaluation+of+novel+conformationally+constrained+inhibitors+targeting+EGFR"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Fml4002437&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml4002437%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DW.%26aulast%3DXia%26aufirst%3DG.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DShao%26aufirst%3DJ.%26aulast%3DTan%26aufirst%3DB.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DYu%26aufirst%3DW.%26aulast%3DWeng%26aufirst%3DQ.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DHu%26aufirst%3DM.%26aulast%3DDeng%26aufirst%3DH.%26aulast%3DHao%26aufirst%3DY.%26aulast%3DShen%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DY.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520biological%2520evaluation%2520of%2520novel%2520conformationally%2520constrained%2520inhibitors%2520targeting%2520EGFR%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D4%26spage%3D974%26epage%3D978" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Kajjout, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zemmouri, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eddarir, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rolando, C.</span><span> </span><span class="NLM_article-title">An efficient access to (<i>Z</i>)-Î²-fluoroallyl alcohols based on the two carbon homologation of aromatic aldehydes by HornerâWadsworthâEmmons reaction with 2-(diethoxyphosphinyl)-2-fluoro-ethanethioic acid, <i>S</i>-ethyl ester followed by reduction with sodium borohydride</span> <span class="citation_source-journal">Tetrahedron</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x">, </span> <span class="NLM_fpage">3225</span><span class="NLM_x">â</span> <span class="NLM_lpage">3230</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2012&pages=3225-3230&author=M.+Kajjoutauthor=R.+Zemmouriauthor=S.+Eddarirauthor=C.+Rolando&title=An+efficient+access+to+%28Z%29-%CE%B2-fluoroallyl+alcohols+based+on+the+two+carbon+homologation+of+aromatic+aldehydes+by+Horner%E2%80%93Wadsworth%E2%80%93Emmons+reaction+with+2-%28diethoxyphosphinyl%29-2-fluoro-ethanethioic+acid%2C+S-ethyl+ester+followed+by+reduction+with+sodium+borohydride"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKajjout%26aufirst%3DM.%26aulast%3DZemmouri%26aufirst%3DR.%26aulast%3DEddarir%26aufirst%3DS.%26aulast%3DRolando%26aufirst%3DC.%26atitle%3DAn%2520efficient%2520access%2520to%2520%2528Z%2529-%25CE%25B2-fluoroallyl%2520alcohols%2520based%2520on%2520the%2520two%2520carbon%2520homologation%2520of%2520aromatic%2520aldehydes%2520by%2520Horner%25E2%2580%2593Wadsworth%25E2%2580%2593Emmons%2520reaction%2520with%25202-%2528diethoxyphosphinyl%2529-2-fluoro-ethanethioic%2520acid%252C%2520S-ethyl%2520ester%2520followed%2520by%2520reduction%2520with%2520sodium%2520borohydride%26jtitle%3DTetrahedron%26date%3D2012%26volume%3D68%26spage%3D3225%26epage%3D3230" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">GansÃ¤uer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Worgull, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knebel, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huth, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schnakenburg, G.</span><span> </span><span class="NLM_article-title">4-Exo cyclizations by template</span> <span class="citation_source-journal">Angew. Chem., Int. Ed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">8882</span><span class="NLM_x">â</span> <span class="NLM_lpage">8885</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2009&pages=8882-8885&author=A.+Gans%C3%A4uerauthor=D.+Worgullauthor=K.+Knebelauthor=I.+Huthauthor=G.+Schnakenburg&title=4-Exo+cyclizations+by+template"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGans%25C3%25A4uer%26aufirst%3DA.%26aulast%3DWorgull%26aufirst%3DD.%26aulast%3DKnebel%26aufirst%3DK.%26aulast%3DHuth%26aufirst%3DI.%26aulast%3DSchnakenburg%26aufirst%3DG.%26atitle%3D4-Exo%2520cyclizations%2520by%2520template%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2009%26volume%3D48%26spage%3D8882%26epage%3D8885" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Short, K. M.; Pham, S. M.; Williams, D. C.; Datta, S.</span><span> </span><span class="NLM_article-title">Multisubstituted aromatic compounds as inhibitors of thrombin</span>. WO 2011/126903,<span class="NLM_x"> </span><span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=K.+M.+Short&author=S.+M.+Pham&author=D.+C.+Williams&author=S.+Datta&title=Multisubstituted+aromatic+compounds+as+inhibitors+of+thrombin"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DShort%26aufirst%3DK.%2BM.%26atitle%3DMultisubstituted%2520aromatic%2520compounds%2520as%2520inhibitors%2520of%2520thrombin%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Barf, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaptein, A.</span><span> </span><span class="NLM_article-title">Irreversible protein kinase inhibitors: balancing the benefits and risks</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">6243</span><span class="NLM_x">â</span> <span class="NLM_lpage">6644</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm3003203" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Fjm5014659&amp;key=1%3ACAS%3A528%3ADC%252BC38XnsVerur8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=6243-6644&author=T.+Barfauthor=A.+Kaptein&title=Irreversible+protein+kinase+inhibitors%3A+balancing+the+benefits+and+risks"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Irreversible Protein Kinase Inhibitors: Balancing the Benefits and Risks</span></div><div class="casAuthors">Barf, Tjeerd; Kaptein, Allard</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">6243-6262</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Not applicable for a Perspective.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4PLlisO0OVbVg90H21EOLACvtfcHk0lhkg3zxiMv0mw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XnsVerur8%253D&md5=5d87850857d37faab02e6037ef8140a4</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Fjm3003203&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm3003203%26sid%3Dliteratum%253Aachs%26aulast%3DBarf%26aufirst%3DT.%26aulast%3DKaptein%26aufirst%3DA.%26atitle%3DIrreversible%2520protein%2520kinase%2520inhibitors%253A%2520balancing%2520the%2520benefits%2520and%2520risks%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D6243%26epage%3D6644" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Diaz, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daniell, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leitza, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDermott, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cox, B. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gintant, G. A.</span><span> </span><span class="NLM_article-title">The [<sup>3</sup>H]dofetilide binding assay is a predictive screening tool for hERG blockade and proarrhythmia: Comparison of intact cell and membrane preparations and effects of altering [K+]o</span> <span class="citation_source-journal">J. Pharmacol. Toxicol. Methods</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">187</span><span class="NLM_x">â</span> <span class="NLM_lpage">199</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Fjm5014659&amp;key=10.1016%2Fj.vascn.2004.04.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Fjm5014659&amp;key=15519905" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Fjm5014659&amp;key=1%3ACAS%3A528%3ADC%252BD2cXptFOmtLk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2004&pages=187-199&author=G.+J.+Diazauthor=K.+Daniellauthor=S.+T.+Leitzaauthor=R.+L.+Martinauthor=Z.+Suauthor=J.+S.+McDermottauthor=B.+F.+Coxauthor=G.+A.+Gintant&title=The+%5B3H%5Ddofetilide+binding+assay+is+a+predictive+screening+tool+for+hERG+blockade+and+proarrhythmia%3A+Comparison+of+intact+cell+and+membrane+preparations+and+effects+of+altering+%5BK%2B%5Do"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">The [3H]dofetilide binding assay is a predictive screening tool for hERG blockade and proarrhythmia: Comparison of intact cell and membrane preparations and effects of altering [K+]o</span></div><div class="casAuthors">Diaz, Gilbert J.; Daniell, Katina; Leitza, Sandra T.; Martin, Ruth L.; Su, Zhi; McDermott, Jeffrey S.; Cox, Bryan F.; Gintant, Gary A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacological and Toxicological Methods</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">187-199</span>CODEN:
                <span class="NLM_cas:coden">JPTMEZ</span>;
        ISSN:<span class="NLM_cas:issn">1056-8719</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Introduction: The human ether-a-go-go-related gene (hERG) encodes a potassium channel responsible for the cardiac delayed rectifier current (IKr) involved in ventricular repolarization.  Drugs that block hERG have been assocd. with QT interval prolongation and serious, sometimes fatal, cardiac arrhythmias (including torsade de pointes).  While displacement of [3H]dofetilide, a potent methanesulfonanilide hERG blocker, from cells heterologously expressing hERG has been suggested as a screening assay, questions have been raised about its predictive value.Methods: To validate the utility of this assay as a screening tool, we performed a series of satn. and competition binding studies using [3H]dofetilide as ligand and either intact cells or membrane prepns. from HEK 293 cells stably transfected with hERG K+ channels.  The object of these expts. was to (1) compare binding Ki values for 22 hERG blockers using intact cells or membrane homogenates to det. whether maintaining cell integrity enhanced assay reliability; (2) evaluate the ability of different K+ concns. (2, 5, 10, 20, and 60 mM) to modulate hERG binding; and (3) to establish the predictive value of the assay by comparing Ki values from binding studies at 5 and 60 mM [K+]o to functional IC50 values for hERG current block using 56 structurally diverse drugs.Results: We found (a) comparable Ki values in the intact cell and isolated membrane binding assays, although there were some differences in rank order; (b) increasing [K+]o lowered the Kd and increased the Bmax for [3H]dofetilide, particularly in the membrane assay; and (c) good correlation between binding Ki values and functional IC50 values for hERG current block.Discussion: In conclusion, increasing K+ concns. results in an increase in both [3H]dofetilide affinity for hERG and available binding sites, particularly when using membrane homogenates.  There are no meaningful differences between Ki values when comparing intact cell vs. membrane assay, neither are there meaningful trends with increasing [K+]o within assays.  There is good correlation between binding Ki values and functional (whole-cell patch clamp) IC50 values at both 5 and 60 mM K+ concns. (R2 values of .824 and .863, resp.).  The simplicity, predictability, and adaptability to high-throughput platforms make the [3H]dofetilide membrane binding assay a useful tool for screening and ranking compds. for their potential to block the hERG K+ channel.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJEs_DWLzvI7Vg90H21EOLACvtfcHk0li6ror2_9L0pg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXptFOmtLk%253D&md5=28c925ef02404c53443dc90eae961ed1</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2Fj.vascn.2004.04.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.vascn.2004.04.001%26sid%3Dliteratum%253Aachs%26aulast%3DDiaz%26aufirst%3DG.%2BJ.%26aulast%3DDaniell%26aufirst%3DK.%26aulast%3DLeitza%26aufirst%3DS.%2BT.%26aulast%3DMartin%26aufirst%3DR.%2BL.%26aulast%3DSu%26aufirst%3DZ.%26aulast%3DMcDermott%26aufirst%3DJ.%2BS.%26aulast%3DCox%26aufirst%3DB.%2BF.%26aulast%3DGintant%26aufirst%3DG.%2BA.%26atitle%3DThe%2520%255B3H%255Ddofetilide%2520binding%2520assay%2520is%2520a%2520predictive%2520screening%2520tool%2520for%2520hERG%2520blockade%2520and%2520proarrhythmia%253A%2520Comparison%2520of%2520intact%2520cell%2520and%2520membrane%2520preparations%2520and%2520effects%2520of%2520altering%2520%255BK%252B%255Do%26jtitle%3DJ.%2520Pharmacol.%2520Toxicol.%2520Methods%26date%3D2004%26volume%3D50%26spage%3D187%26epage%3D199" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14a','cit14b','cit14c'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 40 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Adam Birkholz, David J. Kopecky, Laurie P. Volak, Michael D. Bartberger, Yuping Chen, Christopher M. Tegley, Tara Arvedson, John D. McCarter, Christopher Fotsch, <span class="NLM_string-name hlFld-ContribAuthor">Victor J. Cee</span>. </span><span class="cited-content_cbyCitation_article-title">Systematic Study of the Glutathione Reactivity of N-Phenylacrylamides: 2. Effects of Acrylamide Substitution. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (20)
                                     , 11602-11614. <a href="https://doi.org/10.1021/acs.jmedchem.0c00749" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00749</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00749&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00749%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSystematic%252BStudy%252Bof%252Bthe%252BGlutathione%252BReactivity%252Bof%252BN-Phenylacrylamides%25253A%252B2.%252BEffects%252Bof%252BAcrylamide%252BSubstitution%26aulast%3DBirkholz%26aufirst%3DAdam%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D04052020%26date%3D09102020%26date%3D23092020%26volume%3D63%26issue%3D20%26spage%3D11602%26epage%3D11614" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Ronen Gabizon, <span class="NLM_string-name hlFld-ContribAuthor">Nir London</span>. </span><span class="cited-content_cbyCitation_article-title">Hitting KRAS When Itâs Down. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (13)
                                     , 6677-6678. <a href="https://doi.org/10.1021/acs.jmedchem.0c00785" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00785</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00785&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00785%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DHitting%252BKRAS%252BWhen%252BIt%2525E2%252580%252599s%252BDown%26aulast%3DGabizon%26aufirst%3DRonen%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D09052020%26date%3D22062020%26volume%3D63%26issue%3D13%26spage%3D6677%26epage%3D6678" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Jay B. Fell, John P. Fischer, Brian R. Baer, James F. Blake, Karyn Bouhana, David M. Briere, Karin D. Brown, Laurence E. Burgess, Aaron C. Burns, Michael R. Burkard, Harrah Chiang, Mark J. Chicarelli, Adam W. Cook, John J. Gaudino, Jill Hallin, Lauren Hanson, Dylan P. Hartley, Erik J. Hicken, Gary P. Hingorani, Ronald J. Hinklin, Macedonio J. Mejia, Peter Olson, Jennifer N. Otten, Susan P. Rhodes, Martha E. Rodriguez, Pavel Savechenkov, Darin J. Smith, Niranjan Sudhakar, Francis X. Sullivan, Tony P. Tang, Guy P. Vigers, Lance Wollenberg, James G. Christensen, <span class="NLM_string-name hlFld-ContribAuthor">Matthew A. Marx</span>. </span><span class="cited-content_cbyCitation_article-title">Identification of the Clinical Development Candidate MRTX849, a Covalent KRASG12C Inhibitor for the Treatment of Cancer. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (13)
                                     , 6679-6693. <a href="https://doi.org/10.1021/acs.jmedchem.9b02052" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b02052</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b02052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b02052%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DIdentification%252Bof%252Bthe%252BClinical%252BDevelopment%252BCandidate%252BMRTX849%25252C%252Ba%252BCovalent%252BKRASG12C%252BInhibitor%252Bfor%252Bthe%252BTreatment%252Bof%252BCancer%26aulast%3DFell%26aufirst%3DJay%2BB.%26date%3D2020%26date%3D2020%26date%3D2019%26date%3D10122019%26date%3D06042020%26volume%3D63%26issue%3D13%26spage%3D6679%26epage%3D6693" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Elizabeth H.  Krenske</span>, <span class="hlFld-ContribAuthor ">Russell C.  Petter</span>, and <span class="hlFld-ContribAuthor ">K. N.  Houk</span>  . </span><span class="cited-content_cbyCitation_article-title">Kinetics and Thermodynamics of Reversible Thiol Additions to Mono- and Diactivated Michael Acceptors: Implications for the Design of Drugs That Bind Covalently to Cysteines. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2016,</strong> <em>81 </em>
                                    (23)
                                     , 11726-11733. <a href="https://doi.org/10.1021/acs.joc.6b02188" title="DOI URL">https://doi.org/10.1021/acs.joc.6b02188</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.joc.6b02188&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.joc.6b02188%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DKinetics%252Band%252BThermodynamics%252Bof%252BReversible%252BThiol%252BAdditions%252Bto%252BMono-%252Band%252BDiactivated%252BMichael%252BAcceptors%25253A%252BImplications%252Bfor%252Bthe%252BDesign%252Bof%252BDrugs%252BThat%252BBind%252BCovalently%252Bto%252BCysteines%26aulast%3DKrenske%26aufirst%3DElizabeth%2BH.%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D06092016%26date%3D08112016%26date%3D02122016%26volume%3D81%26issue%3D23%26spage%3D11726%26epage%3D11733" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zhendong  Song</span>, <span class="hlFld-ContribAuthor ">Yang  Ge</span>, <span class="hlFld-ContribAuthor ">Changyuan  Wang</span>, <span class="hlFld-ContribAuthor ">Shanshan  Huang</span>, <span class="hlFld-ContribAuthor ">Xiaohong  Shu</span>, <span class="hlFld-ContribAuthor ">Kexin  Liu</span>, <span class="hlFld-ContribAuthor ">Youwen  Zhou</span>, and <span class="hlFld-ContribAuthor ">Xiaodong  Ma</span>  . </span><span class="cited-content_cbyCitation_article-title">Challenges and Perspectives on the Development of Small-Molecule EGFR Inhibitors against T790M-Mediated Resistance in Non-Small-Cell Lung Cancer. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>59 </em>
                                    (14)
                                     , 6580-6594. <a href="https://doi.org/10.1021/acs.jmedchem.5b00840" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.5b00840</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.5b00840&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.5b00840%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DChallenges%252Band%252BPerspectives%252Bon%252Bthe%252BDevelopment%252Bof%252BSmall-Molecule%252BEGFR%252BInhibitors%252Bagainst%252BT790M-Mediated%252BResistance%252Bin%252BNon-Small-Cell%252BLung%252BCancer%26aulast%3DSong%26aufirst%3DZhendong%26date%3D2016%26date%3D2016%26date%3D2015%26date%3D02062015%26date%3D26022016%26date%3D28072016%26date%3D16022016%26volume%3D59%26issue%3D14%26spage%3D6580%26epage%3D6594" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hengmiao  Cheng</span>, <span class="hlFld-ContribAuthor ">Sajiv K.  Nair</span>, <span class="hlFld-ContribAuthor ">Brion W.  Murray</span>, <span class="hlFld-ContribAuthor ">Chau  Almaden</span>, <span class="hlFld-ContribAuthor ">Simon  Bailey</span>, <span class="hlFld-ContribAuthor ">Sangita  Baxi</span>, <span class="hlFld-ContribAuthor ">Doug  Behenna</span>, <span class="hlFld-ContribAuthor ">Sujin  Cho-Schultz</span>, <span class="hlFld-ContribAuthor ">Deepak  Dalvie</span>, <span class="hlFld-ContribAuthor ">Dac M.  Dinh</span>, <span class="hlFld-ContribAuthor ">Martin P.  Edwards</span>, <span class="hlFld-ContribAuthor ">Jun Li  Feng</span>, <span class="hlFld-ContribAuthor ">Rose Ann  Ferre</span>, <span class="hlFld-ContribAuthor ">Ketan S.  Gajiwala</span>, <span class="hlFld-ContribAuthor ">Michelle D.  Hemkens</span>, <span class="hlFld-ContribAuthor ">Amy  Jackson-Fisher</span>, <span class="hlFld-ContribAuthor ">Mehran  Jalaie</span>, <span class="hlFld-ContribAuthor ">Ted O.  Johnson</span>, <span class="hlFld-ContribAuthor ">Robert S.  Kania</span>, <span class="hlFld-ContribAuthor ">Susan  Kephart</span>, <span class="hlFld-ContribAuthor ">Jennifer  Lafontaine</span>, <span class="hlFld-ContribAuthor ">Beth  Lunney</span>, <span class="hlFld-ContribAuthor ">Kevin K.-C.  Liu</span>, <span class="hlFld-ContribAuthor ">Zhengyu  Liu</span>, <span class="hlFld-ContribAuthor ">Jean  Matthews</span>, <span class="hlFld-ContribAuthor ">Asako  Nagata</span>, <span class="hlFld-ContribAuthor ">Sherry  Niessen</span>, <span class="hlFld-ContribAuthor ">Martha A.  Ornelas</span>, <span class="hlFld-ContribAuthor ">Suvi T. M.  Orr</span>, <span class="hlFld-ContribAuthor ">Mason  Pairish</span>, <span class="hlFld-ContribAuthor ">Simon  Planken</span>, <span class="hlFld-ContribAuthor ">Shijian  Ren</span>, <span class="hlFld-ContribAuthor ">Daniel  Richter</span>, <span class="hlFld-ContribAuthor ">Kevin  Ryan</span>, <span class="hlFld-ContribAuthor ">Neal  Sach</span>, <span class="hlFld-ContribAuthor ">Hong  Shen</span>, <span class="hlFld-ContribAuthor ">Tod  Smeal</span>, <span class="hlFld-ContribAuthor ">Jim  Solowiej</span>, <span class="hlFld-ContribAuthor ">Scott  Sutton</span>, <span class="hlFld-ContribAuthor ">Khanh  Tran</span>, <span class="hlFld-ContribAuthor ">Elaine  Tseng</span>, <span class="hlFld-ContribAuthor ">William  Vernier</span>, <span class="hlFld-ContribAuthor ">Marlena  Walls</span>, <span class="hlFld-ContribAuthor ">Shuiwang  Wang</span>, <span class="hlFld-ContribAuthor ">Scott L.  Weinrich</span>, <span class="hlFld-ContribAuthor ">Shuibo  Xin</span>, <span class="hlFld-ContribAuthor ">Haiwei  Xu</span>, <span class="hlFld-ContribAuthor ">Min-Jean  Yin</span>, <span class="hlFld-ContribAuthor ">Michael  Zientek</span>, <span class="hlFld-ContribAuthor ">Ru  Zhou</span>, and <span class="hlFld-ContribAuthor ">John C.  Kath</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of 1-{(3R,4R)-3-[({5-Chloro-2-[(1-methyl-1H-pyrazol-4-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}oxy)methyl]-4-methoxypyrrolidin-1-yl}prop-2-en-1-one (PF-06459988), a Potent, WT Sparing, Irreversible Inhibitor of T790M-Containing EGFR Mutants. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>59 </em>
                                    (5)
                                     , 2005-2024. <a href="https://doi.org/10.1021/acs.jmedchem.5b01633" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.5b01633</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.5b01633&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.5b01633%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252B1-%25257B%2525283R%25252C4R%252529-3-%25255B%252528%25257B5-Chloro-2-%25255B%2525281-methyl-1H-pyrazol-4-yl%252529amino%25255D-7H-pyrrolo%25255B2%25252C3-d%25255Dpyrimidin-4-yl%25257Doxy%252529methyl%25255D-4-methoxypyrrolidin-1-yl%25257Dprop-2-en-1-one%252B%252528PF-06459988%252529%25252C%252Ba%252BPotent%25252C%252BWT%252BSparing%25252C%252BIrreversible%252BInhibitor%252Bof%252BT790M-Containing%252BEGFR%252BMutants%26aulast%3DCheng%26aufirst%3DHengmiao%26date%3D2016%26date%3D2016%26date%3D2015%26date%3D17102015%26date%3D28012016%26date%3D10032016%26date%3D12012016%26volume%3D59%26issue%3D5%26spage%3D2005%26epage%3D2024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ryan P.  Wurz</span>, <span class="hlFld-ContribAuthor ">Liping H.  Pettus</span>, <span class="hlFld-ContribAuthor ">Kate  Ashton</span>, <span class="hlFld-ContribAuthor ">James  Brown</span>, <span class="hlFld-ContribAuthor ">Jian Jeffrey  Chen</span>, <span class="hlFld-ContribAuthor ">Brad  Herberich</span>, <span class="hlFld-ContribAuthor ">Fang-Tsao  Hong</span>, <span class="hlFld-ContribAuthor ">Essa  Hu-Harrington</span>, <span class="hlFld-ContribAuthor ">Tom  Nguyen</span>, <span class="hlFld-ContribAuthor ">David J.  St. Jean, Jr.</span>, <span class="hlFld-ContribAuthor ">Seifu  Tadesse</span>, <span class="hlFld-ContribAuthor ">David  Bauer</span>, <span class="hlFld-ContribAuthor ">Michele  Kubryk</span>, <span class="hlFld-ContribAuthor ">Jinghui  Zhan</span>, <span class="hlFld-ContribAuthor ">Keegan  Cooke</span>, <span class="hlFld-ContribAuthor ">Petia  Mitchell</span>, <span class="hlFld-ContribAuthor ">Kristin L.  Andrews</span>, <span class="hlFld-ContribAuthor ">Faye  Hsieh</span>, <span class="hlFld-ContribAuthor ">Dean  Hickman</span>, <span class="hlFld-ContribAuthor ">Nataraj  Kalyanaraman</span>, <span class="hlFld-ContribAuthor ">Tian  Wu</span>, <span class="hlFld-ContribAuthor ">Darren L.  Reid</span>, <span class="hlFld-ContribAuthor ">Edward K.  Lobenhofer</span>, <span class="hlFld-ContribAuthor ">Dina A.  Andrews</span>, <span class="hlFld-ContribAuthor ">Nancy  Everds</span>, <span class="hlFld-ContribAuthor ">Roberto  Guzman</span>, <span class="hlFld-ContribAuthor ">Andrew T.  Parsons</span>, <span class="hlFld-ContribAuthor ">Simon J.  Hedley</span>, <span class="hlFld-ContribAuthor ">Jason  Tedrow</span>, <span class="hlFld-ContribAuthor ">Oliver R.  Thiel</span>, <span class="hlFld-ContribAuthor ">Matthew  Potter</span>, <span class="hlFld-ContribAuthor ">Robert  Radinsky</span>, <span class="hlFld-ContribAuthor ">Pedro J.  Beltran</span>, and <span class="hlFld-ContribAuthor ">Andrew S.  Tasker</span>  . </span><span class="cited-content_cbyCitation_article-title">Oxopyrido[2,3-d]pyrimidines as Covalent L858R/T790M Mutant Selective Epidermal Growth Factor Receptor (EGFR) Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2015,</strong> <em>6 </em>
                                    (9)
                                     , 987-992. <a href="https://doi.org/10.1021/acsmedchemlett.5b00193" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.5b00193</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.5b00193&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.5b00193%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DOxopyrido%25255B2%25252C3-d%25255Dpyrimidines%252Bas%252BCovalent%252BL858R%25252FT790M%252BMutant%252BSelective%252BEpidermal%252BGrowth%252BFactor%252BReceptor%252B%252528EGFR%252529%252BInhibitors%26aulast%3DWurz%26aufirst%3DRyan%2BP.%26date%3D2015%26date%3D2015%26date%3D2015%26date%3D2015%26date%3D08052015%26date%3D27072015%26date%3D31072015%26date%3D10092015%26date%3D27072015%26volume%3D6%26issue%3D9%26spage%3D987%26epage%3D992" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Saeb  Aliwaini</span>, <span class="hlFld-ContribAuthor ">Bassam  Abu Thaher</span>, <span class="hlFld-ContribAuthor ">Ihab  Al-Masri</span>, <span class="hlFld-ContribAuthor ">Nabil  Shurrab</span>, <span class="hlFld-ContribAuthor ">Said  El-Kurdi</span>, <span class="hlFld-ContribAuthor ">Dieter  Schollmeyer</span>, <span class="hlFld-ContribAuthor ">Basem  Qeshta</span>, <span class="hlFld-ContribAuthor ">Mariam  Ghunaim</span>, <span class="hlFld-ContribAuthor ">RenÃ©  Csuk</span>, <span class="hlFld-ContribAuthor ">Stefan  Laufer</span>, <span class="hlFld-ContribAuthor ">Lars  Kaiser</span>, <span class="hlFld-ContribAuthor ">Hans-Peter  Deigner</span>. </span><span class="cited-content_cbyCitation_article-title">Design, Synthesis and Biological Evaluation of Novel Pyrazolo[1,2,4]triazolopyrimidine Derivatives as Potential Anticancer Agents. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2021,</strong> <em>26 </em>
                                    (13)
                                     , 4065. <a href="https://doi.org/10.3390/molecules26134065" title="DOI URL">https://doi.org/10.3390/molecules26134065</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules26134065&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules26134065%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DDesign%25252C%252BSynthesis%252Band%252BBiological%252BEvaluation%252Bof%252BNovel%252BPyrazolo%25255B1%25252C2%25252C4%25255Dtriazolopyrimidine%252BDerivatives%252Bas%252BPotential%252BAnticancer%252BAgents%26aulast%3DAliwaini%26aufirst%3DSaeb%26date%3D2021%26date%3D2021%26volume%3D26%26issue%3D13%26spage%3D4065" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Elena De  Vita</span>. </span><span class="cited-content_cbyCitation_article-title">10 years into the resurgence of covalent drugs. </span><span class="cited-content_cbyCitation_journal-name">Future Medicinal Chemistry</span><span> <strong>2021,</strong> <em>13 </em>
                                    (2)
                                     , 193-210. <a href="https://doi.org/10.4155/fmc-2020-0236" title="DOI URL">https://doi.org/10.4155/fmc-2020-0236</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4155/fmc-2020-0236&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4155%2Ffmc-2020-0236%26sid%3Dliteratum%253Aachs%26jtitle%3DFuture%2520Medicinal%2520Chemistry%26atitle%3D10%252Byears%252Binto%252Bthe%252Bresurgence%252Bof%252Bcovalent%252Bdrugs%26aulast%3DVita%26aufirst%3DElena%2BDe%26date%3D2021%26volume%3D13%26issue%3D2%26spage%3D193%26epage%3D210" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Amit  Shraga</span>, <span class="hlFld-ContribAuthor ">Efrat  Resnick</span>, <span class="hlFld-ContribAuthor ">Ronen  Gabizon</span>, <span class="hlFld-ContribAuthor ">Nir  London</span>. </span><span class="cited-content_cbyCitation_article-title">Covalent fragment screening. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,, 243-265. <a href="https://doi.org/10.1016/bs.armc.2021.04.001" title="DOI URL">https://doi.org/10.1016/bs.armc.2021.04.001</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/bs.armc.2021.04.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fbs.armc.2021.04.001%26sid%3Dliteratum%253Aachs%26atitle%3DCovalent%252Bfragment%252Bscreening%26aulast%3DShraga%26aufirst%3DAmit%26date%3D2021%26spage%3D243%26epage%3D265%26pub%3DElsevier%26atitle%3DThe%252BDesign%252Bof%252BCovalent-Based%252BInhibitors%26date%3D2021%26volume%3D56" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Anjleena  Malhotra</span>, <span class="hlFld-ContribAuthor ">Ranju  Bansal</span>, <span class="hlFld-ContribAuthor ">Clarissa Esmeralda  Halim</span>, <span class="hlFld-ContribAuthor ">Celestial T.  Yap</span>, <span class="hlFld-ContribAuthor ">Gautam  Sethi</span>, <span class="hlFld-ContribAuthor ">Alan Prem  Kumar</span>, <span class="hlFld-ContribAuthor ">Mahendra  Bishnoi</span>, <span class="hlFld-ContribAuthor ">Kamalendra  Yadav</span>. </span><span class="cited-content_cbyCitation_article-title">Novel amide analogues of quinazoline carboxylate display selective antiproliferative activity and potent EGFR inhibition. </span><span class="cited-content_cbyCitation_journal-name">Medicinal Chemistry Research</span><span> <strong>2020,</strong> <em>29 </em>
                                    (12)
                                     , 2112-2122. <a href="https://doi.org/10.1007/s00044-020-02634-0" title="DOI URL">https://doi.org/10.1007/s00044-020-02634-0</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s00044-020-02634-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs00044-020-02634-0%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicinal%2520Chemistry%2520Research%26atitle%3DNovel%252Bamide%252Banalogues%252Bof%252Bquinazoline%252Bcarboxylate%252Bdisplay%252Bselective%252Bantiproliferative%252Bactivity%252Band%252Bpotent%252BEGFR%252Binhibition%26aulast%3DMalhotra%26aufirst%3DAnjleena%26date%3D2020%26date%3D2020%26volume%3D29%26issue%3D12%26spage%3D2112%26epage%3D2122" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zhen  Xiao</span>, <span class="hlFld-ContribAuthor ">Cilong  Chu</span>, <span class="hlFld-ContribAuthor ">Lingjia  Zhou</span>, <span class="hlFld-ContribAuthor ">Zhihui  Zhou</span>, <span class="hlFld-ContribAuthor ">Qian  Zhang</span>, <span class="hlFld-ContribAuthor ">Feiyi  Yang</span>, <span class="hlFld-ContribAuthor ">Zunhua  Yang</span>, <span class="hlFld-ContribAuthor ">Pengwu  Zheng</span>, <span class="hlFld-ContribAuthor ">Shan  Xu</span>, <span class="hlFld-ContribAuthor ">Wufu  Zhu</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of thiapyran-pyrimidine derivatives as potential EGFR inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2020,</strong> <em>28 </em>
                                    (19)
                                     , 115669. <a href="https://doi.org/10.1016/j.bmc.2020.115669" title="DOI URL">https://doi.org/10.1016/j.bmc.2020.115669</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2020.115669&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2020.115669%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bthiapyran-pyrimidine%252Bderivatives%252Bas%252Bpotential%252BEGFR%252Binhibitors%26aulast%3DXiao%26aufirst%3DZhen%26date%3D2020%26volume%3D28%26issue%3D19%26spage%3D115669" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jiaan  Shao</span>, <span class="hlFld-ContribAuthor ">Shuangrong  Liu</span>, <span class="hlFld-ContribAuthor ">Xingyu  Liu</span>, <span class="hlFld-ContribAuthor ">Youlu  Pan</span>, <span class="hlFld-ContribAuthor ">Wenteng  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and SAR study of 2-aminopyrimidines with diverse Michael addition acceptors for chemically tuning the potency against EGFRL858R/T790M. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2020,</strong> <em>28 </em>
                                    (19)
                                     , 115680. <a href="https://doi.org/10.1016/j.bmc.2020.115680" title="DOI URL">https://doi.org/10.1016/j.bmc.2020.115680</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2020.115680&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2020.115680%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252BSAR%252Bstudy%252Bof%252B2-aminopyrimidines%252Bwith%252Bdiverse%252BMichael%252Baddition%252Bacceptors%252Bfor%252Bchemically%252Btuning%252Bthe%252Bpotency%252Bagainst%252BEGFRL858R%25252FT790M%26aulast%3DShao%26aufirst%3DJiaan%26date%3D2020%26volume%3D28%26issue%3D19%26spage%3D115680" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zhen  Xiao</span>, <span class="hlFld-ContribAuthor ">Zhihui  Zhou</span>, <span class="hlFld-ContribAuthor ">Cilong  Chu</span>, <span class="hlFld-ContribAuthor ">Qian  Zhang</span>, <span class="hlFld-ContribAuthor ">Lingjia  Zhou</span>, <span class="hlFld-ContribAuthor ">Zunhua  Yang</span>, <span class="hlFld-ContribAuthor ">Xin  Li</span>, <span class="hlFld-ContribAuthor ">Liying  Yu</span>, <span class="hlFld-ContribAuthor ">Pengwu  Zheng</span>, <span class="hlFld-ContribAuthor ">Shan  Xu</span>, <span class="hlFld-ContribAuthor ">Wufu  Zhu</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and antitumor activity of novel thiophene-pyrimidine derivatives as EGFR inhibitors overcoming T790M and L858R/T790M mutations. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>203 </em>, 112511. <a href="https://doi.org/10.1016/j.ejmech.2020.112511" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112511</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112511&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112511%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bantitumor%252Bactivity%252Bof%252Bnovel%252Bthiophene-pyrimidine%252Bderivatives%252Bas%252BEGFR%252Binhibitors%252Bovercoming%252BT790M%252Band%252BL858R%25252FT790M%252Bmutations%26aulast%3DXiao%26aufirst%3DZhen%26date%3D2020%26volume%3D203%26spage%3D112511" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yang  Chen</span>, <span class="hlFld-ContribAuthor ">Linlin  Yang</span>, <span class="hlFld-ContribAuthor ">Hui  Qiao</span>, <span class="hlFld-ContribAuthor ">Zhongyu  Cheng</span>, <span class="hlFld-ContribAuthor ">Jiahao  Xie</span>, <span class="hlFld-ContribAuthor ">Wenjuan  Zhou</span>, <span class="hlFld-ContribAuthor ">Xin  Huang</span>, <span class="hlFld-ContribAuthor ">Yaoxuan  Jiang</span>, <span class="hlFld-ContribAuthor ">Bin  Yu</span>, <span class="hlFld-ContribAuthor ">Wen  Zhao</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of new thieno[3,2-d]pyrimidine derivatives targeting EGFRL858R/T790M NSCLCs by the conformation constrained strategy. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>199 </em>, 112388. <a href="https://doi.org/10.1016/j.ejmech.2020.112388" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112388</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112388&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112388%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bnew%252Bthieno%25255B3%25252C2-d%25255Dpyrimidine%252Bderivatives%252Btargeting%252BEGFRL858R%25252FT790M%252BNSCLCs%252Bby%252Bthe%252Bconformation%252Bconstrained%252Bstrategy%26aulast%3DChen%26aufirst%3DYang%26date%3D2020%26volume%3D199%26spage%3D112388" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Binglu  Wu</span>, <span class="hlFld-ContribAuthor ">Zhi-Jiang  Jiang</span>, <span class="hlFld-ContribAuthor ">Jianbo  Tang</span>, <span class="hlFld-ContribAuthor ">Zhanghua  Gao</span>, <span class="hlFld-ContribAuthor ">Hongze  Liang</span>, <span class="hlFld-ContribAuthor ">Bencan  Tang</span>, <span class="hlFld-ContribAuthor ">Jia  Chen</span>, <span class="hlFld-ContribAuthor ">Kewei  Lei</span>. </span><span class="cited-content_cbyCitation_article-title">Total synthesis study of rauvomines A and B: construction of the pentacyclic core structure. </span><span class="cited-content_cbyCitation_journal-name">Organic Chemistry Frontiers</span><span> <strong>2020,</strong> <em>7 </em>
                                    (13)
                                     , 1685-1689. <a href="https://doi.org/10.1039/C9QO01531K" title="DOI URL">https://doi.org/10.1039/C9QO01531K</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C9QO01531K&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC9QO01531K%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Chemistry%2520Frontiers%26atitle%3DTotal%252Bsynthesis%252Bstudy%252Bof%252Brauvomines%252BA%252Band%252BB%25253A%252Bconstruction%252Bof%252Bthe%252Bpentacyclic%252Bcore%252Bstructure%26aulast%3DWu%26aufirst%3DBinglu%26date%3D2020%26date%3D2020%26volume%3D7%26issue%3D13%26spage%3D1685%26epage%3D1689" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Debasis  Das</span>, <span class="hlFld-ContribAuthor ">Lingzhi  Xie</span>, <span class="hlFld-ContribAuthor ">Jingbing  Wang</span>, <span class="hlFld-ContribAuthor ">Jingli  Shi</span>, <span class="hlFld-ContribAuthor ">Jian  Hong</span>. </span><span class="cited-content_cbyCitation_article-title">In vivo efficacy studies of novel quinazoline derivatives as irreversible dual EGFR/HER2 inhibitors, in lung cancer xenografts (NCI-H1975) mice models. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2020,</strong> <em>99 </em>, 103790. <a href="https://doi.org/10.1016/j.bioorg.2020.103790" title="DOI URL">https://doi.org/10.1016/j.bioorg.2020.103790</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2020.103790&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2020.103790%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DIn%252Bvivo%252Befficacy%252Bstudies%252Bof%252Bnovel%252Bquinazoline%252Bderivatives%252Bas%252Birreversible%252Bdual%252BEGFR%25252FHER2%252Binhibitors%25252C%252Bin%252Blung%252Bcancer%252Bxenografts%252B%252528NCI-H1975%252529%252Bmice%252Bmodels%26aulast%3DDas%26aufirst%3DDebasis%26date%3D2020%26volume%3D99%26spage%3D103790" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Naoya  Shindo</span>, <span class="hlFld-ContribAuthor ">Akio  Ojida</span>. </span><span class="cited-content_cbyCitation_article-title">
                In Vivo
              
              Targeting of Endogenous Proteins with Reactive Small Molecules. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2020,</strong>,, 281-307. <a href="https://doi.org/10.1002/9783527344406.ch10" title="DOI URL">https://doi.org/10.1002/9783527344406.ch10</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/9783527344406.ch10&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F9783527344406.ch10%26sid%3Dliteratum%253Aachs%26atitle%3DIn%252BVivo%252BTargeting%252Bof%252BEndogenous%252BProteins%252Bwith%252BReactive%252BSmall%252BMolecules%26aulast%3DShindo%26aufirst%3DNaoya%26date%3D2020%26date%3D2019%26spage%3D281%26epage%3D307%26pub%3DWiley%26atitle%3DHandbook%252Bof%252BIn%252BVivo%252BChemistry%252Bin%252BMice%26aulast%3DTanaka%26aufirst%3DKatsunori%26date%3D2020%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Garima  Verma</span>, <span class="hlFld-ContribAuthor ">Mohemmed Faraz  Khan</span>, <span class="hlFld-ContribAuthor ">Wasim  Akhtar</span>, <span class="hlFld-ContribAuthor ">Mohammad Mumtaz  Alam</span>, <span class="hlFld-ContribAuthor ">Mymoona  Akhter</span>, <span class="hlFld-ContribAuthor ">Ozair  Alam</span>, <span class="hlFld-ContribAuthor ">Syed Misbahul  Hasan</span>, <span class="hlFld-ContribAuthor ">Mohammad  Shaquiquzzaman</span>. </span><span class="cited-content_cbyCitation_article-title">Pharmacophore modeling, 3D-QSAR, docking and ADME prediction of quinazoline based EGFR inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Arabian Journal of Chemistry</span><span> <strong>2019,</strong> <em>12 </em>
                                    (8)
                                     , 4815-4839. <a href="https://doi.org/10.1016/j.arabjc.2016.09.019" title="DOI URL">https://doi.org/10.1016/j.arabjc.2016.09.019</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.arabjc.2016.09.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.arabjc.2016.09.019%26sid%3Dliteratum%253Aachs%26jtitle%3DArabian%2520Journal%2520of%2520Chemistry%26atitle%3DPharmacophore%252Bmodeling%25252C%252B3D-QSAR%25252C%252Bdocking%252Band%252BADME%252Bprediction%252Bof%252Bquinazoline%252Bbased%252BEGFR%252Binhibitors%26aulast%3DVerma%26aufirst%3DGarima%26date%3D2019%26volume%3D12%26issue%3D8%26spage%3D4815%26epage%3D4839" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wen-Xue  Sun</span>, <span class="hlFld-ContribAuthor ">Hong-Wei  Han</span>, <span class="hlFld-ContribAuthor ">Min-Kai  Yang</span>, <span class="hlFld-ContribAuthor ">Zhong-Ling  Wen</span>, <span class="hlFld-ContribAuthor ">Yin-Song  Wang</span>, <span class="hlFld-ContribAuthor ">Jiang-Yan  Fu</span>, <span class="hlFld-ContribAuthor ">Yun-Ting  Lu</span>, <span class="hlFld-ContribAuthor ">Ming-Yue  Wang</span>, <span class="hlFld-ContribAuthor ">Jia-Xin  Bao</span>, <span class="hlFld-ContribAuthor ">Gui-Hua  Lu</span>, <span class="hlFld-ContribAuthor ">Jin-Liang  Qi</span>, <span class="hlFld-ContribAuthor ">Xiao-Ming  Wang</span>, <span class="hlFld-ContribAuthor ">Hong-Yan  Lin</span>, <span class="hlFld-ContribAuthor ">Yong-Hua  Yang</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and biological evaluation of benzoylacrylic acid shikonin ester derivatives as irreversible dual inhibitors of tubulin and EGFR. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2019,</strong> <em>27 </em>
                                    (23)
                                     , 115153. <a href="https://doi.org/10.1016/j.bmc.2019.115153" title="DOI URL">https://doi.org/10.1016/j.bmc.2019.115153</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2019.115153&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2019.115153%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Bbenzoylacrylic%252Bacid%252Bshikonin%252Bester%252Bderivatives%252Bas%252Birreversible%252Bdual%252Binhibitors%252Bof%252Btubulin%252Band%252BEGFR%26aulast%3DSun%26aufirst%3DWen-Xue%26date%3D2019%26volume%3D27%26issue%3D23%26spage%3D115153" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yaling  Zhang</span>, <span class="hlFld-ContribAuthor ">Qiaoli  Hou</span>, <span class="hlFld-ContribAuthor ">Xiabing  Li</span>, <span class="hlFld-ContribAuthor ">Jiuling  Zhu</span>, <span class="hlFld-ContribAuthor ">Wei  Wang</span>, <span class="hlFld-ContribAuthor ">Baolin  Li</span>, <span class="hlFld-ContribAuthor ">Lijun  Zhao</span>, <span class="hlFld-ContribAuthor ">Haibin  Xia</span>. </span><span class="cited-content_cbyCitation_article-title">Enrichment of novel quinazoline derivatives with high antitumor activity in mitochondria tracked by its self-fluorescence. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>178 </em>, 417-432. <a href="https://doi.org/10.1016/j.ejmech.2019.06.015" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.06.015</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.06.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.06.015%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DEnrichment%252Bof%252Bnovel%252Bquinazoline%252Bderivatives%252Bwith%252Bhigh%252Bantitumor%252Bactivity%252Bin%252Bmitochondria%252Btracked%252Bby%252Bits%252Bself-fluorescence%26aulast%3DZhang%26aufirst%3DYaling%26date%3D2019%26volume%3D178%26spage%3D417%26epage%3D432" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ao  Niu</span>, <span class="hlFld-ContribAuthor ">Yang  Wang</span>, <span class="hlFld-ContribAuthor ">Yushe  Yang</span>, <span class="hlFld-ContribAuthor ">Jianhai  Wei</span>, <span class="hlFld-ContribAuthor ">Jian  Ding</span>, <span class="hlFld-ContribAuthor ">Yi  Chen</span>, <span class="hlFld-ContribAuthor ">Linjiang  Tong</span>, <span class="hlFld-ContribAuthor ">Hua  Xie</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and Biological Evaluation of Oxopyrido[2,3-d] Pyrimidine-7- ones Derivatives as Covalent L858R/T790M Mutant Selective Epidermal Growth Factor Receptor (EGFR) Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Letters in Drug Design & Discovery</span><span> <strong>2019,</strong> <em>16 </em>
                                    (8)
                                     , 826-834. <a href="https://doi.org/10.2174/1570180815666180523090558" title="DOI URL">https://doi.org/10.2174/1570180815666180523090558</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/1570180815666180523090558&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F1570180815666180523090558%26sid%3Dliteratum%253Aachs%26jtitle%3DLetters%2520in%2520Drug%2520Design%2520%2526%2520Discovery%26atitle%3DSynthesis%252Band%252BBiological%252BEvaluation%252Bof%252BOxopyrido%25255B2%25252C3-d%25255D%252BPyrimidine-7-%252Bones%252BDerivatives%252Bas%252BCovalent%252BL858R%25252FT790M%252BMutant%252BSelective%252BEpidermal%252BGrowth%252BFactor%252BReceptor%252B%252528EGFR%252529%252BInhibitors%26aulast%3DNiu%26aufirst%3DAo%26date%3D2019%26volume%3D16%26issue%3D8%26spage%3D826%26epage%3D834" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Bingbing  Zhao</span>, <span class="hlFld-ContribAuthor ">Zhen  Xiao</span>, <span class="hlFld-ContribAuthor ">Jianguo  Qi</span>, <span class="hlFld-ContribAuthor ">Rong  Luo</span>, <span class="hlFld-ContribAuthor ">Zhou  Lan</span>, <span class="hlFld-ContribAuthor ">Yanzhuo  Zhang</span>, <span class="hlFld-ContribAuthor ">Xiaohan  Hu</span>, <span class="hlFld-ContribAuthor ">Qidong  Tang</span>, <span class="hlFld-ContribAuthor ">Pengwu  Zheng</span>, <span class="hlFld-ContribAuthor ">Shan  Xu</span>, <span class="hlFld-ContribAuthor ">Wufu  Zhu</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and biological evaluation of AZD9291 derivatives as selective and potent EGFRL858R/T790M inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>163 </em>, 367-380. <a href="https://doi.org/10.1016/j.ejmech.2018.11.069" title="DOI URL">https://doi.org/10.1016/j.ejmech.2018.11.069</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2018.11.069&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2018.11.069%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252BAZD9291%252Bderivatives%252Bas%252Bselective%252Band%252Bpotent%252BEGFRL858R%25252FT790M%252Binhibitors%26aulast%3DZhao%26aufirst%3DBingbing%26date%3D2019%26volume%3D163%26spage%3D367%26epage%3D380" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Min  Zou</span>, <span class="hlFld-ContribAuthor ">Bo  Jin</span>, <span class="hlFld-ContribAuthor ">Yanrong  Liu</span>, <span class="hlFld-ContribAuthor ">Huiping  Chen</span>, <span class="hlFld-ContribAuthor ">Zhuangli  Zhang</span>, <span class="hlFld-ContribAuthor ">Changzheng  Zhang</span>, <span class="hlFld-ContribAuthor ">Zhihong  Zhao</span>, <span class="hlFld-ContribAuthor ">Liyun  Zheng</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and Biological Evaluation of Some Novel Thiophene-bearing Quinazoline Derivatives as EGFR Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Letters in Drug Design & Discovery</span><span> <strong>2018,</strong> <em>16 </em>
                                    (2)
                                     , 102-110. <a href="https://doi.org/10.2174/1570180815666180803125935" title="DOI URL">https://doi.org/10.2174/1570180815666180803125935</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/1570180815666180803125935&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F1570180815666180803125935%26sid%3Dliteratum%253Aachs%26jtitle%3DLetters%2520in%2520Drug%2520Design%2520%2526%2520Discovery%26atitle%3DSynthesis%252Band%252BBiological%252BEvaluation%252Bof%252BSome%252BNovel%252BThiophene-bearing%252BQuinazoline%252BDerivatives%252Bas%252BEGFR%252BInhibitors%26aulast%3DZou%26aufirst%3DMin%26date%3D2018%26volume%3D16%26issue%3D2%26spage%3D102%26epage%3D110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Christian  Steinebach</span>, <span class="hlFld-ContribAuthor ">Agnieszka  AmbroÅ¼ak</span>, <span class="hlFld-ContribAuthor ">Stefan  Dosa</span>, <span class="hlFld-ContribAuthor ">Shaunna L.  Beedie</span>, <span class="hlFld-ContribAuthor ">Jonathan D.  Strope</span>, <span class="hlFld-ContribAuthor ">Gregor  Schnakenburg</span>, <span class="hlFld-ContribAuthor ">William D.  Figg</span>, <span class="hlFld-ContribAuthor ">Michael  GÃ¼tschow</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis, Structural Characterization, and Antiangiogenic Activity of Polyfluorinated Benzamides. </span><span class="cited-content_cbyCitation_journal-name">ChemMedChem</span><span> <strong>2018,</strong> <em>13 </em>
                                    (19)
                                     , 2080-2089. <a href="https://doi.org/10.1002/cmdc.201800263" title="DOI URL">https://doi.org/10.1002/cmdc.201800263</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cmdc.201800263&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcmdc.201800263%26sid%3Dliteratum%253Aachs%26jtitle%3DChemMedChem%26atitle%3DSynthesis%25252C%252BStructural%252BCharacterization%25252C%252Band%252BAntiangiogenic%252BActivity%252Bof%252BPolyfluorinated%252BBenzamides%26aulast%3DSteinebach%26aufirst%3DChristian%26date%3D2018%26date%3D2018%26volume%3D13%26issue%3D19%26spage%3D2080%26epage%3D2089" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">David S.  Huang</span>, <span class="hlFld-ContribAuthor ">Henry L.  Wong</span>, <span class="hlFld-ContribAuthor ">Gunda I.  Georg</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and evaluation of C2 functionalized analogs of the Î±-tubulin-binding natural product pironetin. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2018,</strong> <em>28 </em>
                                    (16)
                                     , 2789-2793. <a href="https://doi.org/10.1016/j.bmcl.2017.10.057" title="DOI URL">https://doi.org/10.1016/j.bmcl.2017.10.057</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2017.10.057&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2017.10.057%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DSynthesis%252Band%252Bevaluation%252Bof%252BC2%252Bfunctionalized%252Banalogs%252Bof%252Bthe%252B%2525CE%2525B1-tubulin-binding%252Bnatural%252Bproduct%252Bpironetin%26aulast%3DHuang%26aufirst%3DDavid%2BS.%26date%3D2018%26volume%3D28%26issue%3D16%26spage%3D2789%26epage%3D2793" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yaling  Zhang</span>, <span class="hlFld-ContribAuthor ">Li  Chen</span>, <span class="hlFld-ContribAuthor ">Hongjiang  Xu</span>, <span class="hlFld-ContribAuthor ">Xiabing  Li</span>, <span class="hlFld-ContribAuthor ">Lijun  Zhao</span>, <span class="hlFld-ContribAuthor ">Wei  Wang</span>, <span class="hlFld-ContribAuthor ">Baolin  Li</span>, <span class="hlFld-ContribAuthor ">Xiquan  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">6,7-Dimorpholinoalkoxy quinazoline derivatives as potent EGFR inhibitors with enhanced antiproliferative activities against tumor cells. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>147 </em>, 77-89. <a href="https://doi.org/10.1016/j.ejmech.2018.01.090" title="DOI URL">https://doi.org/10.1016/j.ejmech.2018.01.090</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2018.01.090&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2018.01.090%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3D6%25252C7-Dimorpholinoalkoxy%252Bquinazoline%252Bderivatives%252Bas%252Bpotent%252BEGFR%252Binhibitors%252Bwith%252Benhanced%252Bantiproliferative%252Bactivities%252Bagainst%252Btumor%252Bcells%26aulast%3DZhang%26aufirst%3DYaling%26date%3D2018%26volume%3D147%26spage%3D77%26epage%3D89" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">R.S.  Obach</span>, <span class="hlFld-ContribAuthor ">A.S.  Kalgutkar</span>. </span><span class="cited-content_cbyCitation_article-title">Reactive Electrophiles and Metabolic Activation. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2018,</strong>,, 295-331. <a href="https://doi.org/10.1016/B978-0-12-801238-3.64290-3" title="DOI URL">https://doi.org/10.1016/B978-0-12-801238-3.64290-3</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-801238-3.64290-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-801238-3.64290-3%26sid%3Dliteratum%253Aachs%26atitle%3DReactive%252BElectrophiles%252Band%252BMetabolic%252BActivation%26aulast%3DObach%26aufirst%3DR.S.%26date%3D2018%26spage%3D295%26epage%3D331%26pub%3DElsevier%26atitle%3DComprehensive%252BToxicology%26date%3D2018%26volume%3D46" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Deheng  Chen</span>, <span class="hlFld-ContribAuthor ">Dexiang  Guo</span>, <span class="hlFld-ContribAuthor ">Ziqin  Yan</span>, <span class="hlFld-ContribAuthor ">Yujun  Zhao</span>. </span><span class="cited-content_cbyCitation_article-title">Allenamide as a bioisostere of acrylamide in the design and synthesis of targeted covalent inhibitors. </span><span class="cited-content_cbyCitation_journal-name">MedChemComm</span><span> <strong>2018,</strong> <em>9 </em>
                                    (2)
                                     , 244-253. <a href="https://doi.org/10.1039/C7MD00571G" title="DOI URL">https://doi.org/10.1039/C7MD00571G</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C7MD00571G&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC7MD00571G%26sid%3Dliteratum%253Aachs%26jtitle%3DMedChemComm%26atitle%3DAllenamide%252Bas%252Ba%252Bbioisostere%252Bof%252Bacrylamide%252Bin%252Bthe%252Bdesign%252Band%252Bsynthesis%252Bof%252Btargeted%252Bcovalent%252Binhibitors%26aulast%3DChen%26aufirst%3DDeheng%26date%3D2018%26date%3D2018%26volume%3D9%26issue%3D2%26spage%3D244%26epage%3D253" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Li  Chen</span>, <span class="hlFld-ContribAuthor ">Yaling  Zhang</span>, <span class="hlFld-ContribAuthor ">Juan  Liu</span>, <span class="hlFld-ContribAuthor ">Weijia  Wang</span>, <span class="hlFld-ContribAuthor ">Xiabing  Li</span>, <span class="hlFld-ContribAuthor ">Lijun  Zhao</span>, <span class="hlFld-ContribAuthor ">Wei  Wang</span>, <span class="hlFld-ContribAuthor ">Baolin  Li</span>. </span><span class="cited-content_cbyCitation_article-title">Novel 4-arylaminoquinazoline derivatives with ( E )-propen-1-yl moiety as potent EGFR inhibitors with enhanced antiproliferative activities against tumor cells. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>138 </em>, 689-697. <a href="https://doi.org/10.1016/j.ejmech.2017.06.023" title="DOI URL">https://doi.org/10.1016/j.ejmech.2017.06.023</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2017.06.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2017.06.023%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DNovel%252B4-arylaminoquinazoline%252Bderivatives%252Bwith%252B%252528%252BE%252B%252529-propen-1-yl%252Bmoiety%252Bas%252Bpotent%252BEGFR%252Binhibitors%252Bwith%252Benhanced%252Bantiproliferative%252Bactivities%252Bagainst%252Btumor%252Bcells%26aulast%3DChen%26aufirst%3DLi%26date%3D2017%26volume%3D138%26spage%3D689%26epage%3D697" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Weiwei  Han</span>, <span class="hlFld-ContribAuthor ">Yongli  Du</span>. </span><span class="cited-content_cbyCitation_article-title">Recent Development of the Second and Third Generation Irreversible Epidermal Growth Factor Receptor Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Chemistry & Biodiversity</span><span> <strong>2017,</strong> <em>14 </em>
                                    (7)
                                     , e1600372. <a href="https://doi.org/10.1002/cbdv.201600372" title="DOI URL">https://doi.org/10.1002/cbdv.201600372</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cbdv.201600372&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcbdv.201600372%26sid%3Dliteratum%253Aachs%26jtitle%3DChemistry%2520%2526%2520Biodiversity%26atitle%3DRecent%252BDevelopment%252Bof%252Bthe%252BSecond%252Band%252BThird%252BGeneration%252BIrreversible%252BEpidermal%252BGrowth%252BFactor%252BReceptor%252BInhibitors%26aulast%3DHan%26aufirst%3DWeiwei%26date%3D2017%26date%3D2017%26volume%3D14%26issue%3D7%26spage%3De1600372" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yuanbiao  Tu</span>, <span class="hlFld-ContribAuthor ">Caolin  Wang</span>, <span class="hlFld-ContribAuthor ">Shan  Xu</span>, <span class="hlFld-ContribAuthor ">Zhou  Lan</span>, <span class="hlFld-ContribAuthor ">Wei  Li</span>, <span class="hlFld-ContribAuthor ">Jiaqian  Han</span>, <span class="hlFld-ContribAuthor ">Yuanzhang  Zhou</span>, <span class="hlFld-ContribAuthor ">Pengwu  Zheng</span>, <span class="hlFld-ContribAuthor ">Wufu  Zhu</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis, and docking studies of quinazoline analogues bearing aryl semicarbazone scaffolds as potent EGFR inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2017,</strong> <em>25 </em>
                                    (12)
                                     , 3148-3157. <a href="https://doi.org/10.1016/j.bmc.2017.04.001" title="DOI URL">https://doi.org/10.1016/j.bmc.2017.04.001</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2017.04.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2017.04.001%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%25252C%252Band%252Bdocking%252Bstudies%252Bof%252Bquinazoline%252Banalogues%252Bbearing%252Baryl%252Bsemicarbazone%252Bscaffolds%252Bas%252Bpotent%252BEGFR%252Binhibitors%26aulast%3DTu%26aufirst%3DYuanbiao%26date%3D2017%26volume%3D25%26issue%3D12%26spage%3D3148%26epage%3D3157" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ramalingam  Boobalan</span>, <span class="hlFld-ContribAuthor ">Kuang-Kai  Liu</span>, <span class="hlFld-ContribAuthor ">Jui-I.  Chao</span>, <span class="hlFld-ContribAuthor ">Chinpiao  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and biological assay of erlotinib analogues and BSA-conjugated erlotinib analogue. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2017,</strong> <em>27 </em>
                                    (8)
                                     , 1784-1788. <a href="https://doi.org/10.1016/j.bmcl.2017.02.059" title="DOI URL">https://doi.org/10.1016/j.bmcl.2017.02.059</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2017.02.059&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2017.02.059%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DSynthesis%252Band%252Bbiological%252Bassay%252Bof%252Berlotinib%252Banalogues%252Band%252BBSA-conjugated%252Berlotinib%252Banalogue%26aulast%3DBoobalan%26aufirst%3DRamalingam%26date%3D2017%26volume%3D27%26issue%3D8%26spage%3D1784%26epage%3D1788" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Thomas A.  Baillie</span>. </span><span class="cited-content_cbyCitation_article-title">Zielgerichtete kovalente Inhibitoren fÃ¼r das Wirkstoffdesign. </span><span class="cited-content_cbyCitation_journal-name">Angewandte Chemie</span><span> <strong>2016,</strong> <em>128 </em>
                                    (43)
                                     , 13606-13619. <a href="https://doi.org/10.1002/ange.201601091" title="DOI URL">https://doi.org/10.1002/ange.201601091</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ange.201601091&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fange.201601091%26sid%3Dliteratum%253Aachs%26jtitle%3DAngewandte%2520Chemie%26atitle%3DZielgerichtete%252Bkovalente%252BInhibitoren%252Bf%2525C3%2525BCr%252Bdas%252BWirkstoffdesign%26aulast%3DBaillie%26aufirst%3DThomas%2BA.%26date%3D2016%26date%3D2016%26volume%3D128%26issue%3D43%26spage%3D13606%26epage%3D13619" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Thomas A.  Baillie</span>. </span><span class="cited-content_cbyCitation_article-title">Targeted Covalent Inhibitors for Drug Design. </span><span class="cited-content_cbyCitation_journal-name">Angewandte Chemie International Edition</span><span> <strong>2016,</strong> <em>55 </em>
                                    (43)
                                     , 13408-13421. <a href="https://doi.org/10.1002/anie.201601091" title="DOI URL">https://doi.org/10.1002/anie.201601091</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/anie.201601091&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fanie.201601091%26sid%3Dliteratum%253Aachs%26jtitle%3DAngewandte%2520Chemie%2520International%2520Edition%26atitle%3DTargeted%252BCovalent%252BInhibitors%252Bfor%252BDrug%252BDesign%26aulast%3DBaillie%26aufirst%3DThomas%2BA.%26date%3D2016%26date%3D2016%26volume%3D55%26issue%3D43%26spage%3D13408%26epage%3D13421" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Monia  Hossam</span>, <span class="hlFld-ContribAuthor ">Deena S.  Lasheen</span>, <span class="hlFld-ContribAuthor ">Khaled A. M.  Abouzid</span>. </span><span class="cited-content_cbyCitation_article-title">Covalent EGFR Inhibitors: Binding Mechanisms, Synthetic Approaches, and Clinical Profiles. </span><span class="cited-content_cbyCitation_journal-name">Archiv der Pharmazie</span><span> <strong>2016,</strong> <em>349 </em>
                                    (8)
                                     , 573-593. <a href="https://doi.org/10.1002/ardp.201600063" title="DOI URL">https://doi.org/10.1002/ardp.201600063</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ardp.201600063&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fardp.201600063%26sid%3Dliteratum%253Aachs%26jtitle%3DArchiv%2520der%2520Pharmazie%26atitle%3DCovalent%252BEGFR%252BInhibitors%25253A%252BBinding%252BMechanisms%25252C%252BSynthetic%252BApproaches%25252C%252Band%252BClinical%252BProfiles%26aulast%3DHossam%26aufirst%3DMonia%26date%3D2016%26date%3D2016%26volume%3D349%26issue%3D8%26spage%3D573%26epage%3D593" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jiaan  Shao</span>, <span class="hlFld-ContribAuthor ">En  Chen</span>, <span class="hlFld-ContribAuthor ">Ke  Shu</span>, <span class="hlFld-ContribAuthor ">Wenteng  Chen</span>, <span class="hlFld-ContribAuthor ">Guolin  Zhang</span>, <span class="hlFld-ContribAuthor ">Yongping  Yu</span>. </span><span class="cited-content_cbyCitation_article-title">6-Oxooxazolidineâquinazolines as noncovalent inhibitors with the potential to target mutant forms of EGFR. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2016,</strong> <em>24 </em>
                                    (16)
                                     , 3359-3370. <a href="https://doi.org/10.1016/j.bmc.2016.04.046" title="DOI URL">https://doi.org/10.1016/j.bmc.2016.04.046</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2016.04.046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2016.04.046%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3D6-Oxooxazolidine%2525E2%252580%252593quinazolines%252Bas%252Bnoncovalent%252Binhibitors%252Bwith%252Bthe%252Bpotential%252Bto%252Btarget%252Bmutant%252Bforms%252Bof%252BEGFR%26aulast%3DShao%26aufirst%3DJiaan%26date%3D2016%26volume%3D24%26issue%3D16%26spage%3D3359%26epage%3D3370" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yuanbiao  Tu</span>, <span class="hlFld-ContribAuthor ">Yiqiang  OuYang</span>, <span class="hlFld-ContribAuthor ">Shan  Xu</span>, <span class="hlFld-ContribAuthor ">Yan  Zhu</span>, <span class="hlFld-ContribAuthor ">Gen  Li</span>, <span class="hlFld-ContribAuthor ">Chao  Sun</span>, <span class="hlFld-ContribAuthor ">Pengwu  Zheng</span>, <span class="hlFld-ContribAuthor ">Wufu  Zhu</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis, and docking studies of afatinib analogs bearing cinnamamide moiety as potent EGFR inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2016,</strong> <em>24 </em>
                                    (7)
                                     , 1495-1503. <a href="https://doi.org/10.1016/j.bmc.2016.02.017" title="DOI URL">https://doi.org/10.1016/j.bmc.2016.02.017</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2016.02.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2016.02.017%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%25252C%252Band%252Bdocking%252Bstudies%252Bof%252Bafatinib%252Banalogs%252Bbearing%252Bcinnamamide%252Bmoiety%252Bas%252Bpotent%252BEGFR%252Binhibitors%26aulast%3DTu%26aufirst%3DYuanbiao%26date%3D2016%26volume%3D24%26issue%3D7%26spage%3D1495%26epage%3D1503" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Changyan  Wang</span>, <span class="hlFld-ContribAuthor ">Yajun  Sun</span>, <span class="hlFld-ContribAuthor ">Xingqi  Zhu</span>, <span class="hlFld-ContribAuthor ">Bin  Wu</span>, <span class="hlFld-ContribAuthor ">Qiao  Wang</span>, <span class="hlFld-ContribAuthor ">Yuhong  Zhen</span>, <span class="hlFld-ContribAuthor ">Xiaohong  Shu</span>, <span class="hlFld-ContribAuthor ">Kexin  Liu</span>, <span class="hlFld-ContribAuthor ">Youwen  Zhou</span>, <span class="hlFld-ContribAuthor ">Xiaodong  Ma</span>. </span><span class="cited-content_cbyCitation_article-title">Novel Quinazoline Derivatives Bearing Various 4-Aniline Moieties as Potent EGFR Inhibitors with Enhanced Activity Against NSCLC Cell Lines. </span><span class="cited-content_cbyCitation_journal-name">Chemical Biology & Drug Design</span><span> <strong>2016,</strong> <em>87 </em>
                                    (4)
                                     , 635-643. <a href="https://doi.org/10.1111/cbdd.12692" title="DOI URL">https://doi.org/10.1111/cbdd.12692</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/cbdd.12692&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fcbdd.12692%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Biology%2520%2526%2520Drug%2520Design%26atitle%3DNovel%252BQuinazoline%252BDerivatives%252BBearing%252BVarious%252B4-Aniline%252BMoieties%252Bas%252BPotent%252BEGFR%252BInhibitors%252Bwith%252BEnhanced%252BActivity%252BAgainst%252BNSCLC%252BCell%252BLines%26aulast%3DWang%26aufirst%3DChangyan%26date%3D2016%26date%3D2015%26volume%3D87%26issue%3D4%26spage%3D635%26epage%3D643" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xuemei  Qin</span>, <span class="hlFld-ContribAuthor ">Yongjuan  Lv</span>, <span class="hlFld-ContribAuthor ">Peng  Liu</span>, <span class="hlFld-ContribAuthor ">Zhipeng  Li</span>, <span class="hlFld-ContribAuthor ">Liming  Hu</span>, <span class="hlFld-ContribAuthor ">Chengchu  Zeng</span>, <span class="hlFld-ContribAuthor ">Leifu  Yang</span>. </span><span class="cited-content_cbyCitation_article-title">Novel morpholin-3-one fused quinazoline derivatives as EGFR tyrosine kinase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2016,</strong> <em>26 </em>
                                    (6)
                                     , 1571-1575. <a href="https://doi.org/10.1016/j.bmcl.2016.02.009" title="DOI URL">https://doi.org/10.1016/j.bmcl.2016.02.009</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2016.02.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2016.02.009%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DNovel%252Bmorpholin-3-one%252Bfused%252Bquinazoline%252Bderivatives%252Bas%252BEGFR%252Btyrosine%252Bkinase%252Binhibitors%26aulast%3DQin%26aufirst%3DXuemei%26date%3D2016%26volume%3D26%26issue%3D6%26spage%3D1571%26epage%3D1575" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm5014659/20141205/images/medium/jm-2014-014659_0001.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm5014659/20141205/images/large/jm-2014-014659_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5014659&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm5014659/20141205/images/medium/jm-2014-014659_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm5014659/20141205/images/large/jm-2014-014659_0003.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. GSH conjugate addition to fluoro-substituted olefins. (1-a) model reaction between <i>N</i>-phenylacrylamide (A) or 2-fluoro-<i>N</i>-phenylacrylamide (B) and reduced GSH in PBS buffer. (1-b) Conjugate addition reactions of GSH (10 mM) with <b>A</b> (1 mM) or <b>B</b> (1 mM) at various time points (0â1440 min) and monitored by HPLC-HRMS. (1-c) <b>B</b> (1 mM) was treated with increasing concentrations of GSH (10â200 mM) and monitored by HPLC-HRMS.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm5014659/20141205/images/large/jm-2014-014659_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5014659&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm5014659/20141205/images/medium/jm-2014-014659_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm5014659/20141205/images/large/jm-2014-014659_0008.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Compounds <b>1</b>â<b>12</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm5014659/20141205/images/large/jm-2014-014659_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5014659&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Conditions and reagents: (a) NaOH, EtOH, 0â5 Â°C; (b) (COCl<sub>2</sub>), Et<sub>3</sub>N, DCM/DMF, 0 Â°Cârt; (c) K<sub>2</sub>CO<sub>3</sub>, DMF, 90 Â°C; (d) conc HCl, relux; (e) NaOH, EtOHâH<sub>2</sub>O, rt.</p></p></figure><figure data-id="fig2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm5014659/20141205/images/medium/jm-2014-014659_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm5014659/20141205/images/large/jm-2014-014659_0004.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. GSH conjugate addition of afatinib or compound <b>5a</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm5014659/20141205/images/large/jm-2014-014659_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5014659&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm5014659/20141205/images/medium/jm-2014-014659_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm5014659/20141205/images/large/jm-2014-014659_0005.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Antiproliferative activities and the kinase inhibitory activities of selected compounds. IC<sub>50</sub> values for A431 (4-a), NSCLC H1975 cell (4-b), EGFR<sup>WT</sup> (4-c), EGFR<sup>T790M</sup> (4-d), and HER2 (4-e), treated with indicated drugs. Values were calculated from at least eight data points. In general three independent determinations were performed.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm5014659/20141205/images/large/jm-2014-014659_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5014659&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm5014659/20141205/images/medium/jm-2014-014659_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm5014659/20141205/images/large/jm-2014-014659_0006.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Cytotoxicity comparison of compound <b>5a</b> and afatinib in EGFR-independent cancer cell line SW620.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm5014659/20141205/images/large/jm-2014-014659_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5014659&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm5014659/20141205/images/medium/jm-2014-014659_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm5014659/20141205/images/large/jm-2014-014659_0007.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Effect on tumor volume in xenograft model of H1975 of compounds <b>2a</b>, <b>3a</b>, <b>5a</b>, and afatinib. (<i>T</i>/<i>C</i> (%) = mean RTV of the treated group/mean RTV of the control group Ã 100%. The individual relative tumor volume (RTV) was calculated as follows: RTV = <i>V</i><sub>t</sub>/<i>V</i><sub>0</sub>, where <i>V</i><sub>t</sub> is the volume on each day of measurement, and <i>V</i><sub>0</sub> is the volume on the day of initial treatment.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm5014659/20141205/images/large/jm-2014-014659_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5014659&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i74">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_87672" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_87672" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 25 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Yarden, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sliwknowski, M. X.</span><span> </span><span class="NLM_article-title">Untangling the ErbB signalling network</span> <span class="citation_source-journal">Nature Rev. Mol. Cell. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">127</span><span class="NLM_x">â</span> <span class="NLM_lpage">137</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Fjm5014659&amp;key=10.1038%2F35052073" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Fjm5014659&amp;key=11252954" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Fjm5014659&amp;key=1%3ACAS%3A528%3ADC%252BD3MXivVWnt7k%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2001&pages=127-137&author=Y.+Yardenauthor=M.+X.+Sliwknowski&title=Untangling+the+ErbB+signalling+network"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Untangling the ErbB signalling network</span></div><div class="casAuthors">Yarden, Yosef; Sliwkowski, Mark X.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">127-137</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review, with 112 refs.  When epidermal growth factor and its relatives bind the ErbB family of receptors, they trigger a rich network of signaling pathways, culminating in responses ranging from cell division to death, motility to adhesion.  The network is often dysregulated in cancer and lends credence to the mantra that mol. understanding yields clin. benefit: over 25,000 women with breast cancer have now been treated with Herceptin, a recombinant antibody designed to block the receptor ErbB2.  Likewise, small-mol. enzyme inhibitors and monoclonal antibodies to ErbB1 are in advanced phases of clin. testing.  What can this pathway teach us about translating basic science into clin. use.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovhWL1HObvNrVg90H21EOLACvtfcHk0liapb4xfuR-YA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXivVWnt7k%253D&md5=1561a9666f77fce888be821399870cd6</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2F35052073&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F35052073%26sid%3Dliteratum%253Aachs%26aulast%3DYarden%26aufirst%3DY.%26aulast%3DSliwknowski%26aufirst%3DM.%2BX.%26atitle%3DUntangling%2520the%2520ErbB%2520signalling%2520network%26jtitle%3DNature%2520Rev.%2520Mol.%2520Cell.%2520Biol.%26date%3D2001%26volume%3D2%26spage%3D127%26epage%3D137" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Hynes, N. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lane, H. A.</span><span> </span><span class="NLM_article-title">ErbB receptors and cancer: the complexity of targeted inhibitors</span> <span class="citation_source-journal">Nature Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">341</span><span class="NLM_x">â</span> <span class="NLM_lpage">354</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Fjm5014659&amp;key=10.1038%2Fnrc1609" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Fjm5014659&amp;key=15864276" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Fjm5014659&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjslertb0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2005&pages=341-354&author=N.+E.+Hynesauthor=H.+A.+Lane&title=ErbB+receptors+and+cancer%3A+the+complexity+of+targeted+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">ERBB receptors and cancer: the complexity of targeted inhibitors</span></div><div class="casAuthors">Hynes, Nancy E.; Lane, Heidi A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">341-354</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  ERBB receptor tyrosine kinases have important roles in human cancer.  In particular, the expression or activation of epidermal growth factor receptor and ERBB2 are altered in many epithelial tumors, and clin. studies indicate that they have important roles in tumor etiol. and progression.  Accordingly, these receptors have been intensely studied to understand their importance in cancer biol. and as therapeutic targets, and many ERBB inhibitors are now used in the clinic.  We will discuss the significance of these receptors as clin. targets, in particular the mol. mechanisms underlying response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrimBiy4bn4LrVg90H21EOLACvtfcHk0liapb4xfuR-YA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjslertb0%253D&md5=54a45e004711da7017ee0f016696a36e</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fnrc1609&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1609%26sid%3Dliteratum%253Aachs%26aulast%3DHynes%26aufirst%3DN.%2BE.%26aulast%3DLane%26aufirst%3DH.%2BA.%26atitle%3DErbB%2520receptors%2520and%2520cancer%253A%2520the%2520complexity%2520of%2520targeted%2520inhibitors%26jtitle%3DNature%2520Rev.%2520Cancer%26date%3D2005%26volume%3D5%26spage%3D341%26epage%3D354" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Ciardiello, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tortora, G.</span><span> </span><span class="NLM_article-title">EGFR antagonists in cancer treatment</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">358</span><span class="NLM_x">, </span> <span class="NLM_fpage">1160</span><span class="NLM_x">â</span> <span class="NLM_lpage">1174</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Fjm5014659&amp;key=10.1056%2FNEJMra0707704" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Fjm5014659&amp;key=18337605" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Fjm5014659&amp;key=1%3ACAS%3A528%3ADC%252BD1cXjt1ahsL4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=358&publication_year=2008&pages=1160-1174&author=F.+Ciardielloauthor=G.+Tortora&title=EGFR+antagonists+in+cancer+treatment"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">EGFR antagonists in cancer treatment</span></div><div class="casAuthors">Ciardiello, Fortunato; Tortora, Giampaolo</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">358</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1160-1174</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">A review on epidermal growth factor receptor (EGFR) in human carcinogenesis, development of EGFR antagonists for anticancer therapy, and clin. efficacy of EGFR antagonists in human cancers.  Predicting the response to anti-EGFR drugs and future directions are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGNHvRENSffLVg90H21EOLACvtfcHk0liapb4xfuR-YA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXjt1ahsL4%253D&md5=2834999545fd643c6f727d80d357134d</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1056%2FNEJMra0707704&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMra0707704%26sid%3Dliteratum%253Aachs%26aulast%3DCiardiello%26aufirst%3DF.%26aulast%3DTortora%26aufirst%3DG.%26atitle%3DEGFR%2520antagonists%2520in%2520cancer%2520treatment%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2008%26volume%3D358%26spage%3D1160%26epage%3D1174" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Roskoski, R.,  Jr.</span><span> </span><span class="NLM_article-title">Anaplastic lymphoma kinase (ALK): structure, oncogenic activation, and pharmacological inhibition</span> <span class="citation_source-journal">Pharmacol. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x">, </span> <span class="NLM_fpage">68</span><span class="NLM_x">â</span> <span class="NLM_lpage">94</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Fjm5014659&amp;key=10.1016%2Fj.phrs.2012.11.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Fjm5014659&amp;key=23201355" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Fjm5014659&amp;key=1%3ACAS%3A528%3ADC%252BC3sXovVygtg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2013&pages=68-94&author=R.+Roskoski&title=Anaplastic+lymphoma+kinase+%28ALK%29%3A+structure%2C+oncogenic+activation%2C+and+pharmacological+inhibition"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Anaplastic lymphoma kinase (ALK): Structure, oncogenic activation, and pharmacological inhibition</span></div><div class="casAuthors">Roskoski, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">68-94</span>CODEN:
                <span class="NLM_cas:coden">PHMREP</span>;
        ISSN:<span class="NLM_cas:issn">1043-6618</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Anaplastic lymphoma kinase was first described in 1994 as the NPM-ALK fusion protein that is expressed in the majority of anaplastic large-cell lymphomas.  ALK is a receptor protein-tyrosine kinase that was more fully characterized in 1997.  Physiol. ALK participates in embryonic nervous system development, but its expression decreases after birth.  ALK is a member of the insulin receptor superfamily and is most closely related to leukocyte tyrosine kinase (Ltk), which is a receptor protein-tyrosine kinase.  Twenty different ALK-fusion proteins have been described that result from various chromosomal rearrangements, and they have been implicated in the pathogenesis of several diseases including anaplastic large-cell lymphoma, diffuse large B-cell lymphoma, and inflammatory myofibroblastic tumors.  The EML4-ALK fusion protein and four other ALK-fusion proteins play a fundamental role in the development in about 5% of non-small cell lung cancers.  The formation of dimers by the amino-terminal portion of the ALK fusion proteins results in the activation of the ALK protein kinase domain that plays a key role in the tumorigenic process.  Downstream signaling from ALK fusion proteins involves the Ras/Raf/MEK/ERK1/2 cell proliferation module and the JAK/STAT cell survival pathway.  Furthermore, nearly two dozen ALK activating mutations participate in the pathogenesis of childhood neuroblastomas along with ALK overexpression.  The occurrence of oncogenic ALK, particularly in non-small cell lung cancer, has generated considerable interest and effort in developing ALK inhibitors.  Currently, crizotinib has been approved by the US Food and Drug Administration for the treatment of ALK-pos. non-small cell lung cancer along with an approved fluorescence in situ hybridization kit used for the diagnosis of the disease.  The emergence of crizotinib drug resistance with a median occurrence at approx. 10 mo after the initiation of therapy has stimulated the development of second-generation drugs for the treatment of non-small cell lung cancer and other disorders.  About 28% of the cases of crizotinib resistance are related to nearly a dozen different mutations of ALK in the EML4-ALK fusion protein; the other cases of resistance are related to the upregulation of alternative signaling pathways or to undefined mechanisms.  It is remarkable that the EML4-ALK fusion protein was discovered in 2007 and crizotinib was approved for the treatment of ALK-pos. non-small cell lung cancer in 2011, which is a remarkably short timeframe in the overall scheme of drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpv-sp0x0gqkrVg90H21EOLACvtfcHk0ljI22AG3BNu7Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXovVygtg%253D%253D&md5=c48d1a4b88a68d395b7acdf403f1875d</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2Fj.phrs.2012.11.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.phrs.2012.11.007%26sid%3Dliteratum%253Aachs%26aulast%3DRoskoski%26aufirst%3DR.%26atitle%3DAnaplastic%2520lymphoma%2520kinase%2520%2528ALK%2529%253A%2520structure%252C%2520oncogenic%2520activation%252C%2520and%2520pharmacological%2520inhibition%26jtitle%3DPharmacol.%2520Res.%26date%3D2013%26volume%3D68%26spage%3D68%26epage%3D94" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Maemondo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inoue, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobayashi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oizumi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isobe, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saijo, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hagiwara, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gemma, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nukiwa, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kudoh, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanazawa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagao, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakai, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shibuya, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akie, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chonabayashi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hasegawa, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayashibara, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hino, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hino, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ikebuchi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishii, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaneko, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kimura, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koba, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kojima, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kosaihira, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koyama, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miki, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minegishi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morikawa, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moriyama, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murayama, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagashima, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niizuma, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nitanai, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogura, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okamoto, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Osaki, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakai, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sugita, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suzuki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanaka, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tokunaga, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsukamoto, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uematsu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Usui, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yasuda, K.</span><span> </span><span class="NLM_article-title">Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">362</span><span class="NLM_x">, </span> <span class="NLM_fpage">2380</span><span class="NLM_x">â</span> <span class="NLM_lpage">2388</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Fjm5014659&amp;key=10.1056%2FNEJMoa0909530" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Fjm5014659&amp;key=20573926" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Fjm5014659&amp;key=1%3ACAS%3A528%3ADC%252BC3cXot1Gjt7Y%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=362&publication_year=2010&pages=2380-2388&author=M.+Maemondoauthor=A.+Inoueauthor=K.+Kobayashiauthor=S.+Oizumiauthor=H.+Isobeauthor=Y.+Saijoauthor=K.+Hagiwaraauthor=A.+Gemmaauthor=T.+Nukiwaauthor=S.+Kudohauthor=M.+Kanazawaauthor=K.+Nagaoauthor=Y.+Nakaiauthor=M.+Shibuyaauthor=K.+Akieauthor=N.+Chonabayashiauthor=Y.+Hasegawaauthor=K.+Hayashibaraauthor=M.+Hinoauthor=T.+Hinoauthor=K.+Ikebuchiauthor=Y.+Ishiiauthor=N.+Kanekoauthor=Y.+Kimuraauthor=H.+Kobaauthor=T.+Kojimaauthor=S.+Kosaihiraauthor=N.+Koyamaauthor=H.+Mikiauthor=Y.+Minegishiauthor=N.+Morikawaauthor=G.+Moriyamaauthor=Y.+Murayamaauthor=M.+Nagashimaauthor=K.+Niizumaauthor=H.+Nitanaiauthor=S.+Oguraauthor=Y.+Okamotoauthor=Y.+Osakiauthor=H.+Sakaiauthor=H.+Sugitaauthor=T.+Suzukiauthor=J.+Tanakaauthor=H.+Tokunagaauthor=T.+Tsukamotoauthor=K.+Uematsuauthor=K.+Usuiauthor=K.+Yasuda&title=Gefitinib+or+chemotherapy+for+non-small-cell+lung+cancer+with+mutated+EGFR"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR</span></div><div class="casAuthors">Maemondo, Makoto; Inoue, Akira; Kobayashi, Kunihiko; Sugawara, Shunichi; Oizumi, Satoshi; Isobe, Hiroshi; Gemma, Akihiko; Harada, Masao; Yoshizawa, Hirohisa; Kinoshita, Ichiro; Fujita, Yuka; Okinaga, Shoji; Hirano, Haruto; Yoshimori, Kozo; Harada, Toshiyuki; Ogura, Takashi; Ando, Masahiro; Miyazawa, Hitoshi; Tanaka, Tomoaki; Saijo, Yasuo; Hagiwara, Koichi; Morita, Satoshi; Nukiwa, Toshihiro</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">362</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">2380-2388</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Non-small-cell lung cancer with sensitive mutations of the epidermal growth factor receptor (EGFR) is highly responsive to EGFR tyrosine kinase inhibitors such as gefitinib, but little is known about how its efficacy and safety profile compares with that of std. chemotherapy.  We randomly assigned 230 patients with metastatic, non-small-cell lung cancer and EGFR mutations who had not previously received chemotherapy to receive gefitinib or carboplatin-paclitaxel.  The primary end point was progression-free survival; secondary end points included overall survival, response rate, and toxic effects.  In the planned interim anal. of data for the first 200 patients, progression-free survival was significantly longer in the gefitinib group than in the std.-chemotherapy group (hazard ratio for death or disease progression with gefitinib, 0.36; P<0.001), resulting in early termination of the study.  The gefitinib group had a significantly longer median progression-free survival (10.8 mo, vs. 5.4 mo in the chemotherapy group; hazard ratio, 0.30; 95% confidence interval, 0.22 to 0.41; P<0.001), as well as a higher response rate (73.7% vs. 30.7%, P<0.001).  The median overall survival was 30.5 mo in the gefitinib group and 23.6 mo in the chemotherapy group (P = 0.31).  The most common adverse events in the gefitinib group were rash (71.1%) and elevated aminotransferase levels (55.3%), and in the chemotherapy group, neutropenia (77.0%), anemia (64.6%), appetite loss (56.6%), and sensory neuropathy (54.9%).  One patient receiving gefitinib died from interstitial lung disease.  First-line gefitinib for patients with advanced non-small-cell lung cancer who were selected on the basis of EGFR mutations improved progression-free survival, with acceptable toxicity, as compared with std. chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1G31xQ-ZFWLVg90H21EOLACvtfcHk0lhxNBENyGD7GA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXot1Gjt7Y%253D&md5=603963e646bf20ecfd936fc98467f5fd</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa0909530&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa0909530%26sid%3Dliteratum%253Aachs%26aulast%3DMaemondo%26aufirst%3DM.%26aulast%3DInoue%26aufirst%3DA.%26aulast%3DKobayashi%26aufirst%3DK.%26aulast%3DOizumi%26aufirst%3DS.%26aulast%3DIsobe%26aufirst%3DH.%26aulast%3DSaijo%26aufirst%3DY.%26aulast%3DHagiwara%26aufirst%3DK.%26aulast%3DGemma%26aufirst%3DA.%26aulast%3DNukiwa%26aufirst%3DT.%26aulast%3DKudoh%26aufirst%3DS.%26aulast%3DKanazawa%26aufirst%3DM.%26aulast%3DNagao%26aufirst%3DK.%26aulast%3DNakai%26aufirst%3DY.%26aulast%3DShibuya%26aufirst%3DM.%26aulast%3DAkie%26aufirst%3DK.%26aulast%3DChonabayashi%26aufirst%3DN.%26aulast%3DHasegawa%26aufirst%3DY.%26aulast%3DHayashibara%26aufirst%3DK.%26aulast%3DHino%26aufirst%3DM.%26aulast%3DHino%26aufirst%3DT.%26aulast%3DIkebuchi%26aufirst%3DK.%26aulast%3DIshii%26aufirst%3DY.%26aulast%3DKaneko%26aufirst%3DN.%26aulast%3DKimura%26aufirst%3DY.%26aulast%3DKoba%26aufirst%3DH.%26aulast%3DKojima%26aufirst%3DT.%26aulast%3DKosaihira%26aufirst%3DS.%26aulast%3DKoyama%26aufirst%3DN.%26aulast%3DMiki%26aufirst%3DH.%26aulast%3DMinegishi%26aufirst%3DY.%26aulast%3DMorikawa%26aufirst%3DN.%26aulast%3DMoriyama%26aufirst%3DG.%26aulast%3DMurayama%26aufirst%3DY.%26aulast%3DNagashima%26aufirst%3DM.%26aulast%3DNiizuma%26aufirst%3DK.%26aulast%3DNitanai%26aufirst%3DH.%26aulast%3DOgura%26aufirst%3DS.%26aulast%3DOkamoto%26aufirst%3DY.%26aulast%3DOsaki%26aufirst%3DY.%26aulast%3DSakai%26aufirst%3DH.%26aulast%3DSugita%26aufirst%3DH.%26aulast%3DSuzuki%26aufirst%3DT.%26aulast%3DTanaka%26aufirst%3DJ.%26aulast%3DTokunaga%26aufirst%3DH.%26aulast%3DTsukamoto%26aufirst%3DT.%26aulast%3DUematsu%26aufirst%3DK.%26aulast%3DUsui%26aufirst%3DK.%26aulast%3DYasuda%26aufirst%3DK.%26atitle%3DGefitinib%2520or%2520chemotherapy%2520for%2520non-small-cell%2520lung%2520cancer%2520with%2520mutated%2520EGFR%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2010%26volume%3D362%26spage%3D2380%26epage%3D2388" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Rosell, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carcereny, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gervais, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vergnenegre, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Massuti, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Felip, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palmero, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia-Gomez, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pallares, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanchez, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Porta, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cobo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garrido, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Longo, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moran, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Insa, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Marinis, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corre, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bover, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Illiano, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dansin, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Castro, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milella, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reguart, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Altavilla, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jimenez, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Provencio, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moreno, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Terrasa, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MuÃ±oz-Langa, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valdivia, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isla, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Domine, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Molinier, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mazieres, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baize, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia-Campelo, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robinet, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodriguez-Abreu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lopez-Vivanco, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gebbia, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferrera-Delgado, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bombaron, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bernabe, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bearz, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Artal, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortesi, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rolfo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanchez-Ronco, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drozdowskyj, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Queralt, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Aguirre, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramirez, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanchez, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Molina, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taron, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paz-Ares, L.</span><span> </span><span class="NLM_article-title">Spanish Lung Cancer Group in collaboration with Groupe FranÃ§ais de Pneumo-CancÃ©rologie and Associazione Italiana Oncologia Toracica. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomized phase 3 trial</span> <span class="citation_source-journal">Lancet Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">239</span><span class="NLM_x">â</span> <span class="NLM_lpage">246</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Fjm5014659&amp;key=10.1016%2FS1470-2045%2811%2970393-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Fjm5014659&amp;key=22285168" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Fjm5014659&amp;key=1%3ACAS%3A528%3ADC%252BC38XjsVCgsbk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2012&pages=239-246&author=R.+Rosellauthor=E.+Carcerenyauthor=R.+Gervaisauthor=A.+Vergnenegreauthor=B.+Massutiauthor=E.+Felipauthor=R.+Palmeroauthor=R.+Garcia-Gomezauthor=C.+Pallaresauthor=J.+M.+Sanchezauthor=R.+Portaauthor=M.+Coboauthor=P.+Garridoauthor=F.+Longoauthor=T.+Moranauthor=A.+Insaauthor=F.+De+Marinisauthor=R.+Correauthor=I.+Boverauthor=A.+Illianoauthor=E.+Dansinauthor=J.+de+Castroauthor=M.+Milellaauthor=N.+Reguartauthor=G.+Altavillaauthor=U.+Jimenezauthor=M.+Provencioauthor=M.+A.+Morenoauthor=J.+Terrasaauthor=J.+Mu%C3%B1oz-Langaauthor=J.+Valdiviaauthor=D.+Islaauthor=M.+Domineauthor=O.+Molinierauthor=J.+Mazieresauthor=N.+Baizeauthor=R.+Garcia-Campeloauthor=G.+Robinetauthor=D.+Rodriguez-Abreuauthor=G.+Lopez-Vivancoauthor=V.+Gebbiaauthor=L.+Ferrera-Delgadoauthor=P.+Bombaronauthor=R.+Bernabeauthor=A.+Bearzauthor=A.+Artalauthor=E.+Cortesiauthor=C.+Rolfoauthor=M.+Sanchez-Roncoauthor=A.+Drozdowskyjauthor=C.+Queraltauthor=I.+de+Aguirreauthor=J.+L.+Ramirezauthor=J.+J.+Sanchezauthor=M.+A.+Molinaauthor=M.+Taronauthor=L.+Paz-Ares&title=Spanish+Lung+Cancer+Group+in+collaboration+with+Groupe+Fran%C3%A7ais+de+Pneumo-Canc%C3%A9rologie+and+Associazione+Italiana+Oncologia+Toracica.+Erlotinib+versus+standard+chemotherapy+as+first-line+treatment+for+European+patients+with+advanced+EGFR+mutation-positive+non-small-cell+lung+cancer+%28EURTAC%29%3A+a+multicentre%2C+open-label%2C+randomized+phase+3+trial"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial</span></div><div class="casAuthors">Rosell, Rafael; Carcereny, Enric; Gervais, Radj; Vergnenegre, Alain; Massuti, Bartomeu; Felip, Enriqueta; Palmero, Ramon; Garcia-Gomez, Ramon; Pallares, Cinta; Sanchez, Jose Miguel; Porta, Rut; Cobo, Manuel; Garrido, Pilar; Longo, Flavia; Moran, Teresa; Insa, Amelia; De Marinis, Filippo; Corre, Romain; Bover, Isabel; Illiano, Alfonso; Dansin, Eric; de Castro, Javier; Milella, Michele; Reguart, Noemi; Altavilla, Giuseppe; Jimenez, Ulpiano; Provencio, Mariano; Moreno, Miguel Angel; Terrasa, Josefa; Munoz-Langa, Jose; Valdivia, Javier; Isla, Dolores; Domine, Manuel; Molinier, Olivier; Mazieres, Julien; Baize, Nathalie; Garcia-Campelo, Rosario; Robinet, Gilles; Rodriguez-Abreu, Delvys; Lopez-Vivanco, Guillermo; Gebbia, Vittorio; Ferrera-Delgado, Lioba; Bombaron, Pierre; Bernabe, Reyes; Bearz, Alessandra; Artal, Angel; Cortesi, Enrico; Rolfo, Christian; Sanchez-Ronco, Maria; Drozdowskyj, Ana; Queralt, Cristina; de Aguirre, Itziar; Ramirez, Jose Luis; Sanchez, Jose Javier; Molina, Miguel Angel; Taron, Miquel; Paz-Ares, Luis</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">239-246</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Summary: Background: Erlotinib has been shown to improve progression-free survival compared with chemotherapy when given as first-line treatment for Asian patients with non-small-cell lung cancer (NSCLC) with activating EGFR mutations.  We aimed to assess the safety and efficacy of erlotinib compared with std. chemotherapy for first-line treatment of European patients with advanced EGFR-mutation pos. NSCLC.  Methods: We undertook the open-label, randomized phase 3 EURTAC trial at 42 hospitals in France, Italy, and Spain.  Eligible participants were adults (>18 years) with NSCLC and EGFR mutations (exon 19 deletion or L858R mutation in exon 21) with no history of chemotherapy for metastatic disease (neoadjuvant or adjuvant chemotherapy ending â¥6 mo before study entry was allowed).  We randomly allocated participants (1:1) according to a computer-generated allocation schedule to receive oral erlotinib 150 mg per day or 3 wk cycles of std. i.v. chemotherapy of cisplatin 75 mg/m2 on day 1 plus docetaxel (75 mg/m2 on day 1) or gemcitabine (1250 mg/m2 on days 1 and 8).  Carboplatin (AUC 6 with docetaxel 75 mg/m2 or AUC 5 with gemcitabine 1000 mg/m2) was allowed in patients unable to have cisplatin.  Patients were stratified by EGFR mutation type and Eastern Cooperative Oncol. Group performance status (0 vs 1 vs 2).  The primary endpoint was progression-free survival (PFS) in the intention-to-treat population.  We assessed safety in all patients who received study drug (â¥1 dose).  This study is registered with ClinicalTrials.gov, no. NCT00446225.  Findings: Between Feb 15, 2007, and Jan 4, 2011, 174 patients with EGFR mutations were enrolled.  One patient received treatment before randomization and was thus withdrawn from the study; of the remaining patients, 86 were randomly assigned to receive erlotinib and 87 to receive std. chemotherapy.  The preplanned interim anal. showed that the study met its primary endpoint; enrollment was halted, and full evaluation of the results was recommended.  At data cutoff (Jan 26, 2011), median PFS was 9Â·7 mo (95% CI 8Â·4-12Â·3) in the erlotinib group, compared with 5Â·2 mo (4Â·5-5Â·8) in the std. chemotherapy group (hazard ratio 0Â·37, 95% CI 0Â·25-0Â·54; p<0Â·0001).  Main grade 3 or 4 toxicities were rash (11 [13%] of 84 patients given erlotinib vs none of 82 patients in the chemotherapy group), neutropenia (none vs 18 [22%]), anemia (one [1%] vs three [4%]), and increased amino-transferase concns. (two [2%] vs 0).  Five (6%) patients on erlotinib had treatment-related severe adverse events compared with 16 patients (20%) on chemotherapy.  One patient in the erlotinib group and two in the std. chemotherapy group died from treatment-related causes.  Interpretation: Our findings strengthen the rationale for routine baseline tissue-based assessment of EGFR mutations in patients with NSCLC and for treatment of mutation-pos. patients with EGFR tyrosine-kinase inhibitors.  Funding: Spanish Lung Cancer Group, Roche Farma, Hoffmann-La Roche, and Red Tematica de Investigacion Cooperativa en Cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFHsqWOF3EU7Vg90H21EOLACvtfcHk0lg6se-Caq_t5g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjsVCgsbk%253D&md5=9b7c83e16707fba2bc2f4a878effbfb3</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2811%2970393-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252811%252970393-X%26sid%3Dliteratum%253Aachs%26aulast%3DRosell%26aufirst%3DR.%26aulast%3DCarcereny%26aufirst%3DE.%26aulast%3DGervais%26aufirst%3DR.%26aulast%3DVergnenegre%26aufirst%3DA.%26aulast%3DMassuti%26aufirst%3DB.%26aulast%3DFelip%26aufirst%3DE.%26aulast%3DPalmero%26aufirst%3DR.%26aulast%3DGarcia-Gomez%26aufirst%3DR.%26aulast%3DPallares%26aufirst%3DC.%26aulast%3DSanchez%26aufirst%3DJ.%2BM.%26aulast%3DPorta%26aufirst%3DR.%26aulast%3DCobo%26aufirst%3DM.%26aulast%3DGarrido%26aufirst%3DP.%26aulast%3DLongo%26aufirst%3DF.%26aulast%3DMoran%26aufirst%3DT.%26aulast%3DInsa%26aufirst%3DA.%26aulast%3DDe%2BMarinis%26aufirst%3DF.%26aulast%3DCorre%26aufirst%3DR.%26aulast%3DBover%26aufirst%3DI.%26aulast%3DIlliano%26aufirst%3DA.%26aulast%3DDansin%26aufirst%3DE.%26aulast%3Dde%2BCastro%26aufirst%3DJ.%26aulast%3DMilella%26aufirst%3DM.%26aulast%3DReguart%26aufirst%3DN.%26aulast%3DAltavilla%26aufirst%3DG.%26aulast%3DJimenez%26aufirst%3DU.%26aulast%3DProvencio%26aufirst%3DM.%26aulast%3DMoreno%26aufirst%3DM.%2BA.%26aulast%3DTerrasa%26aufirst%3DJ.%26aulast%3DMu%25C3%25B1oz-Langa%26aufirst%3DJ.%26aulast%3DValdivia%26aufirst%3DJ.%26aulast%3DIsla%26aufirst%3DD.%26aulast%3DDomine%26aufirst%3DM.%26aulast%3DMolinier%26aufirst%3DO.%26aulast%3DMazieres%26aufirst%3DJ.%26aulast%3DBaize%26aufirst%3DN.%26aulast%3DGarcia-Campelo%26aufirst%3DR.%26aulast%3DRobinet%26aufirst%3DG.%26aulast%3DRodriguez-Abreu%26aufirst%3DD.%26aulast%3DLopez-Vivanco%26aufirst%3DG.%26aulast%3DGebbia%26aufirst%3DV.%26aulast%3DFerrera-Delgado%26aufirst%3DL.%26aulast%3DBombaron%26aufirst%3DP.%26aulast%3DBernabe%26aufirst%3DR.%26aulast%3DBearz%26aufirst%3DA.%26aulast%3DArtal%26aufirst%3DA.%26aulast%3DCortesi%26aufirst%3DE.%26aulast%3DRolfo%26aufirst%3DC.%26aulast%3DSanchez-Ronco%26aufirst%3DM.%26aulast%3DDrozdowskyj%26aufirst%3DA.%26aulast%3DQueralt%26aufirst%3DC.%26aulast%3Dde%2BAguirre%26aufirst%3DI.%26aulast%3DRamirez%26aufirst%3DJ.%2BL.%26aulast%3DSanchez%26aufirst%3DJ.%2BJ.%26aulast%3DMolina%26aufirst%3DM.%2BA.%26aulast%3DTaron%26aufirst%3DM.%26aulast%3DPaz-Ares%26aufirst%3DL.%26atitle%3DSpanish%2520Lung%2520Cancer%2520Group%2520in%2520collaboration%2520with%2520Groupe%2520Fran%25C3%25A7ais%2520de%2520Pneumo-Canc%25C3%25A9rologie%2520and%2520Associazione%2520Italiana%2520Oncologia%2520Toracica.%2520Erlotinib%2520versus%2520standard%2520chemotherapy%2520as%2520first-line%2520treatment%2520for%2520European%2520patients%2520with%2520advanced%2520EGFR%2520mutation-positive%2520non-small-cell%2520lung%2520cancer%2520%2528EURTAC%2529%253A%2520a%2520multicentre%252C%2520open-label%252C%2520randomized%2520phase%25203%2520trial%26jtitle%3DLancet%2520Oncol.%26date%3D2012%26volume%3D13%26spage%3D239%26epage%3D246" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Kobayashi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boggon, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dayaram, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">JÃ¤nne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kocher, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tenen, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halmos, B.</span><span> </span><span class="NLM_article-title">EGFR mutation and resistance of non-small-cell lung cancer to gefitinib</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">352</span><span class="NLM_x">, </span> <span class="NLM_fpage">786</span><span class="NLM_x">â</span> <span class="NLM_lpage">792</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Fjm5014659&amp;key=10.1056%2FNEJMoa044238" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Fjm5014659&amp;key=15728811" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Fjm5014659&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhsFCiurk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=352&publication_year=2005&pages=786-792&author=S.+Kobayashiauthor=T.+J.+Boggonauthor=T.+Dayaramauthor=P.+A.+J%C3%A4nneauthor=O.+Kocherauthor=M.+Meyersonauthor=B.+E.+Johnsonauthor=M.+J.+Eckauthor=D.+G.+Tenenauthor=B.+Halmos&title=EGFR+mutation+and+resistance+of+non-small-cell+lung+cancer+to+gefitinib"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">EGFR mutation and resistance of non-small-cell lung cancer to gefitinib</span></div><div class="casAuthors">Kobayashi, Susumu; Boggon, Titus J.; Dayaram, Tajhal; Jaenne, Pasi A.; Kocher, Olivier; Meyerson, Matthew; Johnson, Bruce E.; Eck, Michael J.; Tenen, Daniel G.; Halmos, Balizs</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">352</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">786-792</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Mutations of the epidermal growth factor receptor (EGFR) gene were identified in specimens from patients with non-small-cell lung cancer who have a response to anilinoquinazoline EGFR inhibitors.  Despite the dramatic responses to such inhibitors, most patients ultimately have a relapse.  The mechanism of the drug resistance is unknown.  Here the authors report the case of a patient with EGFR-mutant, gefitinib-responsive, advanced non-small-cell lung cancer who had a relapse after 2 years of complete remission during treatment with gefitinib.  The DNA sequence of the EGFR gene in his tumor biopsy specimen at relapse revealed the presence of a second point mutation, resulting in threonine-to-methionine amino acid change at position 790 of EGFR.  Structural modeling and biochem. studies showed that this second mutation led to gefitinib resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8XXhT1hrbe7Vg90H21EOLACvtfcHk0lg6se-Caq_t5g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhsFCiurk%253D&md5=808223ad566e2a3748977727cc5a9846</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa044238&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa044238%26sid%3Dliteratum%253Aachs%26aulast%3DKobayashi%26aufirst%3DS.%26aulast%3DBoggon%26aufirst%3DT.%2BJ.%26aulast%3DDayaram%26aufirst%3DT.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26aulast%3DKocher%26aufirst%3DO.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DJohnson%26aufirst%3DB.%2BE.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DTenen%26aufirst%3DD.%2BG.%26aulast%3DHalmos%26aufirst%3DB.%26atitle%3DEGFR%2520mutation%2520and%2520resistance%2520of%2520non-small-cell%2520lung%2520cancer%2520to%2520gefitinib%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2005%26volume%3D352%26spage%3D786%26epage%3D792" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Lee, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shin, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koh, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keam, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Min, H. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeon, Y. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chung, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heo, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, J. I.</span><span> </span><span class="NLM_article-title">Primary resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with non-small-cell lung cancer harboring TKI-sensitive EGFR mutations: an exploratory study</span> <span class="citation_source-journal">Ann. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">2080</span><span class="NLM_x">â</span> <span class="NLM_lpage">2087</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Fjm5014659&amp;key=10.1093%2Fannonc%2Fmdt127" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Fjm5014659&amp;key=23559152" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Fjm5014659&amp;key=1%3ACAS%3A280%3ADC%252BC3srisVOmsg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2013&pages=2080-2087&author=J.+K.+Leeauthor=J.+Y.+Shinauthor=S.+Kimauthor=S.+Leeauthor=C.+Parkauthor=J.+Y.+Kimauthor=Y.+Kohauthor=B.+Keamauthor=H.+S.+Minauthor=T.+M.+Kimauthor=Y.+K.+Jeonauthor=D.+W.+Kimauthor=D.+H.+Chungauthor=D.+S.+Heoauthor=S.+H.+Leeauthor=J.+I.+Kim&title=Primary+resistance+to+epidermal+growth+factor+receptor+%28EGFR%29+tyrosine+kinase+inhibitors+%28TKIs%29+in+patients+with+non-small-cell+lung+cancer+harboring+TKI-sensitive+EGFR+mutations%3A+an+exploratory+study"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Primary resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with non-small-cell lung cancer harboring TKI-sensitive EGFR mutations: an exploratory study</span></div><div class="casAuthors">Lee J K; Shin J-Y; Kim S; Lee S; Park C; Kim J-Y; Koh Y; Keam B; Min H S; Kim T M; Jeon Y-K; Kim D-W; Chung D H; Heo D S; Lee S-H; Kim J-I</div><div class="citationInfo"><span class="NLM_cas:title">Annals of oncology : official journal of the European Society for Medical Oncology / ESMO</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2080-7</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  The mechanism of primary resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in EGFR-mutant non-small-cell lung cancer (NSCLC) has not been clearly understood.  PATIENTS AND METHODS:  Eleven patients exhibiting primary resistance (disease progression <3 months) were identified among 197 consecutive NSCLC patients with TKI-sensitive EGFR mutations who received EGFR TKIs at Seoul National University Hospital.  Treatment-naive tumors were examined for concurrent genetic alterations using fluorescence in situ hybridization and targeted deep sequencing of cancer-related genes.  Deletion polymorphism of Bcl-2-interacting mediator of cell death (BIM) gene was examined to validate its predictive role for TKI outcome.  RESULTS:  The median progression-free survival (PFS) for patients receiving EGFR TKIs was 11.9 months, and the response rate 78.8%.  Among the 11 patients exhibiting primary resistance, a de novo T790M mutation was identified in one patient, and two exhibited mesenchymal-epithelial transition amplification and anaplastic lymphoma kinase fusion.  Targeted deep sequencing identified no recurrent, coexistent drivers of NSCLC.  Survival analysis revealed that patients with recurrent disease after surgery had a longer PFS than those with initial stage IV disease.  However, BIM deletion polymorphism, line of treatment, EGFR genotype, and smoking were not predictive of PFS for EGFR TKIs.  CONCLUSIONS:  We identified coexistent genetic alterations of cancer-related genes that could explain primary resistance in a small proportion of patients.  Our result suggests that the mechanism of primary resistance might be heterogeneous.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTHIZXFf_U3krjnyZkbE8yXfW6udTcc2eb5mSoLXIi1LLntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3srisVOmsg%253D%253D&md5=ecaa76fdc8df60e276aa3792fa3b6338</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdt127&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdt127%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DJ.%2BK.%26aulast%3DShin%26aufirst%3DJ.%2BY.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DS.%26aulast%3DPark%26aufirst%3DC.%26aulast%3DKim%26aufirst%3DJ.%2BY.%26aulast%3DKoh%26aufirst%3DY.%26aulast%3DKeam%26aufirst%3DB.%26aulast%3DMin%26aufirst%3DH.%2BS.%26aulast%3DKim%26aufirst%3DT.%2BM.%26aulast%3DJeon%26aufirst%3DY.%2BK.%26aulast%3DKim%26aufirst%3DD.%2BW.%26aulast%3DChung%26aufirst%3DD.%2BH.%26aulast%3DHeo%26aufirst%3DD.%2BS.%26aulast%3DLee%26aufirst%3DS.%2BH.%26aulast%3DKim%26aufirst%3DJ.%2BI.%26atitle%3DPrimary%2520resistance%2520to%2520epidermal%2520growth%2520factor%2520receptor%2520%2528EGFR%2529%2520tyrosine%2520kinase%2520inhibitors%2520%2528TKIs%2529%2520in%2520patients%2520with%2520non-small-cell%2520lung%2520cancer%2520harboring%2520TKI-sensitive%2520EGFR%2520mutations%253A%2520an%2520exploratory%2520study%26jtitle%3DAnn.%2520Oncol.%26date%3D2013%26volume%3D24%26spage%3D2080%26epage%3D2087" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Yun, C.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mengwasser, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toms, A. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woo, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greulich, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span> </span><span class="NLM_article-title">The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">105</span><span class="NLM_x">, </span> <span class="NLM_fpage">2070</span><span class="NLM_x">â</span> <span class="NLM_lpage">2075</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Fjm5014659&amp;key=10.1073%2Fpnas.0709662105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Fjm5014659&amp;key=18227510" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Fjm5014659&amp;key=1%3ACAS%3A528%3ADC%252BD1cXitl2mu7k%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2008&pages=2070-2075&author=C.-H.+Yunauthor=K.+E.+Mengwasserauthor=A.+V.+Tomsauthor=M.+S.+Wooauthor=H.+Greulichauthor=K.+K.+Wongauthor=M.+Meyersonauthor=M.+J.+Eck&title=The+T790M+mutation+in+EGFR+kinase+causes+drug+resistance+by+increasing+the+affinity+for+ATP"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP</span></div><div class="casAuthors">Yun, Cai-Hong; Mengwasser, Kristen E.; Toms, Angela V.; Woo, Michele S.; Greulich, Heidi; Wong, Kwok-Kin; Meyerson, Matthew; Eck, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2070-2075</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Lung cancers caused by activating mutations in the epidermal growth factor receptor (EGFR) are initially responsive to small mol. tyrosine kinase inhibitors (TKIs), but the efficacy of these agents is often limited because of the emergence of drug resistance conferred by a second mutation, T790M.  Threonine 790 is the "gatekeeper" residue, an important determinant of inhibitor specificity in the ATP binding pocket.  The T790M mutation has been thought to cause resistance by sterically blocking binding of TKIs such as gefitinib and erlotinib, but this explanation is difficult to reconcile with the fact that it remains sensitive to structurally similar irreversible inhibitors.  Here, we show by using a direct binding assay that T790M mutants retain low-nanomolar affinity for gefitinib.  Furthermore, we show that the T790M mutation activates WT EGFR and that introduction of the T790M mutation increases the ATP affinity of the oncogenic L858R mutant by more than an order of magnitude.  The increased ATP affinity is the primary mechanism by which the T790M mutation confers drug resistance.  Crystallog. anal. of the T790M mutant shows how it can adapt to accommodate tight binding of diverse inhibitors, including the irreversible inhibitor HKI-272, and also suggests a structural mechanism for catalytic activation.  We conclude that the T790M mutation is a "generic" resistance mutation that will reduce the potency of any ATP-competitive kinase inhibitor and that irreversible inhibitors overcome this resistance simply through covalent binding, not as a result of an alternative binding mode.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXXP7TBlyrdrVg90H21EOLACvtfcHk0liQRdY4vzqUOA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXitl2mu7k%253D&md5=f5f5d791a65f73ca628d95e9922b8ea8</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0709662105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0709662105%26sid%3Dliteratum%253Aachs%26aulast%3DYun%26aufirst%3DC.-H.%26aulast%3DMengwasser%26aufirst%3DK.%2BE.%26aulast%3DToms%26aufirst%3DA.%2BV.%26aulast%3DWoo%26aufirst%3DM.%2BS.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DWong%26aufirst%3DK.%2BK.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26atitle%3DThe%2520T790M%2520mutation%2520in%2520EGFR%2520kinase%2520causes%2520drug%2520resistance%2520by%2520increasing%2520the%2520affinity%2520for%2520ATP%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2008%26volume%3D105%26spage%3D2070%26epage%3D2075" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Kwak, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sordella, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bell, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Godin-Heymann, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okimoto, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brannigan, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Driscoll, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fidias, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rabindran, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGinnis, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wissner, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharma, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isselbacher, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settleman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haber, D. A.</span><span> </span><span class="NLM_article-title">Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">102</span><span class="NLM_x">, </span> <span class="NLM_fpage">7665</span><span class="NLM_x">â</span> <span class="NLM_lpage">7670</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2005&pages=7665-7670&author=E.+L.+Kwakauthor=R.+Sordellaauthor=D.+W.+Bellauthor=N.+Godin-Heymannauthor=R.+A.+Okimotoauthor=B.+W.+Branniganauthor=P.+L.+Harrisauthor=D.+R.+Driscollauthor=P.+Fidiasauthor=T.+J.+Lynchauthor=S.+K.+Rabindranauthor=J.+P.+McGinnisauthor=A.+Wissnerauthor=S.+V.+Sharmaauthor=K.+J.+Isselbacherauthor=J.+Settlemanauthor=D.+A.+Haber&title=Irreversible+inhibitors+of+the+EGF+receptor+may+circumvent+acquired+resistance+to+gefitinib"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKwak%26aufirst%3DE.%2BL.%26aulast%3DSordella%26aufirst%3DR.%26aulast%3DBell%26aufirst%3DD.%2BW.%26aulast%3DGodin-Heymann%26aufirst%3DN.%26aulast%3DOkimoto%26aufirst%3DR.%2BA.%26aulast%3DBrannigan%26aufirst%3DB.%2BW.%26aulast%3DHarris%26aufirst%3DP.%2BL.%26aulast%3DDriscoll%26aufirst%3DD.%2BR.%26aulast%3DFidias%26aufirst%3DP.%26aulast%3DLynch%26aufirst%3DT.%2BJ.%26aulast%3DRabindran%26aufirst%3DS.%2BK.%26aulast%3DMcGinnis%26aufirst%3DJ.%2BP.%26aulast%3DWissner%26aufirst%3DA.%26aulast%3DSharma%26aufirst%3DS.%2BV.%26aulast%3DIsselbacher%26aufirst%3DK.%2BJ.%26aulast%3DSettleman%26aufirst%3DJ.%26aulast%3DHaber%26aufirst%3DD.%2BA.%26atitle%3DIrreversible%2520inhibitors%2520of%2520the%2520EGF%2520receptor%2520may%2520circumvent%2520acquired%2520resistance%2520to%2520gefitinib%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2005%26volume%3D102%26spage%3D7665%26epage%3D7670" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Bowles, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weickhardt, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jimeno, A.</span><span> </span><span class="NLM_article-title">Afatinib for the treatment of patients with EGFR-positive non-small cell lung cancer</span> <span class="citation_source-journal">Drugs Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">523</span><span class="NLM_x">â</span> <span class="NLM_lpage">535</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Fjm5014659&amp;key=10.1358%2Fdot.2013.49.09.2016610" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Fjm5014659&amp;key=1%3ACAS%3A280%3ADC%252BC2c%252FlslyltQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2013&pages=523-535&author=D.+W.+Bowlesauthor=A.+Weickhardtauthor=A.+Jimeno&title=Afatinib+for+the+treatment+of+patients+with+EGFR-positive+non-small+cell+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Afatinib for the treatment of patients with EGFR-positive non-small cell lung cancer</span></div><div class="casAuthors">Bowles D W; Weickhardt A; Jimeno A</div><div class="citationInfo"><span class="NLM_cas:title">Drugs of today (Barcelona, Spain : 1998)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">523-35</span>
        ISSN:<span class="NLM_cas:issn">1699-3993</span>.
    </div><div class="casAbstract">Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are valuable treatments for EGFR-mutated non-small cell lung cancer (NSCLC).  Anti-EGFR antibodies are widely used in the treatment of head and neck squamous cell carcinomas (HNSCC) and in KRAS wild-type colorectal cancer.  The first-generation, reversible EGFR inhibitors erlotinib and gefitinib in the first-line setting provide superior progression-free survival and quality of life compared to conventional chemotherapy in NSCLC harboring activating EGFR mutations.  However, these therapies eventually fail and new options are needed.  Afatinib is a novel irreversible inhibitor of the ErbB family members EGFR, tyrosine kinase-type cell surface receptors HER2 and HER4.  It shows preclinical efficacy in NSCLC with common EGFR-activating mutations and the T790M mutation typically associated with EGFR TKI resistance.  Preclinical activity is seen in other tumor types as well, including HNSCC.  Clinically, afatinib has been evaluated in the broad-reaching LUX Lung trial program, with significant activity seen in the first and later-line settings.  It is also under investigation in multiple other tumor types.  This review will stress on afatinib's preclinical pharmacology, pharmacokinetics and clinical activity with a focus on NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSlb14qikVjeLt7lRqEFUJVfW6udTcc2eY_sDVDAJGPIrntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2c%252FlslyltQ%253D%253D&md5=d509f8e61df416962613be4a29dd6b47</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1358%2Fdot.2013.49.09.2016610&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1358%252Fdot.2013.49.09.2016610%26sid%3Dliteratum%253Aachs%26aulast%3DBowles%26aufirst%3DD.%2BW.%26aulast%3DWeickhardt%26aufirst%3DA.%26aulast%3DJimeno%26aufirst%3DA.%26atitle%3DAfatinib%2520for%2520the%2520treatment%2520of%2520patients%2520with%2520EGFR-positive%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DDrugs%2520Today%26date%3D2013%26volume%3D49%26spage%3D523%26epage%3D535" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Wissner, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Overbeek, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reich, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brawner Floyd, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mamuya, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosfjord, E. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Discafani, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rabindran, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gruber, B. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hallett, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nilakantan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.-F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greenberger, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsou, H.-R.</span><span> </span><span class="NLM_article-title">Synthesis and structureâactivity relationships of 6, 7-disubstituted 4-anilinoquinoline-3-carbonitriles. The design of an orally active, irreversible inhibitor of the tyrosine kinase activity of the epidermal growth factor receptor (EGFR) and the human epidermal growth factor receptor-2 (HER-2)</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">49</span><span class="NLM_x">â</span> <span class="NLM_lpage">63</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm020241c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=49-63&author=A.+Wissnerauthor=E.+Overbeekauthor=M.+F.+Reichauthor=M.+Brawner+Floydauthor=B.+D.+Johnsonauthor=N.+Mamuyaauthor=E.+C.+Rosfjordauthor=C.+Discafaniauthor=R.+Davisauthor=X.+Shiauthor=S.+K.+Rabindranauthor=B.+C.+Gruberauthor=F.+Yeauthor=W.+A.+Hallettauthor=R.+Nilakantanauthor=R.+Shenauthor=Y.-F.+Wangauthor=L.+M.+Greenbergerauthor=H.-R.+Tsou&title=Synthesis+and+structure%E2%80%93activity+relationships+of+6%2C+7-disubstituted+4-anilinoquinoline-3-carbonitriles.+The+design+of+an+orally+active%2C+irreversible+inhibitor+of+the+tyrosine+kinase+activity+of+the+epidermal+growth+factor+receptor+%28EGFR%29+and+the+human+epidermal+growth+factor+receptor-2+%28HER-2%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1021%2Fjm020241c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm020241c%26sid%3Dliteratum%253Aachs%26aulast%3DWissner%26aufirst%3DA.%26aulast%3DOverbeek%26aufirst%3DE.%26aulast%3DReich%26aufirst%3DM.%2BF.%26aulast%3DBrawner%2BFloyd%26aufirst%3DM.%26aulast%3DJohnson%26aufirst%3DB.%2BD.%26aulast%3DMamuya%26aufirst%3DN.%26aulast%3DRosfjord%26aufirst%3DE.%2BC.%26aulast%3DDiscafani%26aufirst%3DC.%26aulast%3DDavis%26aufirst%3DR.%26aulast%3DShi%26aufirst%3DX.%26aulast%3DRabindran%26aufirst%3DS.%2BK.%26aulast%3DGruber%26aufirst%3DB.%2BC.%26aulast%3DYe%26aufirst%3DF.%26aulast%3DHallett%26aufirst%3DW.%2BA.%26aulast%3DNilakantan%26aufirst%3DR.%26aulast%3DShen%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DY.-F.%26aulast%3DGreenberger%26aufirst%3DL.%2BM.%26aulast%3DTsou%26aufirst%3DH.-R.%26atitle%3DSynthesis%2520and%2520structure%25E2%2580%2593activity%2520relationships%2520of%25206%252C%25207-disubstituted%25204-anilinoquinoline-3-carbonitriles.%2520The%2520design%2520of%2520an%2520orally%2520active%252C%2520irreversible%2520inhibitor%2520of%2520the%2520tyrosine%2520kinase%2520activity%2520of%2520the%2520epidermal%2520growth%2520factor%2520receptor%2520%2528EGFR%2529%2520and%2520the%2520human%2520epidermal%2520growth%2520factor%2520receptor-2%2520%2528HER-2%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D46%26spage%3D49%26epage%3D63" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Schwartz, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuzmic, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solowiej, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergqvist, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bolanos, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Almaden, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagata, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryan, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalvie, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kath, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wani, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, B. M.</span><span> </span><span class="NLM_article-title">Covalent EGFR inhibitor analysis reveals importance of reversible interactions to potency and mechanisms of drug resistance</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">111</span><span class="NLM_x">, </span> <span class="NLM_fpage">173</span><span class="NLM_x">â</span> <span class="NLM_lpage">178</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Fjm5014659&amp;key=10.1073%2Fpnas.1313733111" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Fjm5014659&amp;key=24347635" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Fjm5014659&amp;key=1%3ACAS%3A528%3ADC%252BC2cXps1eluw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2014&pages=173-178&author=P.+A.+Schwartzauthor=P.+Kuzmicauthor=J.+Solowiejauthor=S.+Bergqvistauthor=B.+Bolanosauthor=C.+Almadenauthor=A.+Nagataauthor=K.+Ryanauthor=J.+Fengauthor=D.+Dalvieauthor=J.+C.+Kathauthor=M.+Xuauthor=R.+Waniauthor=B.+M.+Murray&title=Covalent+EGFR+inhibitor+analysis+reveals+importance+of+reversible+interactions+to+potency+and+mechanisms+of+drug+resistance"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Covalent EGFR inhibitor analysis reveals importance of reversible interactions to potency and mechanisms of drug resistance</span></div><div class="casAuthors">Schwartz, Phillip A.; Kuzmic, Petr; Solowiej, James; Bergqvist, Simon; Bolanos, Ben; Almaden, Chau; Nagata, Asako; Ryan, Kevin; Feng, Junli; Dalvie, Deepak; Kath, John C.; Xu, Meirong; Wani, Revati; Murray, Brion William</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">173-178</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Covalent inhibition is a reemerging paradigm in kinase drug design, but the roles of inhibitor binding affinity and chem. reactivity in overall potency are not well-understood.  To characterize the underlying mol. processes at a microscopic level and det. the appropriate kinetic consts., specialized exptl. design and advanced numerical integration of differential equations are developed.  Previously uncharacterized investigational covalent drugs reported here are shown to be extremely effective epidermal growth factor receptor (EGFR) inhibitors (kinact/Ki in the range 105-107 M-1s-1), despite their low specific reactivity (kinact â¤ 2.1 Ã 10-3 s-1), which is compensated for by high binding affinities (Ki < 1 nM).  For inhibitors relying on reactivity to achieve potency, noncovalent enzyme-inhibitor complex partitioning between inhibitor dissocn. and bond formation is central.  Interestingly, reversible binding affinity of EGFR covalent inhibitors is highly correlated with antitumor cell potency.  Furthermore, cellular potency for a subset of covalent inhibitors can be accounted for solely through reversible interactions.  One reversible interaction is between EGFR-Cys797 nucleophile and the inhibitor's reactive group, which may also contribute to drug resistance.  Because covalent inhibitors target a cysteine residue, the effects of its oxidn. on enzyme catalysis and inhibitor pharmacol. are characterized.  Oxidn. of the EGFR cysteine nucleophile does not alter catalysis but has widely varied effects on inhibitor potency depending on the EGFR context (e.g., oncogenic mutations), type of oxidn. (sulfinylation or glutathiolation), and inhibitor architecture.  These methods, parameters, and insights provide a rational framework for assessing and designing effective covalent inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTpPuRq8MwCLVg90H21EOLACvtfcHk0lg5iG4mvwQmHQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXps1eluw%253D%253D&md5=47197c5e7876a238eefb2e8e7de305ea</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1313733111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1313733111%26sid%3Dliteratum%253Aachs%26aulast%3DSchwartz%26aufirst%3DP.%2BA.%26aulast%3DKuzmic%26aufirst%3DP.%26aulast%3DSolowiej%26aufirst%3DJ.%26aulast%3DBergqvist%26aufirst%3DS.%26aulast%3DBolanos%26aufirst%3DB.%26aulast%3DAlmaden%26aufirst%3DC.%26aulast%3DNagata%26aufirst%3DA.%26aulast%3DRyan%26aufirst%3DK.%26aulast%3DFeng%26aufirst%3DJ.%26aulast%3DDalvie%26aufirst%3DD.%26aulast%3DKath%26aufirst%3DJ.%2BC.%26aulast%3DXu%26aufirst%3DM.%26aulast%3DWani%26aufirst%3DR.%26aulast%3DMurray%26aufirst%3DB.%2BM.%26atitle%3DCovalent%2520EGFR%2520inhibitor%2520analysis%2520reveals%2520importance%2520of%2520reversible%2520interactions%2520to%2520potency%2520and%2520mechanisms%2520of%2520drug%2520resistance%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2014%26volume%3D111%26spage%3D173%26epage%3D178" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Serafimova, I. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pufall, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krishnan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duda, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maglathlin, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McFarland, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">FrÃ¶din, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taunton, J.</span><span> </span><span class="NLM_article-title">Reversible targeting of noncatalytic cysteines with chemically tuned electrophiles</span> <span class="citation_source-journal">Nature Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">471</span><span class="NLM_x">â</span> <span class="NLM_lpage">476</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14a&amp;dbid=16&amp;doi=10.1021%2Fjm5014659&amp;key=10.1038%2Fnchembio.925" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14a&amp;dbid=8&amp;doi=10.1021%2Fjm5014659&amp;key=22466421" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14a&amp;dbid=32&amp;doi=10.1021%2Fjm5014659&amp;key=1%3ACAS%3A528%3ADC%252BC38XkvVKitrw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2012&pages=471-476&author=I.+M.+Serafimovaauthor=M.+A.+Pufallauthor=S.+Krishnanauthor=K.+Dudaauthor=M.+S.+Cohenauthor=R.+L.+Maglathlinauthor=J.+M.+McFarlandauthor=R.+M.+Millerauthor=M.+Fr%C3%B6dinauthor=J.+Taunton&title=Reversible+targeting+of+noncatalytic+cysteines+with+chemically+tuned+electrophiles"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14aR"><div class="casContent"><span class="casTitleNuber">14a</span><div class="casTitle"><span class="NLM_cas:atitle">Reversible targeting of noncatalytic cysteines with chemically tuned electrophiles</span></div><div class="casAuthors">Serafimova, Iana M.; Pufall, Miles A.; Krishnan, Shyam; Duda, Katarzyna; Cohen, Michael S.; Maglathlin, Rebecca L.; McFarland, Jesse M.; Miller, Rand M.; Froedin, Morten; Taunton, Jack</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">471-476</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Targeting noncatalytic cysteine residues with irreversible acrylamide-based inhibitors is a powerful approach for enhancing pharmacol. potency and selectivity.  Nevertheless, concerns about off-target modification motivate the development of reversible cysteine-targeting strategies.  Here we show that electron-deficient olefins, including acrylamides, can be tuned to react with cysteine thiols in a rapidly reversible manner.  Installation of a nitrile group increased the olefins' intrinsic reactivity, but, paradoxically, eliminated the formation of irreversible adducts.  Incorporation of these electrophiles into a noncovalent kinase-recognition scaffold produced slowly dissocg., covalent inhibitors of the p90 ribosomal protein S6 kinase RSK2.  A cocrystal structure revealed specific noncovalent interactions that stabilize the complex by positioning the electrophilic carbon near the targeted cysteine.  Disruption of these interactions by protein unfolding or proteolysis promoted instantaneous cleavage of the covalent bond.  Our results establish a chem.-based framework for engineering sustained covalent inhibition without accumulating permanently modified proteins and peptides.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlcv3GjPOB6rVg90H21EOLACvtfcHk0lhrnkYeYIhYdw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XkvVKitrw%253D&md5=6455a9a029714beb317286f71ac1326b</span></div><a href="/servlet/linkout?suffix=cit14a&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.925&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.925%26sid%3Dliteratum%253Aachs%26aulast%3DSerafimova%26aufirst%3DI.%2BM.%26aulast%3DPufall%26aufirst%3DM.%2BA.%26aulast%3DKrishnan%26aufirst%3DS.%26aulast%3DDuda%26aufirst%3DK.%26aulast%3DCohen%26aufirst%3DM.%2BS.%26aulast%3DMaglathlin%26aufirst%3DR.%2BL.%26aulast%3DMcFarland%26aufirst%3DJ.%2BM.%26aulast%3DMiller%26aufirst%3DR.%2BM.%26aulast%3DFr%25C3%25B6din%26aufirst%3DM.%26aulast%3DTaunton%26aufirst%3DJ.%26atitle%3DReversible%2520targeting%2520of%2520noncatalytic%2520cysteines%2520with%2520chemically%2520tuned%2520electrophiles%26jtitle%3DNature%2520Chem.%2520Biol.%26date%3D2012%26volume%3D8%26spage%3D471%26epage%3D476" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit14b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Miller, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paavilainen, V. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krishnan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serafimova, I. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taunton, J.</span><span> </span><span class="NLM_article-title">Electrophilic fragment-based design of reversible covalent kinase inhibitors</span> <span class="citation_source-journal">J. Am. Soc. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">135</span><span class="NLM_x">, </span> <span class="NLM_fpage">5298</span><span class="NLM_x">â</span> <span class="NLM_lpage">5301</span></span><div class="citationLinks">[<a href="/doi/10.1021/ja401221b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref14/cit14b&amp;dbid=32&amp;doi=10.1021%2Fjm5014659&amp;key=1%3ACAS%3A528%3ADC%252BC3sXltVClu7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=135&publication_year=2013&pages=5298-5301&author=R.+M.+Millerauthor=V.+O.+Paavilainenauthor=S.+Krishnanauthor=I.+M.+Serafimovaauthor=J.+Taunton&title=Electrophilic+fragment-based+design+of+reversible+covalent+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14bR"><div class="casContent"><span class="casTitleNuber">14b</span><div class="casTitle"><span class="NLM_cas:atitle">Electrophilic Fragment-Based Design of Reversible Covalent Kinase Inhibitors</span></div><div class="casAuthors">Miller, Rand M.; Paavilainen, Ville O.; Krishnan, Shyam; Serafimova, Iana M.; Taunton, Jack</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">135</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">5298-5301</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Fragment-based ligand design and covalent targeting of noncatalytic cysteines have been employed to develop potent and selective kinase inhibitors.  Here, we combine these approaches, starting with a panel of low-mol.-wt., heteroaryl-substituted cyanoacrylamides, which we have previously shown to form reversible covalent bonds with cysteine thiols.  Using this strategy, we identify electrophilic fragments with sufficient ligand efficiency and selectivity to serve as starting points for the first reported inhibitors of the MSK1 C-terminal kinase domain.  Guided by X-ray co-crystal structures, indazole fragment 1 was elaborated to afford 12 (RMM-46), a reversible covalent inhibitor that exhibits high ligand efficiency and selectivity for MSK/RSK-family kinases.  At nanomolar concns., 12 blocked activation of cellular MSK and RSK, as well as downstream phosphorylation of the crit. transcription factor, CREB.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrax7wBNWOT8rVg90H21EOLACvtfcHk0lhrnkYeYIhYdw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXltVClu7g%253D&md5=c6100b56ce6f587f6afb834aeafec351</span></div><a href="/servlet/linkout?suffix=cit14b&amp;dbid=16384&amp;doi=10.1021%2Fja401221b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja401221b%26sid%3Dliteratum%253Aachs%26aulast%3DMiller%26aufirst%3DR.%2BM.%26aulast%3DPaavilainen%26aufirst%3DV.%2BO.%26aulast%3DKrishnan%26aufirst%3DS.%26aulast%3DSerafimova%26aufirst%3DI.%2BM.%26aulast%3DTaunton%26aufirst%3DJ.%26atitle%3DElectrophilic%2520fragment-based%2520design%2520of%2520reversible%2520covalent%2520kinase%2520inhibitors%26jtitle%3DJ.%2520Am.%2520Soc.%2520Chem.%26date%3D2013%26volume%3D135%26spage%3D5298%26epage%3D5301" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit14c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Nonoo, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Armstrong, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mann, D. J.</span><span> </span><span class="NLM_article-title">Kinetic template-guided tethering of fragments</span> <span class="citation_source-journal">ChemMedChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">2082</span><span class="NLM_x">â</span> <span class="NLM_lpage">2086</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&pages=2082-2086&author=R.+H.+Nonooauthor=A.+Armstrongauthor=D.+J.+Mann&title=Kinetic+template-guided+tethering+of+fragments"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNonoo%26aufirst%3DR.%2BH.%26aulast%3DArmstrong%26aufirst%3DA.%26aulast%3DMann%26aufirst%3DD.%2BJ.%26atitle%3DKinetic%2520template-guided%2520tethering%2520of%2520fragments%26jtitle%3DChemMedChem%26date%3D2012%26volume%3D7%26spage%3D2082%26epage%3D2086" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Bohm, H.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banner, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bendels, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kansy, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuhn, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MÃ¼ller, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Obst-Sander, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stahl, M.</span><span> </span><span class="NLM_article-title">Fluorine in medicinal chemistry</span> <span class="citation_source-journal">ChemBiolChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">637</span><span class="NLM_x">â</span> <span class="NLM_lpage">643</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Fjm5014659&amp;key=10.1002%2Fcbic.200301023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Fjm5014659&amp;key=15122635" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Fjm5014659&amp;key=1%3ACAS%3A280%3ADC%252BD2c3it1egug%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2004&pages=637-643&author=H.-J.+Bohmauthor=D.+Bannerauthor=S.+Bendelsauthor=M.+Kansyauthor=B.+Kuhnauthor=K.+M%C3%BCllerauthor=U.+Obst-Sanderauthor=M.+Stahl&title=Fluorine+in+medicinal+chemistry"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Fluorine in medicinal chemistry</span></div><div class="casAuthors">Bohm Hans-Joachim; Banner David; Bendels Stefanie; Kansy Manfred; Kuhn Bernd; Muller Klaus; Obst-Sander Ulrike; Stahl Martin</div><div class="citationInfo"><span class="NLM_cas:title">Chembiochem : a European journal of chemical biology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">637-43</span>
        ISSN:<span class="NLM_cas:issn">1439-4227</span>.
    </div><div class="casAbstract">Fluorinated compounds are synthesized in pharmaceutical research on a routine basis and many marketed compounds contain fluorine.  The present review summarizes some of the most frequently employed strategies for using fluorine substituents in medicinal chemistry.  Quite often, fluorine is introduced to improve the metabolic stability by blocking metabolically labile sites.  However, fluorine can also be used to modulate the physicochemical properties, such as lipophilicity or basicity.  It may exert a substantial effect on the conformation of a molecule.  Increasingly, fluorine is used to enhance the binding affinity to the target protein.  Recent 3D-structure determinations of protein complexes with bound fluorinated ligands have led to an improved understanding of the nonbonding protein-ligand interactions that involve fluorine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ4zDG_wo1YGtts4TFFB11gfW6udTcc2ebJuf0xvp3aP7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2c3it1egug%253D%253D&md5=fa5ca2cfc278b83c80d5c96b18dfe312</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1002%2Fcbic.200301023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcbic.200301023%26sid%3Dliteratum%253Aachs%26aulast%3DBohm%26aufirst%3DH.-J.%26aulast%3DBanner%26aufirst%3DD.%26aulast%3DBendels%26aufirst%3DS.%26aulast%3DKansy%26aufirst%3DM.%26aulast%3DKuhn%26aufirst%3DB.%26aulast%3DM%25C3%25BCller%26aufirst%3DK.%26aulast%3DObst-Sander%26aufirst%3DU.%26aulast%3DStahl%26aufirst%3DM.%26atitle%3DFluorine%2520in%2520medicinal%2520chemistry%26jtitle%3DChemBiolChem%26date%3D2004%26volume%3D5%26spage%3D637%26epage%3D643" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Kirk, K. L.</span><span> </span><span class="NLM_article-title">Fluorine in medicinal chemistry: recent therapeutic applications of fluorinated small molecules</span> <span class="citation_source-journal">J. Fluorine Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">127</span><span class="NLM_x">, </span> <span class="NLM_fpage">1013</span><span class="NLM_x">â</span> <span class="NLM_lpage">1029</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Fjm5014659&amp;key=10.1016%2Fj.jfluchem.2006.06.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Fjm5014659&amp;key=1%3ACAS%3A528%3ADC%252BD28XnvVSrtb8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=2006&pages=1013-1029&author=K.+L.+Kirk&title=Fluorine+in+medicinal+chemistry%3A+recent+therapeutic+applications+of+fluorinated+small+molecules"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Fluorine in medicinal chemistry: Recent therapeutic applications of fluorinated small molecules</span></div><div class="casAuthors">Kirk, Kenneth L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Fluorine Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">127</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1013-1029</span>CODEN:
                <span class="NLM_cas:coden">JFLCAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-1139</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Advances in the development of newly developed fluorinated drugs, approved or in clin. trials, as organized by biol. targets/disease states, are reviewed.  In a few cases, compds. in early stages of development will be discussed, particularly where new promising targets are involved.  Important topics such as anticancer and antiviral drugs were covered in the two previous reviews in this series.  Included herein will be fluorinated drugs for treatment of diseases of the central nervous system, various cardiovascular diseases and obesity, antibacterial agents, and antifungal therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrd1vhHrZgNN7Vg90H21EOLACvtfcHk0lj1nAXK-uP34A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XnvVSrtb8%253D&md5=890de242b8c5804fec1a9a7d35471ac1</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2Fj.jfluchem.2006.06.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jfluchem.2006.06.007%26sid%3Dliteratum%253Aachs%26aulast%3DKirk%26aufirst%3DK.%2BL.%26atitle%3DFluorine%2520in%2520medicinal%2520chemistry%253A%2520recent%2520therapeutic%2520applications%2520of%2520fluorinated%2520small%2520molecules%26jtitle%3DJ.%2520Fluorine%2520Chem.%26date%3D2006%26volume%3D127%26spage%3D1013%26epage%3D1029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Hagmann, W. K.</span><span> </span><span class="NLM_article-title">The many roles for fluorine in medicinal chemistry</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">4359</span><span class="NLM_x">â</span> <span class="NLM_lpage">4369</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm800219f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Fjm5014659&amp;key=1%3ACAS%3A528%3ADC%252BD1cXns1WjtLo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=4359-4369&author=W.+K.+Hagmann&title=The+many+roles+for+fluorine+in+medicinal+chemistry"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">The Many Roles for Fluorine in Medicinal Chemistry</span></div><div class="casAuthors">Hagmann, William K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4359-4369</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkZV7sio8RhbVg90H21EOLACvtfcHk0lgKo0u9mnWOHw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXns1WjtLo%253D&md5=821f8076bb0f632f687b1c90b05dd382</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Fjm800219f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800219f%26sid%3Dliteratum%253Aachs%26aulast%3DHagmann%26aufirst%3DW.%2BK.%26atitle%3DThe%2520many%2520roles%2520for%2520fluorine%2520in%2520medicinal%2520chemistry%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D4359%26epage%3D4369" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Ilardi, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vitaku, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Njardarson, J. T.</span><span> </span><span class="NLM_article-title">Data-mining for sulfur and fluorine: an evaluation of pharmaceuticals to reveal opportunities for drug design and discovery</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">2832</span><span class="NLM_x">â</span> <span class="NLM_lpage">2842</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm401375q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Fjm5014659&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsFyksb%252FE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=2832-2842&author=E.+A.+Ilardiauthor=E.+Vitakuauthor=J.+T.+Njardarson&title=Data-mining+for+sulfur+and+fluorine%3A+an+evaluation+of+pharmaceuticals+to+reveal+opportunities+for+drug+design+and+discovery"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Data-Mining for Sulfur and Fluorine: An Evaluation of Pharmaceuticals To Reveal Opportunities for Drug Design and Discovery</span></div><div class="casAuthors">Ilardi, Elizabeth A.; Vitaku, Edon; Njardarson, Jon T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2832-2842</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Among carbon, hydrogen, oxygen, and nitrogen, sulfur and fluorine are both leading constituents of the pharmaceuticals that comprise our medicinal history.  In efforts to stimulate the minds of both the general public and expert scientist, statistics were collected from the trends assocd. with therapeutics spanning 12 disease categories (a total of 1969 drugs) from our new graphical montage compilation: disease focused pharmaceuticals posters.  Each poster is a vibrant display of a collection of pharmaceuticals (including structural image, Food and Drug Administration (FDA) approval date, international nonproprietary name (INN), initial market name, and a color-coded subclass of function) organized chronol. and classified according to an assocn. with a particular clin. indication.  Specifically, the evolution and structural diversity of sulfur and the popular integration of fluorine into drugs introduced over the past 50 years are evaluated.  The presented qual. conclusions in this article aim to promote innovative insights into drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvH3H0yeaywrVg90H21EOLACvtfcHk0lgKo0u9mnWOHw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsFyksb%252FE&md5=b684f76341311979d0100ed68cffe714</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1021%2Fjm401375q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401375q%26sid%3Dliteratum%253Aachs%26aulast%3DIlardi%26aufirst%3DE.%2BA.%26aulast%3DVitaku%26aufirst%3DE.%26aulast%3DNjardarson%26aufirst%3DJ.%2BT.%26atitle%3DData-mining%2520for%2520sulfur%2520and%2520fluorine%253A%2520an%2520evaluation%2520of%2520pharmaceuticals%2520to%2520reveal%2520opportunities%2520for%2520drug%2520design%2520and%2520discovery%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D2832%26epage%3D2842" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Rewcastle, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palmer, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bridges, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Showalter, H. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McMichael, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kraker, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fry, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Denny, W. A.</span><span> </span><span class="NLM_article-title">Tyrosine kinase inhibitors. 9. Synthesis and evaluation of fused tricyclic quinazoline analogues as ATP site inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">918</span><span class="NLM_x">â</span> <span class="NLM_lpage">928</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm950692f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=1996&pages=918-928&author=G.+W.+Rewcastleauthor=B.+D.+Palmerauthor=A.+J.+Bridgesauthor=H.+D.+Showalterauthor=L.+Sunauthor=J.+Nelsonauthor=A.+McMichaelauthor=A.+J.+Krakerauthor=D.+W.+Fryauthor=W.+A.+Denny&title=Tyrosine+kinase+inhibitors.+9.+Synthesis+and+evaluation+of+fused+tricyclic+quinazoline+analogues+as+ATP+site+inhibitors+of+the+tyrosine+kinase+activity+of+the+epidermal+growth+factor+receptor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Fjm950692f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm950692f%26sid%3Dliteratum%253Aachs%26aulast%3DRewcastle%26aufirst%3DG.%2BW.%26aulast%3DPalmer%26aufirst%3DB.%2BD.%26aulast%3DBridges%26aufirst%3DA.%2BJ.%26aulast%3DShowalter%26aufirst%3DH.%2BD.%26aulast%3DSun%26aufirst%3DL.%26aulast%3DNelson%26aufirst%3DJ.%26aulast%3DMcMichael%26aufirst%3DA.%26aulast%3DKraker%26aufirst%3DA.%2BJ.%26aulast%3DFry%26aufirst%3DD.%2BW.%26aulast%3DDenny%26aufirst%3DW.%2BA.%26atitle%3DTyrosine%2520kinase%2520inhibitors.%25209.%2520Synthesis%2520and%2520evaluation%2520of%2520fused%2520tricyclic%2520quinazoline%2520analogues%2520as%2520ATP%2520site%2520inhibitors%2520of%2520the%2520tyrosine%2520kinase%2520activity%2520of%2520the%2520epidermal%2520growth%2520factor%2520receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1996%26volume%3D39%26spage%3D918%26epage%3D928" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Wu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xia, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shao, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weng, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deng, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, Y.</span><span> </span><span class="NLM_article-title">Design, synthesis, and biological evaluation of novel conformationally constrained inhibitors targeting EGFR</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">974</span><span class="NLM_x">â</span> <span class="NLM_lpage">978</span></span><div class="citationLinks">[<a href="/doi/10.1021/ml4002437" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=974-978&author=J.+Wuauthor=W.+Chenauthor=G.+Xiaauthor=J.+Zhangauthor=J.+Shaoauthor=B.+Tanauthor=C.+Zhangauthor=W.+Yuauthor=Q.+Wengauthor=H.+Liuauthor=M.+Huauthor=H.+Dengauthor=Y.+Haoauthor=J.+Shenauthor=Y.+Yu&title=Design%2C+synthesis%2C+and+biological+evaluation+of+novel+conformationally+constrained+inhibitors+targeting+EGFR"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Fml4002437&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml4002437%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DW.%26aulast%3DXia%26aufirst%3DG.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DShao%26aufirst%3DJ.%26aulast%3DTan%26aufirst%3DB.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DYu%26aufirst%3DW.%26aulast%3DWeng%26aufirst%3DQ.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DHu%26aufirst%3DM.%26aulast%3DDeng%26aufirst%3DH.%26aulast%3DHao%26aufirst%3DY.%26aulast%3DShen%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DY.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520biological%2520evaluation%2520of%2520novel%2520conformationally%2520constrained%2520inhibitors%2520targeting%2520EGFR%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D4%26spage%3D974%26epage%3D978" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Kajjout, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zemmouri, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eddarir, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rolando, C.</span><span> </span><span class="NLM_article-title">An efficient access to (<i>Z</i>)-Î²-fluoroallyl alcohols based on the two carbon homologation of aromatic aldehydes by HornerâWadsworthâEmmons reaction with 2-(diethoxyphosphinyl)-2-fluoro-ethanethioic acid, <i>S</i>-ethyl ester followed by reduction with sodium borohydride</span> <span class="citation_source-journal">Tetrahedron</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x">, </span> <span class="NLM_fpage">3225</span><span class="NLM_x">â</span> <span class="NLM_lpage">3230</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2012&pages=3225-3230&author=M.+Kajjoutauthor=R.+Zemmouriauthor=S.+Eddarirauthor=C.+Rolando&title=An+efficient+access+to+%28Z%29-%CE%B2-fluoroallyl+alcohols+based+on+the+two+carbon+homologation+of+aromatic+aldehydes+by+Horner%E2%80%93Wadsworth%E2%80%93Emmons+reaction+with+2-%28diethoxyphosphinyl%29-2-fluoro-ethanethioic+acid%2C+S-ethyl+ester+followed+by+reduction+with+sodium+borohydride"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKajjout%26aufirst%3DM.%26aulast%3DZemmouri%26aufirst%3DR.%26aulast%3DEddarir%26aufirst%3DS.%26aulast%3DRolando%26aufirst%3DC.%26atitle%3DAn%2520efficient%2520access%2520to%2520%2528Z%2529-%25CE%25B2-fluoroallyl%2520alcohols%2520based%2520on%2520the%2520two%2520carbon%2520homologation%2520of%2520aromatic%2520aldehydes%2520by%2520Horner%25E2%2580%2593Wadsworth%25E2%2580%2593Emmons%2520reaction%2520with%25202-%2528diethoxyphosphinyl%2529-2-fluoro-ethanethioic%2520acid%252C%2520S-ethyl%2520ester%2520followed%2520by%2520reduction%2520with%2520sodium%2520borohydride%26jtitle%3DTetrahedron%26date%3D2012%26volume%3D68%26spage%3D3225%26epage%3D3230" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">GansÃ¤uer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Worgull, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knebel, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huth, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schnakenburg, G.</span><span> </span><span class="NLM_article-title">4-Exo cyclizations by template</span> <span class="citation_source-journal">Angew. Chem., Int. Ed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">8882</span><span class="NLM_x">â</span> <span class="NLM_lpage">8885</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2009&pages=8882-8885&author=A.+Gans%C3%A4uerauthor=D.+Worgullauthor=K.+Knebelauthor=I.+Huthauthor=G.+Schnakenburg&title=4-Exo+cyclizations+by+template"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGans%25C3%25A4uer%26aufirst%3DA.%26aulast%3DWorgull%26aufirst%3DD.%26aulast%3DKnebel%26aufirst%3DK.%26aulast%3DHuth%26aufirst%3DI.%26aulast%3DSchnakenburg%26aufirst%3DG.%26atitle%3D4-Exo%2520cyclizations%2520by%2520template%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2009%26volume%3D48%26spage%3D8882%26epage%3D8885" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Short, K. M.; Pham, S. M.; Williams, D. C.; Datta, S.</span><span> </span><span class="NLM_article-title">Multisubstituted aromatic compounds as inhibitors of thrombin</span>. WO 2011/126903,<span class="NLM_x"> </span><span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=K.+M.+Short&author=S.+M.+Pham&author=D.+C.+Williams&author=S.+Datta&title=Multisubstituted+aromatic+compounds+as+inhibitors+of+thrombin"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DShort%26aufirst%3DK.%2BM.%26atitle%3DMultisubstituted%2520aromatic%2520compounds%2520as%2520inhibitors%2520of%2520thrombin%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Barf, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaptein, A.</span><span> </span><span class="NLM_article-title">Irreversible protein kinase inhibitors: balancing the benefits and risks</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">6243</span><span class="NLM_x">â</span> <span class="NLM_lpage">6644</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm3003203" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Fjm5014659&amp;key=1%3ACAS%3A528%3ADC%252BC38XnsVerur8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=6243-6644&author=T.+Barfauthor=A.+Kaptein&title=Irreversible+protein+kinase+inhibitors%3A+balancing+the+benefits+and+risks"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Irreversible Protein Kinase Inhibitors: Balancing the Benefits and Risks</span></div><div class="casAuthors">Barf, Tjeerd; Kaptein, Allard</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">6243-6262</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Not applicable for a Perspective.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4PLlisO0OVbVg90H21EOLACvtfcHk0lg5PMCdF-wrOg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XnsVerur8%253D&md5=5d87850857d37faab02e6037ef8140a4</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Fjm3003203&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm3003203%26sid%3Dliteratum%253Aachs%26aulast%3DBarf%26aufirst%3DT.%26aulast%3DKaptein%26aufirst%3DA.%26atitle%3DIrreversible%2520protein%2520kinase%2520inhibitors%253A%2520balancing%2520the%2520benefits%2520and%2520risks%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D6243%26epage%3D6644" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Diaz, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daniell, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leitza, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDermott, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cox, B. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gintant, G. A.</span><span> </span><span class="NLM_article-title">The [<sup>3</sup>H]dofetilide binding assay is a predictive screening tool for hERG blockade and proarrhythmia: Comparison of intact cell and membrane preparations and effects of altering [K+]o</span> <span class="citation_source-journal">J. Pharmacol. Toxicol. Methods</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">187</span><span class="NLM_x">â</span> <span class="NLM_lpage">199</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Fjm5014659&amp;key=10.1016%2Fj.vascn.2004.04.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Fjm5014659&amp;key=15519905" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Fjm5014659&amp;key=1%3ACAS%3A528%3ADC%252BD2cXptFOmtLk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2004&pages=187-199&author=G.+J.+Diazauthor=K.+Daniellauthor=S.+T.+Leitzaauthor=R.+L.+Martinauthor=Z.+Suauthor=J.+S.+McDermottauthor=B.+F.+Coxauthor=G.+A.+Gintant&title=The+%5B3H%5Ddofetilide+binding+assay+is+a+predictive+screening+tool+for+hERG+blockade+and+proarrhythmia%3A+Comparison+of+intact+cell+and+membrane+preparations+and+effects+of+altering+%5BK%2B%5Do"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">The [3H]dofetilide binding assay is a predictive screening tool for hERG blockade and proarrhythmia: Comparison of intact cell and membrane preparations and effects of altering [K+]o</span></div><div class="casAuthors">Diaz, Gilbert J.; Daniell, Katina; Leitza, Sandra T.; Martin, Ruth L.; Su, Zhi; McDermott, Jeffrey S.; Cox, Bryan F.; Gintant, Gary A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacological and Toxicological Methods</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">187-199</span>CODEN:
                <span class="NLM_cas:coden">JPTMEZ</span>;
        ISSN:<span class="NLM_cas:issn">1056-8719</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Introduction: The human ether-a-go-go-related gene (hERG) encodes a potassium channel responsible for the cardiac delayed rectifier current (IKr) involved in ventricular repolarization.  Drugs that block hERG have been assocd. with QT interval prolongation and serious, sometimes fatal, cardiac arrhythmias (including torsade de pointes).  While displacement of [3H]dofetilide, a potent methanesulfonanilide hERG blocker, from cells heterologously expressing hERG has been suggested as a screening assay, questions have been raised about its predictive value.Methods: To validate the utility of this assay as a screening tool, we performed a series of satn. and competition binding studies using [3H]dofetilide as ligand and either intact cells or membrane prepns. from HEK 293 cells stably transfected with hERG K+ channels.  The object of these expts. was to (1) compare binding Ki values for 22 hERG blockers using intact cells or membrane homogenates to det. whether maintaining cell integrity enhanced assay reliability; (2) evaluate the ability of different K+ concns. (2, 5, 10, 20, and 60 mM) to modulate hERG binding; and (3) to establish the predictive value of the assay by comparing Ki values from binding studies at 5 and 60 mM [K+]o to functional IC50 values for hERG current block using 56 structurally diverse drugs.Results: We found (a) comparable Ki values in the intact cell and isolated membrane binding assays, although there were some differences in rank order; (b) increasing [K+]o lowered the Kd and increased the Bmax for [3H]dofetilide, particularly in the membrane assay; and (c) good correlation between binding Ki values and functional IC50 values for hERG current block.Discussion: In conclusion, increasing K+ concns. results in an increase in both [3H]dofetilide affinity for hERG and available binding sites, particularly when using membrane homogenates.  There are no meaningful differences between Ki values when comparing intact cell vs. membrane assay, neither are there meaningful trends with increasing [K+]o within assays.  There is good correlation between binding Ki values and functional (whole-cell patch clamp) IC50 values at both 5 and 60 mM K+ concns. (R2 values of .824 and .863, resp.).  The simplicity, predictability, and adaptability to high-throughput platforms make the [3H]dofetilide membrane binding assay a useful tool for screening and ranking compds. for their potential to block the hERG K+ channel.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJEs_DWLzvI7Vg90H21EOLACvtfcHk0lg5PMCdF-wrOg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXptFOmtLk%253D&md5=28c925ef02404c53443dc90eae961ed1</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2Fj.vascn.2004.04.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.vascn.2004.04.001%26sid%3Dliteratum%253Aachs%26aulast%3DDiaz%26aufirst%3DG.%2BJ.%26aulast%3DDaniell%26aufirst%3DK.%26aulast%3DLeitza%26aufirst%3DS.%2BT.%26aulast%3DMartin%26aufirst%3DR.%2BL.%26aulast%3DSu%26aufirst%3DZ.%26aulast%3DMcDermott%26aufirst%3DJ.%2BS.%26aulast%3DCox%26aufirst%3DB.%2BF.%26aulast%3DGintant%26aufirst%3DG.%2BA.%26atitle%3DThe%2520%255B3H%255Ddofetilide%2520binding%2520assay%2520is%2520a%2520predictive%2520screening%2520tool%2520for%2520hERG%2520blockade%2520and%2520proarrhythmia%253A%2520Comparison%2520of%2520intact%2520cell%2520and%2520membrane%2520preparations%2520and%2520effects%2520of%2520altering%2520%255BK%252B%255Do%26jtitle%3DJ.%2520Pharmacol.%2520Toxicol.%2520Methods%26date%3D2004%26volume%3D50%26spage%3D187%26epage%3D199" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i69"><a href="/doi/suppl/10.1021/jm5014659">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_76735"></div></div></div></div></div><hr /></hr><p class="last">Additional figures and tables illustrating inhibition data, purity data, and <sup>1</sup>H NMR spectra. This material is available free of charge via the Internet at <a class="extLink" href="http://pubs.acs.org">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm5014659/suppl_file/jm5014659_si_001.pdf">jm5014659_si_001.pdf (5.03 MB)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Fjm5014659&amp;pbContext=%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2014.57.issue-23%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Barticle%3Aarticle%3A10.1021%2Fjm5014659" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/jm5014659" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                2MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright Â© 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">Youâve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"67993e89dddfd1ab","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
